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ABSTRACT 
Sjögren’s syndrome (SS) and rheumatoid arthritis (RA) are characterised by breach of 
self-tolerance with high affinity circulating autoantibodies and peripheral B cell 
disturbances in the naïve and memory B cell compartments. In addition, both SS and 
RA develop functional ectopic B cell follicles in the respective target organs, i.e. the 
salivary glands and the joint synovium, whereby autoreactive B cell undergo antigen 
selection and affinity maturation. However, the exact stage at which errors in B cell 
tolerance checkpoints accumulate is unknown.  
In this PhD project, I amplified and sequenced Ig VH and VL gene transcripts from 
single B cells which were FACS sorted either from the peripheral blood of SS patients 
or from the RA synovium. Healthy donors (HD) were used as controls. Subsequently, I 
cloned and expressed recombinant monoclonal antibodies displaying identical 
antigenic specificity of the original B cells. Finally, I tested the poly- and autoreactivity 
profile of these antibodies against SS and RA-associated autoantigens. 
In SS, I analysed 353 VH and 293 VL sequences and obtained 114 recombinant 
antibodies from circulating naïve (n=66) and memory (n=48) B cells of 4 SS patients 
and compared their autoreactive and polyreactive profile to 45 naïve clones from 2 
HD. Analysis of the VH and VL gene usage showed no significant differences between 
SS and HD. Conversely, I observed accumulation of circulating autoreactive naïve B 
cells in SS as demonstrated by Hep-2 cells, ENA, Ro/SSA and/or La/SSB reactivity. The 
elevated frequency of autoreactive naïve B cells in the circulation of SS patients 
supports the existence of early defects in B cell tolerance checkpoints in this condition.  
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In RA, I analysed the Ig gene repertoire and the VH gene somatic mutation rate of 139 
VH and 175 VL sequences of synovial CD19+ B cells which demonstrated evidence of 
antigen selection and hypermutated alpha>gamma>mu VH chains with presence of 
intra-synovial clonal diversification. Recombinant antibodies from synovial B cell clones 
were then screened for reactivity towards citrullinated antigens with a plan for a wider 
analysis using autoantigen microarrays. 
Overall, these results highlighted the existence of B cell abnormalities and loss of 
tolerance for self-antigens both in the peripheral and/or lesional compartment of SS 
and RA. Further analysis of the fine specificity and pathogenicity of recombinant 
antibodies from autoreactive B cells will be invaluable in order to dissect the 
mechanisms and the antigens driving the development and the persistence of 
autoimmunity in RA and SS. 
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1.1 Development of antibody-producing B cells and B cell 
self-tolerance in humans. 
1.1.1 Introduction. 
10-15% of human peripheral blood lymphocytes, 20-30% of lymph node cells, 50% of 
splenic lymphocytes, and around 10% of bone marrow lymphocytes are constituted by 
mature B cells. Each B cell expresses on its surface a unique intramembrane 
immunoglobulin (Ig) molecule, referred as B cell receptor (BCR) capable to bind to a 
specific antigen. Unlike T cells which can recognize only processed antigens expressed 
on the MHC class I and class II molecules on antigen presenting cells (APCs), B cells are 
able to recognize unprocessed native antigens via antigen binding to B cell surface Ig 
receptors. The primary function of B cells is to produce antibodies but they can also act 
as APCs. Moreover, B cells are involved in T cell activation, anergy, and differentiation 
as well as in the expansion of T cells [1]. B cells can also regulate follicular dendritic cell 
differentiation and organization of lymphatic structures [1]. Finally, B cells can produce 
pro-inflammatory cytokines (e.g., tumor necrosis factor- (TNF-) and interleukin-6 
(IL-6)) and anti-inflammatory cytokines such as IL-10 [1]. 
1.1.2 B cell development before antigen encounter. 
B cells arise from stem cells in the bone marrow and they progress through several 
stages of maturation before entering the peripheral compartments – primarily lymph 
nodes and spleen, where they can differentiate into memory B and plasma cells which 
can finally migrate back to the bone marrow as long lived plasma cells (Figure 1.1) [2]. 
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The earliest B cell precursors are pre-pro-B cells which have a low expression of the 
recombination activation genes (RAG-1 and RAG-2), involved in recombination process 
of the variable, diversity (only for the heavy chain), and joining regions or V(D)J, and 
they do not express elements of the BCR [3]. Pre-pro-B cells differentiate into pro-B 
cells which express a precursor form of the BCR formed by Ig, Ig and calnexin (pro-
BCR). At this stage of B cell development, V(D)J recombination starts at the Ig heavy 
(H) locus [3] leading to the synthesis of a productive Igchain. Ig gene recombination 
starts with D to JH segment rearrangements followed by VH and D-JH segment 
rearrangements [4]. This process requires the cytokine IL-7, expressed by several type 
of stromal cells in the bone marrow, the transcription factors Pax5 and YY1, and high 
levels of Rag-1/Rag-2 proteins [4]. Once a productive rearrangement is made, pro-B 
cells differentiate into pre-B cells which have to rearrange their light chain loci. The 
pre-BCR is formed by the transmembrane form of Ig (mIg), the surrogate light 
chains (5 and VpreB), Ig and Ig and its main functions are to start clonal expansion 
in a IL-7 independent way, heavy chain allelic exclusion, and further differentiation. 
Allelic exclusion means that after a successful rearrangement of one IgH allele, the 
other allele is inhibited from going through further rearrangements. After clonal 
expansion, pre-B cells stop in G1 phase, they become smaller and start Ig locus 
rearrangement with the final expression of the IgM BCR [4]. At this stage pre-B cells 
differentiate into immature B cells which are the first B cells to express surface BCR. 
They express IgM but little or no surface IgD [4]. Immature B cells are particularly 
susceptible to BCR-induced apoptosis or deletion, compared to mature B cells. 
Deletion is one of the three main tolerance mechanisms used by the immune system 
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to reduce self-reactive B cells during development. Anergy is the second mechanism 
by which self-tolerance is maintained in immature B cells. Anergic B cells are 
hyporesponsive, short-lived, and chronic exposure to antigen in these cells is 
associated with decreased BCR expression [3]. The third type of tolerance mechanism, 
called receptor editing, leads to the internalization of the self-antigen-BCR complexes 
and to the activation of intracellular signals that initiate secondary light chain 
rearrangements [4]. Immature B cells migrate from the bone marrow to the periphery 
as transitional 1 and 2 (T1 and T2) B cells (new emigrant B cells). T1 B cells precede T2 
B cells which are considered the immediate precursors of naïve B cells. Both types of 
transitional B cells are short-lived, and only 10-30% of these cells enter the mature 
naïve B cell compartment [3, 4]. Transitional 3 (T3) B cells, which were considered to 
be part of the linear development from immature to naïve B cells, are now believed to 
represent self-reactive anergic B cells [5]. Follicular mature, germinal center, and 
plasma B cells belong to the B-2 lineage. A second lineage of B cells called B-1 is found 
mainly in the peritoneum [6]. The mechanism regulating the transition between 
transitional B cells to mature naïve B cells is poorly understood, but it is known that 
this process mainly takes place in the spleen and the BCR signalling has an important 
role in this transition as well in the decision fate between the follicular and marginal 
zone pathway of B cell differentiation [3, 4]. Receptor editing may also occur in 
transitional B cells, but in less extent since these cells express low RAG [3].  
In particular, the BCR signalling together with the B cell-activating factor receptor 
(BAFF-R or BR3) guides the selection of immature B cells after their exit from the bone 
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marrow [7]. BAFF is a fundamental survival factor for B cells which has shown to have 
an important role in the differentiation of T2, mature and MZ B cells [6].  
Indeed, BAFF-/- mice are able to generate and release normally immature B cells from 
the bone marrow, but in the spleen these B cells stop at the T1 stage and fail to 
proceed to the T2 stage [8]. Moreover MZ B cells tend to disappear in the absence of 
BAFF, suggesting that BAFF is also required for their development [6]. Regarding the 
role of BAFF on the development of B-1 B cells, which is a unique population of mature 
cells found mainly in the peritoneum, there are data in mice deficient for BAFF 
showing a normal B-1 population, suggesting an alternative developmental pathway 
for these cells [6].  
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Figure 1.1 Stages of B cell development in both bone marrow and peripheral lymphoid tissue.  
Events corresponding to each stage of B cell maturation from a pro-B cell to a mature B lymphocyte are illustrated. 
Source: Cambier et al., Nature Reviews Immunology 2007 
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1.1.3 V(D)J recombination process. 
The human Ig molecule consists of two identical heavy chains (IgH) and two identical 
light chains (IgL), each of which contains a variable domain for antigen recognition and 
a constant region for the effector functions. The Ig is encoded by three independent 
gene loci, with the IgH genes (for the heavy chain) located on chromosome 14, and the 
Ig and Iggenes (for the light chain) located on chromosome 2 and 22, respectively 
(Figure 1.2). 
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Figure 1.2 Human Ig loci organization.  
Schematic diagram of the human heavy chain, light chain, and  light chain loci. Only 
functional genes are shown. Variable (V), diversity (D) and joining (J) gene segments 
are represented in yellow, orange, and green rectangles, respectively. Constant (C) 
gene segments are shown in violet rectangles, enhancer elements as red ovals. Leader 
sequences (or signal sequences) are represented in grey.  
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The IgH locus consists of 123-129 VH gene segments of which 79 are pseudogenes and 
39 are functional genes, 27 D gene segments, and 6 JH functional gene segments. The 
VH gene segments can be classified into seven different families (VH1-VH7) as well as 
the D gene segments [9, 10]. The Iglocus consists of 76 V genes belonging to 7 
subgroups of which 31 to 36 are functional and 5 Jk gene segments [10]. Finally, the 
Iglocus consists of 73 to 74 genes of which 14 are pseudogenes and 29 to 33 are 
functional, and 7 to 11 J gene segments [10]. Assembly of V-D-J gene segments by 
V(D)J recombination process is the central mechanism that leads to Ig antigen receptor 
diversity. This process is started by a protein complex consisting primarily of the Rag1 
and Rag2 proteins (RAG complex). RAG binds and cleaves the DNA at specific sites 
called recombination signal sequences (RSSs) that flank each V, D and J gene segment 
[11]. The RSSs contain two conserved DNA elements – the heptamer and the nonamer, 
divided by a spacer of 12 (12RSS) or 23 (23RSS) base pairs. Normally, a 12RSS 
recombines only with a 23RSS, the so called 12-23 rule [11]. The ability of RAG to start 
V(D)J recombination relied on the accessibility of RSSs within the chromatin [11, 12]. 
As shown in Figure 1.3, V(D)J recombination starts when the RAG complex, probably 
together with high-mobility group protein B1 (HMGB1), binds to the 12RSS or the 
23RSS, forming a signal complex [11]. Capture of the second RSS (synapsis) results in 
the formation of a paired complex. This step is followed by DNA cleavage by RAG 
(double strand breaks) between the gene segment and the RSSs, with the formation of 
hairpin loop at the end of the gene segment. In the second phase, the hairpin is 
opened and RAG cooperate with non-homologous end joining (NHEJ) factors and 
terminal deoxynucleotidyl transferase (TdT) for the nucleotides addition to rejoin the 
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DNA ends and form the coding joint [11]. Finally, RSSs ends are joined to form the 
signal joint. 
1.1.3.1 Structural characteristic of the immunoglobulin antigen 
binding site. 
Most sequence differences among different antibodies are confined in three short 
regions, named complementary determining regions (CDRs), which are embedded into 
four conserved framework regions. Altogether CDRs and FR regions form the variable 
region of the Ig. Starting from the amino terminus of both VH and VL, the CDRs are 
called CDR1, CDR2, and CDR3. The latter is the most variable region of the CDRs. The 
FR1, 2 and 3 together with the CDR1 and CDR2 are encoded by the V gene segments. 
The FR4 is encoded by the J gene segment. The VH-D-JH join forms the CDR3 which is 
the center of the antigen binding site. Although the antigen binding is mainly 
associated with the CDRs, the FR regions may also interact with the antigen.  
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Figure 1.3 V(D)J recombination. 
V(D)J recombination steps are shown. In the phase 1, the RAG complex binds the signal 
sequences forming a 12 or 23 signal complex. This step is followed by the formation of 
a paired complex with the subsequent cleavage by RAG proteins and hairpin loop 
formation. In the phase 2, the hairpin is opened and the gene segments are joined to 
form the coding joint. 
Source: Schatz and Ji, Nature Reviews Immunology 2011  
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1.1.4 B cell differentiation after antigen encounter. 
After naïve B cells bind protein antigens, they migrate into the outer T cell zones in 
secondary lymphoid organs (SLOs) where they receive cognate T cell help and start to 
differentiate following one of two pathways: i) follicular which gives rise to germinal 
centers (GCs), or ii) extrafollicular from which short-lived plasma cells (PCs) develop 
[4].  
1.1.4.1 The germinal center (GC) reaction. 
B cell affinity maturation takes place in structure called GCs, leading to the generation 
of memory B and plasma cells which produce high-affinity antibodies [13]. These 
structures were first described by Walther Flemming in 1884 as distinct regions of SLOs 
that contained dividing cells [14, 15]. GCs are the main site of somatic hypermutation 
(SHM) and affinity-based selection. They develop in the center of primary follicles 
composed of naïve B cells within SLOs such as spleen and lymph nodes (LN) after 
exposure to antigens, forming secondary follicles. Naïve B cells are pushed outside the 
developing GC, forming the B cell mantle zone. As shown in Figure 1.4, GCs can be 
divided in two distinct compartments, the dark and the light zone (DZ and LZ, 
respectively). The DZ, proximal to the T cell zone, is made of B cells with a high 
nucleus/cytoplasm ratio, thus appearing dark by light microscopy. The DZ is the site of 
B cell clonal expansion and antigen receptor diversification. The B cells in the DZ are 
called “centroblasts” due to their larger size and high-level of proliferation. The LZ, 
proximal to the LN capsule or to the spleen marginal zone, consists of B cells scattered 
among a network of follicular dendritic cells (FDCs), giving this zone a light appearance. 
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The LZ is the site of antigen selection and the B cells within this zone are referred to as 
“centrocytes” because they are smaller and more quiescent. Shuttling between the DZ 
and LZ is regulated by the expression of unique chemokine receptors, as described 
later in this thesis (Chapter 1.4). The LZ contains also naïve B cells, which are always in 
transit through the GC, T cells (mainly CD4+), as well as a small number of conventional 
dendritic cells. Tingible-body macrophages, a specialized group of phagocytes that 
clear dying B cells during GC selection, are also found throughout the GC [14].  




Figure 1.4 Schematic representation of a GC reaction in a lymph node. 
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GC B cells are the fastest dividing mammalian cells with a cell cycle between 6 and 12 
hours [14, 16-19]. GC B cells express the enzyme activation-induced cytidine 
deaminase (AID), which is essential for SHM and class-switch recombination (CSR). 
SHM is a process characterised by the introduction of single point mutations in hot 
spots within the Ig variable genes which encode for the antigen-binding region of the 
antibody, resulting in an increased antibody affinity for antigens [20, 21]. Following 
SHM, B cells undergo CSR which affects the constant Ig region resulting in the 
production of different Ig isotypes (IgG, IgE, and IgA) responsible for the effector 
capacity of the antibody (Figure 1.5A) [22].  
The transcriptional factor Bcl-6 is another important regulator of the GC B cell 
phenotype, and is upregulated during the GC reaction. This transcriptional factor has 
different functions. First, it silences the anti-apoptotic molecule Bcl-2 in GC B cells, a 
way to prevent autoimmunity that could arise as a result of SHM. Second, Bcl-6 
contributes to the ability of GC B cells to tolerate DNA damage, as consequence of 
rapid proliferation and AID activity. Third, Bcl-6 silences the regulator of plasma cell 
differentiation Blimp-1 as well as key mediators associated with both the B cell 
receptor (BCR) and the CD40 signalling [14]. 
Bcl-6 expression is not only restricted to GC B cells but is expressed also by a subset of 
T cells, called T follicular helper cells (TFH cells). TFH cells are an important subset of 
effector T cells in the GC which provide a helper function to B cells. For long time the 
subset of T cells considered important in providing B cell help were the Th2 cells 
producing cytokines like IL-4 and inducing isotype switching to IgG and IgE [23]. 
Nowadays, it is apparent that TFH cells are the real helper T cells to antigen-specific 
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naïve B cells. TFH cells are different from Th1 and Th2 cells by several conditions, i.e., 
expression of the chemokine receptor CXCR5, localization in the B cell follicle, 
transcription factor (Bcl-6), and function [23]. Regarding their function, TFH cells release 
IL-21 a helper cytokine which support B cell proliferation, isotype switching, and 
differentiation [23].  
Another important component of the GC is the FDC network. FDCs retain unprocessed 
antigen on their surface in the form of immune complexes, and are believed to serve 
as an antigen reservoir during the GC reaction [14, 24, 25]. FDCs are also thought to 
support GCs by secreting chemokines and cytokines. Indeed, FDCs produce CXCL13 
which is the major chemoattractant for B cells and follicular T cells. They also express 
cytokines such as IL-6 and BAFF (B cell-activating factor belonging to the TNF family), 
the latter being an important B cell survival factor that promotes the survival and 
differentiation of B cells in vitro and in vivo [14].  
1.1.4.2 Activation induced cytidine deaminase (AID).  
As reported above, AID is essential for SHM of the antibody variable regions and CSR of 
the constant regions. AID belongs to a family of cytidine deaminases sharing sequence 
homology with the RNA editing cytidine deaminase APOBEC1 (apolipoprotein B mRNA-
editing enzyme, catalytic polypeptide 1) (Figure 1.5B, top panel) [26]. Both SHM and 
CSR are started by AID by converting deoxycytidine (dC) to deoxyuracil (dU) [26]. The 
U:G mismatches can be then processed and removed by several mechanisms (Figure 
1.5B, bottom panel). Normally, the mechanisms used to repair the mismatches are the 
base excision repair (BER) and the mismatch repair (MMR) pathways. The first one is 
Page | 34  
 
considered the main pathway during which the deoxyuridine in the switch (S) region 
DNA introduced by AID, is removed by the uracil DNA glycosylase (UNG) enzyme that 
generates an abasic site processed by the apurinic/apyrimidinic endonuclease 1 
(APE1). The nicks generated are finally processed creating a blunt double strand break 
(DSB) that can then be ligated to other breaks on downstream S region DNA to 
complete CSR process [27]. The MMR machinery includes the mutS homologue 1 
(MSH1), MSH6, exonuclease 1 (EXO1), mutL homologue 1 (MLH1) and post-mitotic 
segregation (PMS) proteins which introduce nicks on S region DNA, that are then 
processed similarly to the BER pathway [27]. AID targets the DNA not randomly but on 
specific hotspots defined by the sequences DGYW or WRC (D=A, G or T; Y=C or T; W=A 
or T; R=A or G) and they reverse complements [28]. AID expression is normally 
restricted to GC B cells undergoing CSR and SHM but also to a new subset of B cells, 
called interfollicular (IF) large B cells which will be described in Chapter 1.4.  
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Figure 1.5 Rearrangement of the Ig heavy chain locus.  
(A) Schematic representation of V(D)J recombination which assembles the variable (V), diversity (D) and joining (J) gene segments in the 
bone marrow. In the periphery somatic hypermutation (SHM) and class-switch recombination (CSR) occur and they are both dependent 
on the B cell specific enzyme activation induced cytidine deaminase (AID). CSR exchanges the C constant region for downstream 
constant regions, such as C, C or C. (B) Top: AID structure is shown. It consists of a nuclear-localization sequence (NLS), a nuclear-
export sequence (NES), and other domains based on the structure of APOBEC1 (apolipoprotein B mRNA-editing enzyme, catalytic 
polypeptide 1) with whom AID shares sequence homology. Bottom: the mechanisms used to repair the U-G mismatch introduced by AID 
are represented (on the right, base excision repair pathway (BER) and on the left, mismatch repair (MMR) pathway). Processing the 
mismatches can lead to double stranded breaks (DSBs) formation and then to class-switch recombination. 
Source: adapted from Chaudhuri and Alt, Nature Reviews Immunology and Kinoshita and Honjo, Nature Reviews Molecular Cell Biology 2  
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1.1.4.3 Extrafollicular antibody production. 
Extrafollicular antibody responses are considered the quickest way to produce 
antibodies after antigen encounter. It can be divided into several phases. After antigen 
binding, B cells migrate to the T cell rich area of the SLOs (primarily the spleen or 
Peyer’s patches in the gut) where they interact with antigen-primed T cells. This 
interaction induces local growth of both cell subsets. After two cell cycles, the B blasts 
which were induced to become plasmablasts move to the local extrafollicular site 
where they proliferate and eventually differentiate into short-lived plasma cells 
without contact with T cells [29]. Extrafollicular foci can last only for few days, whereas 
GCs persist for weeks. The signals that lead the B cells to GC formation or to 
extrafollicular growth as plasmablasts are not well defined. It has been proposed that 
certain antigens may preferentially recruit one subset of B cells (i.e. marginal-zone like 
B cells) to extrafollicular growth and another subset (i.e. follicular B cells) to follicular 
differentiation but without absolute restriction to a single B cell subset [29]. 
Additionally, it has been suggested that cells with high affinity BCR move to 
extrafollicular sites where they differentiate into short-lived plasma cells, whereas low 
affinity B cells are more common in the GC environment that gives rise to long-lived 
plasma cells and quiescent memory B cells, thus providing long-term immunological 
protection [30, 31].  
1.1.5 Self-tolerance checkpoints during B cell development. 
In 1901 Paul Ehrlich was the first to speculate that an individual is able to produce toxic 
autoantibodies. He suggested that the immune system can discriminate between self- 
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and non self-antigens thus preventing the so called “horror autotoxicus” [32]. To avoid 
the development of autoimmune diseases, the immune system has introduced several 
mechanisms to discriminate between potentially dangerous autoantibodies and 
protective antibodies [31]. As described above, during B cell development the main 
mechanisms that remove or silence self-reactive antibodies are mainly three: receptor 
editing, deletion and anergy. The maintenance of self-tolerance in the human antibody 
system is of critical importance since a large number of autoimmune diseases (i.e., 
systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren’s syndrome 
(SS), multiple sclerosis, myasthenia gravis, Graves’ disease, and others) are 
characterised by high titers of autoantibodies in the patients’ sera, reflecting a failure 
in the self-tolerance mechanisms that control the production of autoreactive B cells, 
thus underlying abnormalities in B cell self-tolerance checkpoints [31]. 
In order to characterise the number of human B cells that produces autoantibodies at 
each step of differentiation and thus to understand how the generation of 
autoreactive B cells is regulated, Michel Nussenzweig with his fellows Hedda 
Wardemann and Eric Meffre developed an approach to clone and express recombinant 
antibodies from single B cells at different stages of their development (see paragraph 
1.1.5 and Chapter 2) [33, 34]. They found that a large percentage (55%) of newly 
generated early immature B cells in the human bone marrow are polyreactive towards 
different self- and non-self antigens such as DNA, lipopolysaccharides (LPS), and insulin 
while up to 75% are self-reactive against nuclear antigens (ANA reactivity) (Figure 1.6) 
[33]. These percentages strongly decrease during the transition from early immature B 
cells to immature B cells (55 to 7% for polyreactivity and 75 to 40% for ANA reactivity, 
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first self-tolerance checkpoint). It has been proposed that Ig receptor editing has the 
major role during this first checkpoint in the bone marrow [31, 33, 35]. Indeed, in vitro 
studies in humans have revealed that autoreactive antibodies in the early immature B 
cell compartment can go through receptor editing with Ig light chain replacement to 
regain a normal phenotype [31, 36-38]. Moreover, the same group discovered a 
second self-tolerance checkpoint during the differentiation from transitional to mature 
naïve B cells. During this transition the number of ANA reactive B cells decreases 
significantly [33]. However, 20% of mature naïve B cells still display low levels of self-
reactivity and 6% are polyreactive [33]. This physiological small percentage of 
polyreactive and autoreactive circulating naïve B cells is believed to form a reservoir of 
“natural” antibodies, to contribute to peripheral T cell tolerance and to play an 
important role in the immediate response to invading pathogens [39]. A third self-
tolerance checkpoint ensures the removal of most poly- and self-reactive antibodies 
during the IgM+ memory B cell differentiation (pre-GC checkpoint). However, B cells 
can acquire again poly- and self-reactivity during the GC reaction as consequence of 
somatic hypermutation. As a result, polyreactivity increases to 20% and self-reactivity 
to 40% in the IgG+ memory B cell subset [40]. Finally, a fourth tolerance checkpoint 
has been suggested in order to ensure that only a small fraction of the memory B cell 
antibodies is polyreactive and non-pathogenic [39]. 
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Figure 1.6 Tolerance checkpoints during human B cell development.  
Newly generated early immature B cells in the bone marrow of healthy donors express 
polyreactive (55%) and self-reactive antibodies (75%). Highly polyreactive and self-
reactive antibodies are efficiently removed at the first tolerance checkpoint, leading to 
a significant reduction in polyreactivity (7%) in immature B cells in the bone marrow. 
However, a significant percentage of immature B cells retain low levels of self-
reactivity (43%). Self-reactive immature B cells leave the bone marrow as new-
emigrant B cells moving to the peripheral blood. In the periphery, counterselection of 
self-reactive new emigrant B cells occurs again at the second tolerance checkpoint 
before maturation into naïve B cells (~6% polyreactivity and ~20% self-reactivity). 
Polyreactive and self-reactive B cells are efficiently removed from the circulating IgM+ 
memory B cell compartment at a third tolerance checkpoint. However, polyreactivity 
and self-reactivity increase again in circulating IgG+ memory B cells (45% and 22%, 
respectively), the majority of which acquires self-reactivity as a consequence of 
somatic mutation. The last tolerance checkpoint counterselects the entrance of 
polyreactive and self-reactive memory B cells into the long lived plasma cell 
compartment [33, 39, 40]. 
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1.1.5.1 Disturbances of self-tolerance checkpoints during 
autoimmune diseases. 
Several groups have demonstrated that tolerance checkpoints are defective in patients 
with autoimmune diseases, i.e. SLE [41, 42], RA [43] , and type 1 diabetes [44]. The loss 
of self-tolerance that leads to the accumulation of autoreactive and polyreactive 
antibodies is associated with defects in the first and/or second tolerance checkpoint. 
Abnormalities in the first tolerance checkpoint are reflected by abnormalities in the 
immature B cell compartment in the bone marrow [31]. Since the antibody repertoire 
of new emigrant B cells is similar to that of immature B cells [33], defects in the first 
checkpoint are normally associated with abnormalities in the new emigrant B cell 
subset. Conversely, increased level of poly- and self-reactivity in the mature naïve B 
cell compartment reveals abnormalities in the second self-tolerance checkpoint [31]. 
Using the single cell cloning strategy to generate recombinant antibodies from B cells 
isolated from SLE patients, the Nussenzweig laboratory found an increased number of 
self-reactive and polyreactive antibodies in both the new emigrant and mature naïve B 
cell compartments [42]. Similar results were obtained by the Meffre laboratory in RA 
patients using the same technique. They showed that autoreactive B cells increase 
significantly between 30 and 50% in the mature naïve B cell compartment of RA 
patients compared to normal individuals (20%, see Figure 1.6) [43]. This abnormal 
accumulation is most likely the result of early defects in central self-tolerance 
checkpoint in the bone marrow, as demonstrated by increased autoreactivity of new 
bone marrow emigrant B cells, also associated with peripheral defects in reducing 
autoreactive B cells from the mature naïve recirculating B cell pool [43]. Despite the 
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evidence that the naïve B cell compartment is enriched with poly- and self-reactive 
antibodies in patients with different autoimmune diseases, whether similar defects in 
the B cell self-tolerance checkpoints in early stages of the B cell development are also 
associated with SS is currently unknown.  
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1.2 Humoral autoimmunity in Sjögren’s syndrome. 
1.2.1 Introduction. 
The first description of Sjögren’s syndrome (SS) is generally associated with Mikulicz 
who in 1892 described a case study of a patient with enlargement of parotid and 
lacrimal glands characterised by a small-round-cell infiltrate [45]. However, the first 
report of the disease, today known as SS, was given in 1932 by Henrick Sjögren, a 
Swedish ophthalmologist who described a triad of keratoconjunctivitis sicca, 
xerostomia and rheumatoid arthritis (RA). 
SS is a chronic autoimmune disease characterised by immune cell infiltration of the 
exocrine glands leading to glandular dysfunction with clinical symptoms of xerostomia 
(dry mouth) and keratoconjuctivitis (dry eyes), autoantibodies production and 
extraglandular systemic manifestations, including fatigue, arthritis and diverse organs 
involvement [46]. Moreover, it has been estimated that around 5% of patients with SS 
develop extranodal B cell lymphomas [47]. SS can be primary (pSS), or it can occur 
secondary to various other autoimmune diseases, such as RA, scleroderma, or systemic 
lupus erythematosus (SLE).  
1.2.2 Sjögren’s syndrome classification criteria. 
Several classification criteria of SS have been proposed in the last 30 years. The most 
accepted and better validated criteria for SS are those included in the revised version 
of 2002 of the European criteria proposed by the American-European Consensus 
Group [48]. The American-European criteria consist of six elements; each of them is 
Page | 43  
 
divided into one to three criteria (Table 1.1). The criteria combine symptoms of dry 
eyes and dry mouth, ocular signs, e.g., Schirmer’s test positivity which measures the 
reduction of tear flow, histopathology characterisation with positive minor salivary 
glands biopsy results (according to Chisholm and Mason focus score [49]), and the 
presence of anti-Ro/SSA and/or anti-La/SSB autoantibodies [48]. Diagnosis of primary 
SS requires four out of six of these criteria. One of these four criteria must include a 
positive salivary gland biopsy or the presence of autoantibodies [50]. 
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 Revised international classification criteria for Sjögren’s syndrome 
I. Ocular symptoms (at least one positive response to one of the following question) 
 
1. Have you had daily, persistent, troublesome dry eyes for more than three 
months? 
 
2. Do you have a recurrent sensation of sand or gravel in the eyes? 
 
3. Do you use tear substitutes more than 3 times a day? 
II. Oral symptoms (at least one positive response to one of the following question) 
 
1. Have you had a daily feeling of dry mouth for more than three months? 
 
2. Have you had recurrently or persistently swollen salivary glands as an adult? 
 
3. Do you frequently drink liquids to aid in swallowing dry food? 
III. Ocular sign - at least one of the following two tests: 
 
1. Schirmer's test, performed without anaesthesia (≤ 5 mm in 5 minutes) 
 
2. Rose bengal score or other ocular dye score 
IV. Histopathology. In minor salivary glands focal lymphocytic sialoadenitis with a focus 
score ≥ 1, defined as a number of lymphocytic foci per 4 mm
2
 of glandular tissue  
V. Salivary gland involvement. Objective evidence of salivary gland involvement defined by 
a positive result for at least one of the following  diagnostic tests:   
 
1. Unstimulated whole salivary flow (≤ 1.5 ml in 15 minutes) 
 
2. Parotid sialography 
 
3. Salivary scintigraphy 
VI. Autoantibodies: presence in the serum of the following autoantibodies: 
  1. Antibodies to Ro(SSA) or La(SSB) antigens, or both 
Exclusion criteria 
Past head and neck radiation treatment 
Hepatitis C infection 
Acquired immunodeficiency disease (AIDS) 
Pre-existing lymphoma 
Sarcoidosis 
Graft versus host disease 
Use of anticholinergic drugs (since a time shorter than 4-fold the half life of the drug) 
Table 1.1 Classification criteria for Sjögren’s syndrome [48]. 
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1.2.3 Aetiology. 
The aetiology of SS is unknown. However, similarly to the majority of autoimmune 
disorders, it is likely that a multifactorial combination of genetic background, gender, 
immunological alterations and environmental factors is implicated in the disease 
development.  
1.2.3.1 Genetic background.  
A strong association to specific MHC alleles has been shown in SS, in particular HLA-
DR3, HLA-B8 and HLA-Dw3 has been observed in patients affected by primary SS 
compared with normal individuals [51, 52]. In addition, an association between the 
haplotype DR3-DQA1*0501-DQB1*02 and the production of anti-Ro/La antibodies in 
patients affected by SS and SLE has been reported, suggesting a partial overlap in the 
genetic background of these diseases and in the immunological abnormalities leading 
to the production of the Ro/La autoantibody specificities [53]. More recently, 
associations of gene polymorphisms outside the HLA-locus in SS have been 
characterised. In particular, association of IRF5 and STAT4 gene variants have been 
found in a cohort of SS patients; both genes are components of the interferon type-I 
(IFN-I) pathway [52]. 
1.2.3.2 Environmental factors.  
Infection agents have been particularly linked to SS development. Glandular viral 
infection could induce activation of HLA-independent innate immune system through 
Toll-like receptors, leading to inflammatory cytokines production [54]. 
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Cytomegalovirus, Hepatitis C virus (HCV, currently among the exclusion criteria for SS), 
Human Immunodeficiency virus (HIV) and Human T Cell Leukemia Virus type 1 (HTLV-
1) have all been associated with the development of a chronic sialadenitis that mimics 
SS and the occurrence of a SS-like syndrome in humans and in mouse models [52]. 
Epstein-Barr virus (EBV) has been shown to be present as a latent infection in human 
salivary glands [55] and, upon reactivation, EBV seems able to induce T cell-dependent 
B cell activation together with cytokine production [46, 56].   
1.2.3.3 Gender. 
SS is characterised by a strong female prevalence - the female:male ratio is 9:1, 
suggesting the presence of sex-specific predisposing factors. It most commonly affects 
women aged 40-60. Lack of estrogens has been associated with predisposition to 
develop SS. This data has been supported by the fact that in the majority of patients 
the disease is expressed in the perimenopausal period of life of women [52]. 
Moreover, studies in normal mice and in murine experimental models showed that 
estrogens can suppress the development of SS, enhance T cell recruitment in salivary 
glands and prevent cell death in the lacrimal glands [52, 57, 58].  
1.2.4 Extraglandular systemic manifestations. 
Besides exocrine glands, SS can affect several other organs including joint, skin, gut, 
respiratory tract, and neurological system. A briefly overview of the main conditions 
associated with SS will be reported in the following section.  
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 Joint involvement in SS is common, especially among women and it affects mainly 
small joints, symmetrically associated with mild synovitis. The development of a 
proper erosive arthritis has been rarely reported [59].  
 The skin is not infrequently involved in patients with SS. Raynaud’s phenomenon 
can occur in one third of SS patients [60]. Less common skin manifestations include 
vasculitis which can affect small and medium sized vessels, urticaria vasculitis and 
annular vasculitis.  
 The most common gastrointestinal manifestation is dysphagia, i.e. difficulty in 
swallowing [61]. Association with primary biliary cirrhosis as well as coeliac disease has 
been also observed in patients with SS [62]. Signs of sicca syndrome, presence of anti-
nuclear antibodies (ANA), mixed cryoglobulinemia, anti-mitochondrial antibodies, anti-
Ro/SSA, rheumatoid factor and development of salivary gland infiltrates have been 
correlated with liver dysfunction during HCV infection [63, 64].  
 Respiratory tract manifestations of the upper airways have been widely correlated 
with the decreased function of the glands of the nose, trachea and bronchi [65]. Lower 
respiratory tract involvements are associated with lymphocytic interstitial 
pneumonitis, rarely with alveolitis and mild obstructive or restrictive pulmonary deficit 
[66].  
 Neurological manifestations can involve both the central and more commonly the 
peripheral nervous system, including peripheral neuropathy, mononeuropathy and 
autonomic neuropathy [45]. 
 There is an increased risk of congenital heart block in babies with mothers positive 
for anti-Ro/SSA autoantibodies  
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 Autoimmune hypothyroidism is commonly associated SS [45]. 
 Patients with SS have an increased risk of developing lymphoma (up to 44 fold). 
Usually the lymphoma arises within the major salivary glands (e.g., parotids) and most 
often is a low-grade marginal zone B cell lymphoma of the mucosa-associated 
lymphoid tissue (MALT-L) [67].  
1.2.5 Immunopathogenesis of salivary gland inflammation. 
Salivary gland inflammation during SS is sustained by the upregulation of adhesion 
molecules and the production of several chemokines and cytokines which lead to the 
migration into the gland of immune cells [54]. Beside the immune cell component, 
epithelial cells in SS have also an active role in the initiation and perpetuation of 
inflammation and the disease has also been described as an “autoimmune epithelitis”. 
The upregulation of adhesion molecules and the production of chemokines, cytokines, 
and B cell survival factors such as BAFF by the epithelial cells is related to their 
potential role in promoting an aberrant migration, survival and proliferation of DCs, T 
cells and B cells in the inflamed SG [54]. T cells and DCs in the salivary gland contribute 
to the production of inflammatory cytokines (e.g., IL-1, IFN-, TNF) and thus to 
enhance the dysregulation and induction of epithelial cell apoptosis. Through 
apoptosis the epithelial cells present intracellular autoantigens, such as Ro/SSA and 
La/SSB which promote the production of autoantibodies by the B cell infiltrates [54]. 
1.2.5.1 Organization of the inflammatory infiltrates. 
Although SS is defined as systemic autoimmune disease, it can be included within the 
organ-specific autoimmune disorders since it affects mainly exocrine glands. In 
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particular, minor salivary glands have been selected as histological readout for SS since 
they are commonly involved in the disease course and for the easy accessibility to their 
tissue during surgical procedures. Salivary glands (Figure 1.8) can be divided in major 
(parotid, submandibular and sublingual) and minor glands (labial, buccal and palatine). 
The acini represent the secretory component within the glands.  
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Figure 1.7 Salivary gland illustration.  
(1) Parotid, (2) submandibular gland and (3) sublingual gland. 
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In particular, in SS glands, focal infiltrates of T and B cells, DCs and macrophages 
organize characteristically around ductal epithelial cells, particularly of striated and 
intercalated ducts. The definition of focal infiltrates follows the classification originally 
described by Chisholm and Mason, and refers to a periductal aggregate of at least 50 
mononuclear cell/4mm2 [49, 68]. Hence, T and B lymphocytes play a central role in the 
immunopathogenesis of this disease, though which set of lymphocytes has the 
principal role is still debated [69]. It has been proposed that T cells may play the 
principal role in the early immunopathogenesis of SS while there are strong evidences 
to suggest that B cells play the leading role in this autoimmune disease at later stages 
of chronicity, i.e. by promoting a local immune responses to allo- and auto- antigens by 
antibody-dependent and antibody-independent mechanisms [69, 70]. Indeed, around 
20-30% of the infiltrating cellular component within the gland is constituted by B cells 
[71] and normally, during the expansion and organization of the periductal 
inflammatory focus, a progressive increase in the number of recruited B cells can be 
observed. In a number of SS patients, B and T lymphocytes can become highly 
organized, with T/B compartmentalization, and in around 30-40% of SS minor (labial) 
salivary glands the presence of ectopic germinal centers (GC)-like structures 
characterised by CD21+ follicular dendritic cells (FDCs) networks formation and 
peripheral node addressin (PNAd) expression has been demonstrated (Figure 1.7) [72, 
73]. This phenomenon is known as ectopic lymphoid neogenesis and has been 
described in several chronic inflammatory conditions and often related to the 
development of autoantibodies and to a more severe disease outcome [74]. In several 
chronic inflammatory conditions the formation and maintenance of these ectopic 
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lymphoid structures (ELS) is critically dependent on the ectopic expression of 
lymphotoxins (LT) and lymphoid chemokines CXCL13, CCL19, CCL21 and CXCL12 (see 
Chapter 1.4).  
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Figure 1.8 Ectopic GC-like structures in minor salivary glands (mSGs) of SS patients. 
Representative example of ectopic GC-like structure in SS mSG is shown. Ectopic GCs are characterized by the classical T/B cell 
segregation, CD21+ FDC network formation and AID expression within the FDC network. Left panel: staining for CD3 (brown) and CD20 
(purple); middle panel: staining for CD21 (purple) and Bcl-2 (brown); right panel: single staining for AID (purple). 
Source: Bombardieri et al., The Journal of Immunology 2007 
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It has also been shown that ELS in SS are functional in promoting Ag-driven B cell 
activation, selection and proliferation with the in situ production of autoantibodies 
[73].  
Physiologically, antigen-driven BCR selection via affinity maturation takes place within 
GC of SLOs where the processes of SHM and CSR of the Ig genes occur, as explained in 
Chapter 1.1. As previously reported, both CSR and SHM are initiated by and critically 
dependent on the expression of AID [75]. The important demonstration that AID is 
expressed in ELS both in minor SGs and parotids of SS patients has provided evidence 
that these structure are functional and provide the microstructural, molecular and 
cellular environment to sustain Ag-driven B cell activation and autoantibody 
production [73]. 
1.2.5.2 Peripheral B cell disturbances in patients with Sjögren's 
syndrome. 
A significant advance on our understanding of B cell dysregulation in autoimmune 
diseases such as SS and RA, has been recently provided by studies focussing on 
quantitative and qualitative analysis of B cells subpopulations (i.e., frequency of 
autoreactive B cells) and peripheral B cell abnormalities. In humans, circulating B cell 
subsets are divided into three main groups based on the levels of CD27 expression [76, 
77]. CD27 is a tumor necrosis factor receptor expressed on B and also T cells. It binds 
to ligand CD70 which is expressed on T cells (mainly activated CD4+ T cells) and 
activated B cells. The CD27/CD70 interaction is involved in the differentiation of B cells 
into plasma cells [78].  
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The three groups can be divided as follow: 
1) CD27- B cells (~70% of circulating B cells) which include resting naïve Bm1 
(IgM+IgD+CD23-), activated naïve Bm2 (IgM+IgD+CD23+) and pre-germinal center 
(IgD+CD38++CD10+) B cells; 
2) CD27+ B cells (~30% of circulating B cells) which comprise early memory eBm5 
(IgM+IgD+CD38+), memory Bm5 (IgM+IgD-CD38-CD77-CD44+), memory unswitched 
(IgD+CD38-) and switched (IgD-CD38-) B cells and plasmablast (CD138-). 
3) The CD27high group (~1% of circulating B cells) is formed by early plasma cells 
(CD138+).  
The recognition of different B cell subpopulations has led to the discovery that several 
autoimmune diseases display altered frequency of B cells subsets in the peripheral 
blood [76, 79-81]. In particular, patients with pSS are characterised by typical B cell 
disturbances with a predominance of circulating CD27- naïve B cells and a dramatic 
reduction of the percentage and total number of CD27+ memory B cells in the 
peripheral blood compared to healthy individuals [82]. The decrease in circulating 
memory B cells has been explained as a result of accumulation in the affected salivary 
glands [82], where lesional memory B cells have been shown to be characterised by 
heavily mutated VH genes and evidence of ongoing clonal diversification, strongly 
suggesting a local antigen-driven process [72]. The distribution of peripheral B cell 
subpopulations in patients with secondary SS is determined mainly by the associated 
rheumatic disorders [47]. 
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1.2.5.3 Autoantibodies in Sjögren's syndrome. 
SS is characterised by both organ specific and non-specific autoantibodies. Historically, 
anti-Ro/SSA and anti-La/SSB have been considered the two major autoantibodies 
associated with humoral autoimmunity in patients with SS but are also commonly 
detected in sera of patients with SLE. Other autoantibodies found in the sera of 
patients with SS include anti-nuclear antibodies (ANA), rheumatoid factor (RF), type II 
cryoglobulins (displaying monoclonal RF) and less frequently anti-mitochondrial 
antibodies (AMA), anti-centromere antibodies, and anti-smooth muscle antibodies 
[83]. In addition, other autoantibodies, including those against alpha-fodrin, carbonic 
anhydrase II and the muscarinic acetylcholine receptor 3 (M3R), have been described 
in patients with SS and suggested to exert a pathogenic role in this disease (i.e., 
inducing salivary dysfunction), especially the latter [84-87]. 
1.2.5.4 Anti-Ro/SSA and anti-La/SSB autoantibodies.  
Anti-Ro/SSA and anti-La/SSB antibodies are directed against a complex of proteins (Ro 
52 kDa, Ro 60 kDa and La 48 KDa) and small uridine-rich hY RNAs which are short (85-
112 nt) RNA polymerase III transcripts [83, 88]. The protein component of both 
antigens is responsible for the immunogenicity since the autoantibodies are unable to 
recognise the isolated RNA molecules. 
The protein part of the Ro antigen is mainly represented by the 60 KDa (528 amino 
acids) and 52 KDa (475 amino acids) proteins. Ro60 seems to be involved in the post-
transcriptional regulation of 5S ribosomal RNA and other RNA polymerase III 
transcripts [83, 89]. Ro52 is a E3 ligase involved in ubiquitination [83, 90]. La is a 
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phosphoprotein (408 amino acids) with the capacity to bind the 3’ uridine part 
common in all nascent RNA polymerase III transcripts, as well as the EBV RNAs EBER I 
and II and adenoviral VA RNAs [83, 88]. Its function is also associated with the 
regulation of RNA polymerase III transcription [83]. 
Anti-Ro/SSA and anti-La/SSB antibodies are found in around 60% and 40% of patients 
with SS, respectively. Normally, anti-Ro/SSA antibodies are detected either alone or in 
combination with anti-La/SSB, while anti-La/SSB are rarely found without anti-Ro/SSA 
[83, 88]. As mentioned above, both autoantibodies are part of the current 
classification criteria for SS and they are normally used as first screening to support the 
diagnosis of SS in patients suspected to suffer from this disease. Several techniques are 
used to detect anti-Ro/SSA and anti-La/SSB autoantibodies in clinical diagnostic. 
Normally, before anti-Ro/La determination, sera are screened by indirect 
immunofluorescence (IIF) assay on Hep-2 cells. Although both antibodies normally 
show a speckled nuclear pattern by IIF, there are evidence that anti-Ro antibodies can 
react with a fibrous cytoplasmic network similar to cytokeratin [91]. Thus, the 
presence of both autoantibodies is preferentially assessed using other methods, such 
as enzyme-linked immunosorbent assay (ELISA) which has been estimated to have a 
sensitivity of 72% and a specificity of 95%, Western blotting and immunodiffusion 
which are less routinely used due to the lower sensitivity and more complex procedure 
[83].  
Finally, the increased risk to develop neonatal lupus and/or congenital heart block in a 
small minority of pregnant women positive for Ro antibodies is particular important 
among the several clinical manifestations associated with these autoantibodies, i.e., 
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palpable purpura, lymphopenia, hypergammaglobulinemia and minor salivary gland 
infiltration [92, 93]. It has been proposed that maternal anti-Ro antibodies could cross 
the placenta and in this way damage the fetal cardiac conduction system [83].  
1.2.5.5 Anti-muscarinic acetylcholine receptor 3 (M3R) 
autoantibodies. 
To date no specific pathological autoantibodies have been identified in patients with 
SS. However, recent studies have proposed a possible role of autoantibodies directed 
against a muscarinic receptor in inducing glandular dysfunction in SS patients. 
Identification of pathogenic autoantibodies would be an important step in the 
management of SS for three main reasons: (i) their identification could form the basis 
for a diagnostic test, (ii) removal of the pathogenic antibodies could constitute a 
therapy for the patients, and (iii) better knowledge about the pathogenesis of SS could 
lead to the development of new therapies [84].  
Muscarinic receptors (MR) are G-proteins coupled acetylcholine receptors [83]. So far, 
five subtypes of MR (M1R-M5R) have been identified; in particular, M3R seems to play 
important roles in endocrine and exocrine gland secretion (i.e., activation of salivary 
and lachrymal glands), smooth muscle contraction, and calcium concentration in the 
vascular endothelium [83, 94]. M3R expressed on salivary gland cells is activated by 
acetylcholine binding, inducing an increase in Ca2+ via inositol 1, 4, 5-trisphosphate 
(IP3) and IP3 receptor. This event activates the apical membrane Cl- channels to induce 
saliva secretion. M3R activation also induces the aquaporin 5 (AQP5) water channel to 
move from the cytosol to the apical membrane, causing a rapid transport of water 
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across the cell membrane [87]. M3R is characterised by four extracellular domains. 
Recently, it has been suggested that among all these domains, the second extracellular 
loop may be responsible for the immunogenicity, meaning that anti-M3R 
autoantibodies against the second extracellular loop could contribute to the salivary 
dysfunction in patients with SS [87]. 
1.2.6 Treatment. 
Untreated dry mouth and dry eyes symptoms in patients with SS can lead to oral 
diseases (i.e., dental loss, oral candidiasis, and periodontal disease) and corneal ulcers 
/perforation, respectively [95]. When other organs are affected, a delay in the therapy 
can potentially result, although rarely, in organ failure and death such as in the case of 
vasculitic lesions or active glomerulonephritis. Moreover, patients with SS have a 
higher risk to develop lymphoma than healthy individuals, as previously highlighted, a 
factor directly influencing morbidity and mortality in SS. 
Dry eyes symptoms are normally treated with preservative-free teardrops, whereas for 
dry mouth mechanical or gustatory stimulations are used first [95]. However, the 
production of saliva can be increased by drugs such as pilocarpine and cevimeline 
which are muscarinic agonists.  
Systemic therapy is directed by the extent of the extraglandular involvement and more 
in general disease severity. For instance, if a patient develops articular involvement, 
non-steroidal anti-inflammatory drugs (NSAIDs) can be used to provide relief from 
minor symptoms while methotrexate may be prescribed in the presence of 
inflammatory arthritis. To treat chronic symptoms, hydroxychloroquine can be used to 
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ameliorate fatigue, arthralgias, and myalgias symptoms. Finally, B cell targeted 
therapies (rituximab and belimumab) have shown to be more promising therapies 
compared to TNF blockers which are not efficacious in patients with SS. However, such 
B cell modulating agents are not routinely available for the treatment of SS in the NHS 
setting. 
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1.3 Humoral autoimmunity in Rheumatoid Arthritis. 
1.3.1 Introduction. 
Rheumatoid arthritis (RA) is the most common inflammatory erosive polyarthritis, 
affecting around 1% of the worldwide population. RA is associated with progressive 
disability, systemic complication - including cardiovascular, pulmonary, psychological, 
and skeletal disorders, early death, and socioeconomic costs [96, 97]. In RA, the lining 
of the joints - the synovium turns to be the site of an ongoing heterogeneous 
infiltration of leukocytes, synovial lining hyperplasia, and neovascularisation, which 
leads to cartilage destruction, bone erosion and, eventually, joint disability. The 
synovium is a loose connective tissue which is found between the joint capsule and the 
joint cavity of arthrodial joints (Figure 1.9). The normal synovium is composed mainly 
by two distinct layers: the intimal lining layer and the synovial sublining layer. The 
intimal lining layer is mainly composed by fibroblast-like synoviocytes and 
macrophages. The sublining layer is made of connective tissue containing blood 
vessels, fibroblast, adipocytes, and some resident immune cells like macrophages and 
mast cells [98]. During chronic inflammation the intimal lining layer is characterized by 
marked hyperplasia, whereas the sublining layer is the site of massive infiltration of 
immune cells (Figure 1.9).  
RA is also characterised by the presence of circulating autoantibodies such as 
rheumatoid factor (RF) and anti-citrullinated peptide/protein antibodies (ACPA), 
strongly suggesting an autoimmune pathogenesis.  
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1.3.2 Classification criteria for rheumatoid arthritis. 
The first classification criteria used to define RA were the 1987 American College of 
Rheumatology (ACR) criteria [99]. Although well accepted, these criteria had a 
significant limitation since they were helpful to discriminate only between patients 
with already established RA from those with other rheumatological diseases [100]. 
Therefore, in 2010 the American College of Rheumatology and the European League 
Against Rheumatism introduced the 2010 ACR/EULAR RA classification criteria in order 
to facilitate the study of patients at early stage of disease [100]. The new criteria give a 
score for each patient between 0 and 10. If the total score based on four different 
observations is 6 or higher the patient is classified unequivocally as an RA patient as 
long as the patient show at least one joint with synovitis (swelling) that cannot be 
explained by a different disease [100]. The four observations include (I) joint 
involvement, (II) serology, (III) acute phase reactants, and (IV) duration of arthritis 
(Table 1.2).   
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Figure 1.9 Normal and rheumatoid arthritis (RA) joint.  
Schematic structure of a healthy joint (left) and rheumatoid arthritis joint (right) is 
shown. The RA joint is characterised by marked hyperplasia and by massive infiltration 
of immune cells. 
Source: adapted from Strand et al. Nature Reviews Drug Discovery (2007) 
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Table 1.2 Classification criteria for rheumatoid arthritis [100]. 
 
Classification Criteria for RA 
A total score of 6≥10 is needed for classification as RA patients Score 
1. Joint involvement  
1 large joint 0 
2-10 large joints 1 
1-3 small joints 2 
4-10 small joints 3 
> 10 joints 5 
2. Serology 
 Negative RF and negative ACPA 0 
Low-positive RF or low-positive ACPA 2 
High-positive RF or high-positive ACPA 3 
3. Acute-phase reactants 
Normal C-reactive protein (CRP) and normal erythrocyte sedimentation rate (ESR) 0 0 
Abnormal CRP or normal ESR 1 1 
4. Duration of symptoms 
 <6 weeks 0 
≥6 weeks 1 
Clinical practice 
 ≥2 swollen joints 
 Morning stiffness lasting more than one hour for at least 6 weeks 
 Detection of RF and ACPA autoantibodies 
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1.3.3 Aetiology.  
The aetiology of RA is unknown. However, as seen for Sjögren’s syndrome in Chapter 
1.2 and other autoimmune diseases, a combination of genetic, environmental factors, 
gender and immunological alterations has been implicated in the development of RA.  
1.3.3.1 Genetic background.  
In RA the most relevant genetic risk factor is the class II MHC haplotype of an 
individual. In particular, certain human leukocyte antigen (HLA)-DRB1 alleles (HLA-
DRB1*01 and HLA-DRB1*04) that contain a common amino acid motif (QKRAA), known 
as shared epitope, have been strongly associated with susceptibility to develop RA, 
mainly in patients who are positive for RF or ACPA [96, 101]. Regarding non-HLA genes, 
among others, single nucleotide polymorphisms have been identified in loci related to 
immune regulation, involving nuclear factor B (NF-B)-dependent signalling (e.g., 
TRAF1-C5 and c-REL) and T-cell stimulation, activation, and differentiation genes (e.g., 
PTPN22 and CTLA4) [96], mostly in ACPA-positive patients.  
1.3.3.2 Environmental factors. 
Smoking increases the risk of RA mainly in people with susceptibility HLA-DRB1*04 
alleles. Citrullinated peptides have been detected in smoker RA patients, and this could 
induce the generation of ACPA in susceptible individuals [102]. Moreover, infectious 
agents (e.g. Porphyromonas gingivalis, Epstein-Barr virus, cytomegalovirus, Escherichia 
coli, Chlamydia and several other pathogens) have been linked with RA [96]. It has 
been proposed that the pathogen could start the disease through several mechanisms, 
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such as direct infection of the synovium, activation of innate immunity by TLRs 
activation, or molecular mimicry. 
1.3.3.3 Gender. 
RA is also predominant in women with a female:male ratio of 3:1. It has been 
proposed that the hormone milieu (i.e., the role of estrogens) can significantly 
influence some cells which are known to participate in RA pathogenesis. In particular, 
it has been shown that autoantibody-producing B cells are more resistant to apoptosis 
when they are exposed to estradiol, and that the fibroblast-like synoviocytes which 
express the estrogen receptor can increase the production of metalloproteinase when 
stimulated with estrogens [103]. Finally, one interesting finding is that during 
pregnancy RA patients often improve; although the mechanism of protection is not 
well defined. It is believed that a shift from Th1 to Th2-mediated immunity may play a 
role.  
1.3.4 Extra-articular manifestations of rheumatoid arthritis. 
RA is a systemic autoimmune disease. Thus, besides the joints, RA can affect many 
tissues and organs. A summary of the main systemic effects associated with RA is 
reported below. 
 Patients with RA are characterised by an increased risk of cardiovascular diseases, 
i.e. atherosclerosis, myocardial infarction, and stroke [104, 105]. Inflammatory 
mediators including cytokines (e.g., IL-6 and TNF-), immune complexes, and altered 
lipid particles are believed to be responsible for the increased cardiovascular risk in RA 
patients [96]. 
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 Inflammation in patients with RA can also affect the brain, liver, lungs, exocrine 
glands (secondary SS), muscles, and bones (osteoporosis) [96]. 
 The risk of lymphoma is enhanced in patients with RA and is strongly associated 
with inflammation [106, 107]. 
 Patients with RA are characterised by higher risk of developing lung cancer. The 
association between smoking and RA is a likely explanation although also inflammatory 
mediators may have an important role in conferring the increased risk of lung cancer 
[96]. 
1.3.5 B cell in rheumatoid arthritis.  
Several studies in the field of applied immunology, in particular focusing on synovial 
immune abnormalities, together with novel biological therapies targeting specific 
pathways have facilitated considerable progresses in understanding the pathogenesis 
of RA [108]. As outlined above, the hallmark of RA is infiltration of synovial tissue with 
mononuclear cells, mainly T cells, macrophages and B cells, together with synovial 
lining layer hyperplasia. In this paragraph, the role of B cells in the pathogenesis of RA 
is discussed. 
A pathogenic role for B cells has been confirmed without any reasonable doubt by the 
efficacy of rituximab (RTX) in the treatment of RA [96]. RTX is a chimeric monoclonal 
antibody formed by human IgG1 and kappa constant region and by mouse variable 
region. RTX binds the B cell surface antigen CD20, a B cell-specific calcium channel 
expressed in all B cell subsets except pro-B cells and plasma cells [109]. Since pro-B 
cells do not express CD20, after treatment with RTX the bone marrow can start to 
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repopulate B cells. Although effective in up to 60% of RA patients, the remaining 40% 
does not respond and most of the responsive patients relapse within 6-8 months after 
treatment. The mechanisms of resistance/relapse to RTX are currently unknown and 
are not directly dependent on peripheral B cell depletion, which is achieved in all 
cases. In particular, it is unclear whether disease relapse might be determined by B cell 
repopulation of the synovial membrane and whether this repopulation comes from the 
systemic circulation or from “escaped” clones surviving in “protected” synovial niches.  
In any case, efficacy of B cell depletion in RA has placed B cells at the centre stage in 
RA pathogenesis; thus understanding the mechanisms leading to their activation, 
particularly in the RA synovial tissues, is of critical importance.  
In approximately 30% of RA patients, the rheumatoid synovial tissues have been 
shown to acquire features of ectopic GC, such as follicular dendritic cell (FDC) network, 
T/B cell segregation and high endothelial vessels (HEV) formation [13, 110]. As seen for 
SS, these ectopic lymphoid structures (ELS) are functional tertiary lymphoid organs 
capable of sustaining the molecular machinery necessary for SHM and CSR [111]. This 
demonstration, confirmed when RA synovium is transplanted into SCID mice (*), shows 
a capacity for self-sustained proliferation of B cells and local autoantibody production 
in the absence of re-circulating immune cells. Although it is still unknown whether the 
same or different antigen(s) (Ag) drive the production of autoantibodies in the RA 
synovium vs SLOs, these findings support a direct pathogenic role for ELS in 
promoting/maintaining autoimmunity in RA. Furthermore, their presence may also 
explain why drugs that effectively clear B cells from the bloodstream, such as RTX, do 
not always produce a marked clinical improvement in RA. 
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(*) SCID mice 
Severe Combined Immunodefinciency (SCID) mice are routinely used as a model to 
study the biology of the immune system since they are impaired in the ability to make 
T and B lymphocytes or activate components of the complement pathway. Therefore, 
these mice are not able to fight infections, reject tumors and transplants. 
1.3.5.1 Abnormalities in circulating B cell subpopulations in RA 
patients.  
In RA the absolute number of circulating CD19+ B cells is similar to healthy individuals. 
However, patients with RA are characterised by a significant reduction in circulating 
CD27+ memory B cells and by a normal distribution of CD27- naïve B cells and early 
plasma cells [76]. In particular, patients with very early arthritis (i.e., less than 6 weeks 
after arthritis onset) display a selective reduction in CD27+IgD+ unswitched memory B 
cells [112], whereas patients with established RA are characterised by a reduction in 
circulating CD27+IgD- memory switched B cells [113]. Although no direct 
demonstration has been provided, the observed reduction in the RA memory B cell 
compartment has been explained as result of migration of these cells into the inflamed 
synovium. Despite the above evidence supporting that altered frequency of B cell 
subpopulations are a feature of RA, more studies are needed in order to clarify (i) 
whether these abnormalities represent primary pathogenic events or are secondary to 
the establishment of a chronic inflammatory process and (ii) whether they can predict 
disease evolution and response to treatment.  
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1.3.5.2 Autoantibodies in rheumatoid arthritis. 
The first evidence of the autoimmune nature of RA came with the discovery of RF in 
the blood of patients. Along with RF, several autoantibody specificities have been 
described in RA, but only anti-citrullinated protein antibodies (ACPA) have been 
demonstrated of clinical utility and are currently used in clinical practice. However, 
autoantibodies titers normally do not correlate with disease activity although their 
production precedes the onset of clinical arthritis by many years, suggesting that 
breach of B self-tolerance is an early event in RA [114]. 
1.3.5.3 Rheumatoid Factor.  
RF is an autoantibody directed against the Fc portion of the immunoglobulin (Ig), 
either IgG or IgM, although classical RF are IgM directed against IgG. Patients 
seropositive for RF are generally characterised by a more severe clinical disease 
compared to seronegative patients. RF seems able to fix and activate the complement 
locally in the rheumatoid synovium [115], thus contributing to synovial inflammation. 
IgG and IgM RFs are likely pathogenic in RA and large quantities of IgG can be found in 
the rheumatoid synovial tissue. However, there is also evidence of IgE and IgA RF in 
some patients with RA. In RA RFs are produced by B cells characterised by the 
presence of somatic mutations as consequence of affinity maturation [116], whilst 
they are often encoded by germline Ig genes in healthy individuals. 
1.3.5.4 Anti-citrullinated protein/peptide antibodies (ACPA).  
Although RF is detected in the majority of RA patients, it is not highly specific for RA as 
it is found in other chronic inflammatory conditions as well as in healthy individuals in 
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the late stage of their life [117]. However, detection of RF is still included in the 
classification criteria, as listed above. Recently, an increased interest in antibodies 
directed against citrullinated peptides which seem to have a better prognostic 
implication, has been seen in patients with RA. 
In 1964 the first ACPA was reported in patients with RA as the anti-perinuclear factor 
(APF) and later as anti-keratin antibodies (AKA) [117, 118]. Later, it was shown that 
both APF and AKA are directed against the epithelial intermediate filament associated 
protein filaggrin which is involved in the aggregation of cytokeratin filaments during 
cornification of the epidermis. Subsequently, filaggrin citrullination was demonstrated 
as an essential step in its immunogenicity and cyclic citrullinated peptides has since 
been used as antigens in ELISA testing to detect ACPA.  
More recently, antibodies directed against citrullinated keratin, vimentin, fibrinogen 
and xenoproteins as EBV-derived peptides were found in RA patients [119]. ACPA are 
currently the most specific autoantibodies for RA, although a few healthy individuals 
(about 2%) have been found positive for ACPA. Some patients with systemic 
inflammatory diseases like SLE and SS can have ACPA as well [117].  
Citrullination of proteins is a physiological process that can occur also during 
inflammation and is therefore not specific for RA. However, an aberrant B cell 
response against citrullinated antigens may be specific for RA [117, 120]. It is clear that 
ACPA are part of the unique pathogenesis of RA, although it is not known if these 
antibodies are just a manifestation of an early inflammatory process or play a 
causative role [117]. 
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1.3.5.5 Other potential autoantigens in RA. 
The number of potential joint-specific and non-specific antigens that might have a role 
in the pathogenesis or aetiology of RA is extensive and to date there is no evidence of 
one specific RA antigens driving the disease, particularly in the synovial 
microenvironment. Cartilage-specific antigens include type II collagen, the cartilage 
glycoprotein gp39, proteoglycans, aggrecan, and cartilage link proteins. Among the 
non-articular antigens, autoantibodies against glucose-6-phosphate isomerase, 
heterogeneous nuclear ribonucleoprotein-A2, heavy chain binding protein, and heat 
shock proteins have been detected in the sera of some RA patients [121] but their 
diagnostic and/or pathogenic role is unclear. 
1.3.6 Treatment of patients with RA. 
Pharmacological treatments of RA patients are used to control pain and inflammation 
and prevent bone erosions with the aim to achieve remission or a low disease activity 
for all patients. The treatments commonly used include corticosteroids, oral disease-
modifying antirheumatic drugs or DMARDs, and biological DMARDs (anti-TNF drugs as 
adalimumab, etanercept, infliximab; and others like abatacept, anakinra, rituximab, 
and tocilizumab) [122].  
 Corticosteroids. Corticosteroids derive from cortisol which is a hormone produced 
by the adrenal glands. They are used for their anti-inflammatory and 
immunosuppressive properties since they can inhibit recruitment of inflammatory cells 
to the site of inflammation, neutrophil function and prostaglandin production. They 
are commonly administrated orally and the corticosteroids mainly used are 
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methylprednisolone, prednisone, and prednisolone. Their current use is primarily as 
intra-articular or intra-muscular injections or as short-term oral treatments.  
 Oral disease-modifying antirheumatic drugs (DMARDs). Oral DMARDs act 
modifying the course of inflammation. The aim of these drugs is to reduce or prevent 
joint damage, and preserve function and structure during the inflammatory phase. 
They include hydroxychloroquine, leflunomide, methotrexate (MTX), and sulfasalazine.  
 Biological DMARDs. Biological DMARDs are normally given by injection and their 
targets are component of the immune system (i.e., cytokines as TNF, IL-1, and IL-6; or 
immune cells as B cells).  
Anti-TNF drugs. Adalimumab, certolizumab pegol, etanercept, golimumab, and 
infliximab are all anti-TNF drugs licensed for their use in RA. Adalimumab, golimumab, 
certolizumab pegol and infliximab are monoclonal antibodies which target TNF. In 
particular, adalimumab is a fully human monoclonal antibody that binds to TNF, 
blocking its interaction with the TNF receptor. Golimumab is a human monoclonal 
antibody which binds TNF- with high affinity. Infliximab is a human/mouse chimeric 
monoclonal antibody that binds also human TNF-. Certolizumab pegol is a PEGylated 
Fab’ fragment against human TNF that lacks the Fc region. Etanercept is a TNF soluble 
receptor protein linked to the Fc portion of IgG1. It binds circulating TNF, thus blocking 
its interaction with the receptor. 
Other biologics. Rituximab is a chimeric monoclonal antibody that binds CD20 
expressed by B cells and plasma blasts, thus removing almost all the B cells from the 
periphery with the exception of pre-B cells and plasma cells which do not express 
CD20.  Tocilizumab is a monoclonal antibody that blocks IL-6 receptor, thus blocking IL-
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6 action. Anakinra is a IL-1 receptor antagonist. Finally, Abatacept is a soluble fusion 
protein (CTLA-4 with the modified Fc portion of IgG1) that interferes with T cell 
activation. 
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1.4 Ectopic lymphoid neogenesis.  
1.4.1 General aspects. 
The adaptive immune system response to antigens including tolerance induction, 
antigen-specific immunity and immunological memory [123] is, in most cases, 
supported by SLOs which in humans include lymph nodes (LNs), spleen and mucosal 
associated lymphoid tissues (MALT).  
Tertiary lymphoid organs, also known as ectopic lymphoid structures (ELS), form at the 
site of chronic inflammation through a process known as lymphoid neogenesis 
[77],[124]. Immunohistochemical analysis performed on the target tissues from 
patients with autoimmune and infectious diseases show that lymphoid neogenesis is a 
dynamic process during which lymphocytic infiltrates develop into aggregates that can 
eventually organize in secondary B-cell follicles with GCs and T cell compartments 
containing DCs and high HEVs [13] through which lymphocytes can enter from the 
systemic circulation [124].  
The cellular constituents of B- and T-cell zones in SLOs and ELS are similar. ELS include 
proliferating B cells and FDC networks which are essential for B cell maturation and to 
stimulate proliferation and prevent apoptosis of GC B cells [125, 126]. Furthermore, 
naïve B cells, centroblasts, centrocytes, memory B and plasma cells, T cells are all 
detected in ELS or in the nearby biological fluids. However, some elements differ 
markedly from that of classical SLOs. Unlike LNs, but similar to MALT, ELS are 
characterised by the absence of afferent lymphatic vessels and are not encapsulated, 
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which means that they are directly exposed to antigens and cytokines from the 
inflamed environment [13]. 
The role of ELS is not entirely clear, in particular whether they play a beneficial or a 
detrimental function. This may depend on both the site of inflammation and the 
stimuli that are involved in their induction. Furthermore, it is not clear why these 
structures should form in the periphery in living organisms. It has been hypothesized 
that the formation of these immunologically active structures may take place to avoid 
persistent activity in critical SLOs and prevent systemic dissemination of 
(auto)antigens, or to maximize antigen presentation at the local site of inflammation 
which in turn would increase efficiency of the immune response through the 
concentration of cells, cytokines and immunoglobulin in a specific location [108]. Thus, 
when ELS develop at site of pathogenic infection, they can help to eliminate or 
neutralize pathogens by generating antibody-producing plasma cells specific for the 
pathogen. However, when ELS develop at sites where autoantigens are continuously 
being exposed, they may lead to the activation of autoreactive lymphocytes and, 
eventually, induce tissue destruction [124]. Evidence of ELS formation has also been 
obtained in a number of chronic infectious diseases. For instance, Helicobacter Pylori-
induced gastritis is often accompanied by lymphoid tissue neogenesis leading to the 
production of plasma cells producing IgA antibodies specific for H. Pylori-associated 
antigens [13, 127, 128]. Lymphoid neogenesis has been observed also in HCV-mediated 
chronic hepatitis and protozoa-induced pathologies (placental malaria) [13]. Aside 
from chronic infection, ELS are also induced in several autoimmune diseases, such as 
type I diabetes, Hashimoto thyroiditis, myasthenia gravis, multiple sclerosis, and as it 
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will be described in this chapter, RA and SS [13, 128, 129]. Organized lymphocytic 
infiltrates have been observed in murine models of autoimmunity such as spontaneous 
diabetes in NOD mice and autoimmune gastritis [128, 130-132], and also during graft 
rejection. Tissues undergoing chronic graft rejection are characterised by HEV-like 
venules, T cells, B cells producing anti-graft antibodies, while ELS have also been 
reported in rejected human allografts [128, 133, 134]. Lastly, very few data on 
lymphoid neogenesis in cancer have been reported supporting the hypothesis that ELS 
formation is somewhat impaired in malignant conditions, possibly resulting in a less 
efficient immune response against neoplastic cells [13]. In this regard, recent evidence 
suggest that exploitation of lymphoid chemokines, which are critical regulator of ELS 
formation (see Section 1.4.2 below), might be able to drive lymphocyte accumulation 
and induce lymphoid neogenesis at tumor sites as a form of cancer immunotherapy 
[128]. 
1.4.2 Role of lymphoid chemokines in lymphoid organ 
development and organization. 
The cascade of events that lead to ELS formation in pathological conditions shows 
several similarities with the signalling pathways involved in secondary lymphoid tissue 
organogenesis which is the result of a highly coordinated interaction between 
haematopoietic cells, non-lymphoid stromal cells, adhesion molecules, chemokines, 
cytokines, and growth survival factors [13]. Thus, in order to understand the 
development of ELS, it is essential to briefly review the biological basis that lead to 
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SLOs formation giving particular emphasis, in this context, at the active role of 
lymphoid chemokines in this process. 
1.4.2.1 Role of lymphoid chemokines in SLOs development. 
SLOs are highly specialised structures, which develop in order to regulate leukocyte 
trafficking and recirculation at dedicated sites and thus optimize the generation of an 
adaptive immune response following an antigenic challenge. As previously outlined, 
leukocyte trafficking within LNs is a result of a tightly regulated process which involves 
stromal and vascular anatomical structures and chemoattractant gradients. The 
chemoattractant signalling pathways involve several “lymphoid” chemokines, such as 
B-cell activating chemokines-1 (BCA-1)/CXCL13, Epstein-Barr virus-induced gene 1 
ligand chemokines (ELC)/CCL19, secondary lymphoid tissue chemokines (SLC)/CCL21 
and stromal cell-derived factor-1 (SDF-1)/CXCL12 and their specific receptors CXCR5 
(for CXCL13), CCR7 (CCL19 and CCL21) and CXCR4 (for CXCL12). In particular, the 
trafficking of CCR7+ naïve and central memory T cells and mature dendritic cells (DCs) 
is regulated by CCL19/CCL21 and peripheral node addressin (PNAd+) HEVs. CCL19 and 
CCL21 are produced by stromal reticular cells [135] within the T-cell rich area of the 
LN. The concomitant presence of CCL19/CCL21 and HEVs allows the homing of T cells 
and mature DCs to SLOs from the systemic circulation upon binding to PNAd+ HEVs 
through L-selectin and to position themselves in close association with fibroblastic 
reticular cells where T cells receive a strong survival signal mediated by IL-7 [135]. 
Although in lower amount, also naїve B cells express CCR7 and, thus, together with 
CXCR4 they use this receptor to enter SLOs from the systemic circulation [136]. 
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However, it is CXCR5 in response to a CXCL13 gradient (see below) that ultimately 
determines the positioning of B cells in specific B cell follicles. The organisation of B 
cells into follicles is regulated by lymphotoxin-12 (LT12) – a membrane bound 
heterotrimeric member of the tumour-necrosis factor (TNF)-family, and as mentioned 
above by CXCL13 [137]. LT12 can be expressed by B cells themselves, and upon 
ligation of the LT-R on resident follicular stromal cell induces CXCL13 production and 
further LT12 upregulation as well as the clustering of the B cells [137]. Within the 
GC, CXCL13 production is sustained by FDCs. CXCL13 mainly directs GC B cells to the 
light zone of the GC where antigen selection takes place. Within the GC, another 
homeostatic chemokine, CXCL12, is critically involved in the migration of CXCR4high 
centroblasts to the dark zone where SHM takes place.  
CXCL13 is also involved in the initiation of events that lead to lymphoid organs 
formation. Indeed, mice lacking CXCL13 and its receptor CXCR5 show a partial blockage 
of LN organogenesis [137].  
Thus, in addition to the functional role in the organization of lymphoid organs in 
adults, the lymphoid chemokines are extensively involved in the generation of SLO 
during lymphoid organogenesis in prenatal life. In particular, lymphoid chemokines are 
produced pre-natally by VCAM-1+ICAM-1+LTR+ embryonic mesenchymal “organizer” 
cells in response to close interaction with CD3-CD4+CD45+IL-7R+RANK+ embryonic 
hematopoietic “inducer” cells which also express CXCR5. A further key signal necessary 
for lymphoid organ development is sustained by two members of the TNF family, LT 
and LT. LT can exist either as a soluble homotrimer (LT3) or as heterotrimer 
(LT12). The binding of LT12 to its receptor LT-R expressed on stromal cells 
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induces the expression of CXCL13, CCL19 and CCL21, and HEVs formation [128]. The 
non-redundant and upstream role of lymphoid chemokines CXCL13, CCL21 and CCL19 
in promoting lymphoid tissue organization has been clearly demonstrated in vivo in 
transgenic animals, whereby overexpression of these factors in the pancreas or thyroid 
induces, in a LTB dependent fashion, the formation of ELS recapitulating several 
feature of lymphoid organ development [108, 138-140].     
Thus, lymphoid chemokines exert a critical role during lymphoid organogenesis, allow 
the transformation of diffuse infiltrates into highly organized structures which are 
necessary for the initiation of the adaptive immune response, and importantly play an 
important part in ELS development, although they are not sufficient to drive the 
complete formation of lymphoid structure [13]. 
1.4.2.2 Role of lymphoid chemokines in ELS formation. 
It has been postulated that lymphoid chemokines exert a similar role in regulating ELS 
formation and organization, which will be reviewed in the next paragraphs together 
with the potential role of lymphoid chemokines in supporting functional niches of 
autoreactive B cells, in the target organs of two clinical conditions, the synovium of RA 
patients and the salivary glands of patients with SS.  
1.4.3 Ectopic lymphoid neogenesis in rheumatoid arthritis and 
Sjögren’s syndrome. 
It is now clear that a subset of patients with RA (around 40%) and SS (around 30%) 
develops ELS in the synovium and salivary glands, respectively. These structures are 
characterised by aggregated of T and B cells often showing T/B segregation, 
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development of HEVs and FDC networks. Among different patients, inflammatory 
infiltrates are characterised by different degrees of structural and immunological 
organization. Therefore, my laboratory has recently adopted a histomorphometric 
analysis based on the aggregate radial cell count which has led to the development of 
the following grading system: grade 1 (G1) define the first stage of the lymphocytic 
aggregation mainly characterised by CD3+ T cells; grade 2 (G2) are normally enriched in 
the CD20+ B cell component and characterised by a higher level of organization; and 
grade 3 (G3) define larger aggregates with often T/B cell compartmentalization and the 
presence of FDC network [108, 141, 142]. 
Evidences in patients with and animal models of RA and SS have demonstrated that 
the formation and maintenance of these ELS is critically dependent on the ectopic 
expression of lymphotoxins (LT) and homeostatic chemokines CXCL13, CCL19, CCL21 
and CXCL12. These key molecules are produced during chronic inflammation by several 
cell types, including resident epithelial (in SS, see below), stromal and endothelial cells 
as well as different subsets of infiltrating immune cells.  
Briefly, chemokines can have both homeostatic and inflammatory properties. As 
previously reported, the homeostatic chemokines are primarily involved in lymphoid 
neogenesis, though it has been show that they may also be involved in inflammation 
[143].  
1.4.3.1 Role of lymphoid chemokines in rheumatoid arthritis. 
As previously reported, among the factors involved in ectopic lymphoid neogenesis, 
the lymphoid chemokines CXCL13 and the CCR7 ligands CCL21 and CCL19 play a central 
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role in this process. The activation of molecular pathways similar to the mechanisms of 
SLO organogenesis has been demonstrated in RA by gene expression studies showing 
that CXCL13, CCL19 and CCL21 can be upregulated in the rheumatoid synovium. The 
increased level of lymphoid chemokines is also associated with enhanced levels of LT, 
of genes associated with IL-7 signalling pathway, and with the presence of ELS [108, 
111, 138, 144]. Studies on the relationship between chemokine expression and the 
different degree of lymphoid organization in RA synovial tissue have shown that 
CXCL13 and CCL21 can be synthesized both in highly organized structures with FDC 
network, T and B cell segregation, but are also expressed, although at lower levels, in 
smaller and less organized lymphoid follicles. Based on this evidence, the current 
working hypothesis is that lymphoid chemokines are regulated upstream of ELS 
organization [145].  
My laboratory and other groups showed that in the rheumatoid synovium, in addition 
to FDC networks, the homeostatic chemokine CXCL13 is mainly produced by 
hematopoietic cells such as CD14+/CD68+ monocyte/macrophages [146] and a subset 
of memory T cells [147], suggesting that cells of both the innate and adaptive immune 
system in the synovial microenvironment play an important role in the recruitment 
and organization of B cells [148]. Importantly, the expression of CXCL13 is closely 
associated with the formation of B cell-rich aggregates with features of ELS. In keeping 
with an essential role of CXCL13 in ELS formation in the RA synovium, its receptor 
CXCR5 has been shown to be widely expressed by infiltrating B cells and subsets of T 
cells [143].  
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In contrast to CXCL13, CCL21 is mainly expressed in the T cell-rich areas of synovial G3 
lymphoid aggregates and in close association with HEVs co-expressing PNAd. Although 
closely associated with vascular structures, the expression of CCL21 is confined to 
smooth muscle actin (SMA)+ CD45- myofibroblast-like stromal cells, similarly to what 
has been observed in human and murine SLOs [108]. Overall, this demonstrates that in 
the RA synovium the lymphoneogenetic programme is associated with the 
differentiation of stromal cells with the capability of supporting the recruitment of 
CCR7+/L-selectin+ naïve and central memory T cells and CCR7+ mature DCs.  
1.4.3.2 Role of lymphoid chemokines in Sjögren’s syndrome. 
Several studies on the role of lymphoid chemokines in the organization of ELS have 
been performed also in the salivary glands of SS. Similar to RA, our group has shown 
that the expression of CXCL13 and CCL21 is progressively increased with the gradual 
acquisition of lymphoid features in the salivary glands. Indeed, both lymphoid 
chemokines were found to be expressed already in G1 clusters as well as G2 
aggregates in the absence of T/B cell compartmentalization. Analysis performed on the 
identification of the cellular source of lymphoid chemokines in the target organ of SS 
have revealed that both resident, non-lymphoid cells as well as infiltrating immune 
cells can produce lymphoid chemokines. In particular, Xanthou et al showed that 
ductal epithelial cells and infiltrating mononuclear cells were the main source of 
lymphoid chemokines in SS [149]. The presence of lymphoid chemokines on epithelial 
cells were confirmed by Salomonsson et al who showed expression of both CXCL13 
and CCL21 in acinar and ductal epithelial cells. These data would be in keeping with the 
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important role of epithelial cells in the pathogenesis of SS (also described as 
“autoimmune epithelitis”)which are known to actively contribute to the inflammatory 
process in the salivary glands through production of several inflammatory chemokines 
and cytokines. Interestingly, epithelial expression of CXCL13 and CCL21 was not found 
to correlate with the development of ELS or the size of periductal lymphocytic foci in 
SS salivary glands [150]. In contrast with the hypothesis that epithelial cells are the 
main source of lymphoid chemokines in SS, Amft et al reported expression of CXCL13 
mainly in endothelial cells in blood vessel and networks of stromal cells resembling 
FDCs within the inflammatory foci, while ductal epithelial cells displayed primarily high 
levels of CXCL12 [151]. Studies performed by my laboratory confirmed that while 
CXCL12 was strongly expressed by ductal epithelial cells, CXCL13 was only weekly 
expressed by epithelial cells, being primarily produced by infiltrating immune cells as 
well as networks of stromal cells within the inflammatory foci [152]. Importantly, we 
observed that only immune cell- but not epithelial-derived CXCL13 was associated with 
the development of ELS in the salivary glands of SS patients.  
Similar to RA, my laboratory also showed that within the subsets of infiltrating immune 
cells the homeostatic chemokine CXCL13 was mainly produced by CD68+ macrophages 
and CD3+ T cells [152]. Interestingly, high levels of CXCL12 were also observed in a 
subset of CD68+ cells resembling tingible body macrophages within ELS [152]. 
Furthermore, again in keeping with similar data in the RA synovium, CCL21 was mainly 
expressed by HEV-associated stromal cells in the salivary glands developing 
preferentially in the T cell areas of segregated lymphocytic foci [152]. 
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In addition to chronic inflammation in SS, my lab recently showed that lymphoid 
chemokines also exert an additional role in the development of extranodal B cell 
lymphomagenesis and particularly in salivary gland MALT lymphoma (MALT-L), which 
develop in around 5% of SS patients. Interestingly, CXCL13 was found to be expressed 
by malignant B cells in gastric MALT-L as well as in non-Hodgkin B cell lymphoma of the 
central nervous system where also CXCL12 and its receptor CXCR4 were found to be 
expressed [127, 153, 154]. These studies, performed on a large cohort of SS parotid 
glands with lymphoepithelial sialoadenitis (LESA) and MALT-L, have shown that CXCL13 
and CCL21 were expressed at higher levels in SS salivary glands with LESA as compared 
to MALT-L. Conversely, CXCL12 was more expressed in parotid glands with MALT-L in 
comparison to LESA [152]. Interestingly, the expression of CXCL13 and CCL21, 
sustained mostly by macrophages and T cells (for CXCL13) and stromal cells (for 
CCL21), was found to be associated with reactive areas populated by CD20+IgD+Bcl-
2+Bcl-6- follicular B cell and CD20+IgD-Bcl-2-Bcl-6+ GC B cell associated with FDC 
networks. Conversely, CXCL12 was mainly associated with and often produced by 
malignant CD20+IgD-Bcl-2+ marginal zone-like B cells [152].   
Hence, we suggest that CXCL13 and CCL21 can directly control the formation and 
maintenance of functional ELS in SS salivary glands which in turn can promote in a 
subset of patients the progressive development of B cell lymphomagenesis [152]. 
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1.4.4 Functionality of ELS in RA and SS: role of activation 
induced cytidine deaminase. 
A long outstanding question regarding ELS in chronic autoimmune conditions has been 
whether these structures simply recapitulate some cellular and molecular features of 
SLOs or whether they also represent ectopic niches sufficient to promote B cell 
functional activation. In this regard, my laboratory recently provided direct evidence of 
the capability of ELS to support activation and differentiation of B cells both within the 
synovial tissue of RA joints and in the salivary glands of SS patients. In both conditions 
lymphoid aggregates characterised by FDC network formation (as detected by 
immunohistology for CD21 or by expression of CD21 long isoform mRNA) invariably 
express AID at both mRNA and protein level [73, 111]. Importantly, AID expression can 
also take place in the absence of the full compartmentalization of the GC into dark and 
light zones which often differentiates ELS from SLOs. This work supported previous 
evidence both in RA and SS which demonstrated, by performing analysis of the V-gene 
repertoire from follicular structures microdissected from RA synovium and SS salivary 
glands, that a significant proportion of infiltrating B lymphocytes display an oligoclonal 
repertoire with highly mutated V regions, indicating a local antigen-driven process [72, 
155-157].  
In addition to SHM, my laboratory recently provided evidence that B cells also actively 
undergo class switching in the presence of ELS within the RA synovium [111]. 
Interestingly, it has been showed that I-C circular transcripts, which are specific 
transcribed by-products of CSR from IgM to IgG, are continuously expressed in synovial 
tissues engrafted into SCID mice, demonstrating that CSR can be sustained for several 
Page | 87  
 
weeks within the RA synovium characterised by AID+/CD21L+ lymphoid structures even 
in the absence of recirculating immune cells.  
Overall, the conclusion is that ELS developing in the RA synovium and SS salivary glands 
activate the molecular machinery to sustain in situ Ig V repertoire diversification, 
isotype switching, B cell differentiation and oligoclonal expansion. It is important to 
note that this capacity is not an exclusive feature of lymphoid neogenesis in these 
conditions as similar evidence of AID expression in ELS has also been demonstrated in 
multiple sclerosis [158], and in chronic graft rejection [159] suggesting that chronic 
antigen exposure, driven by variable antigens in different target organs, sustain in situ 
B cell differentiation. 
1.4.5 Contribution of ELS to organ specific autoimmunity in RA 
and SS. 
One of the hallmarks of RA and SS is the presence of circulating auto-antibodies (Ab), 
as described earlier in this thesis. Thus, another important aspect to consider regarding 
ELS in autoimmune diseases in general and in RA and SS in particular is whether these 
structures directly contribute to breach of tolerance and autoimmunity over and above 
SLOs by promoting selection of autoreactive B cells, plasma cell differentiation and in 
situ autoantibody production.  
In RA there is now clear evidence that the presence of ELS closely correlate with 
synovial plasma cell number, suggesting in situ differentiation within the GCs [160-
162]. A clear confirmation of this possibility has been recently provided by the analysis 
of the Ig V gene repertoire and clonal relationship between ELS and plasma cells 
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isolated from the synovial tissue using laser capture microdissection. Using this 
approach the Berek’s group provided the first direct demonstration that most synovial 
plasma cells are generated from locally activated B cells which then accumulate and 
migrate within the inflamed tissue [163].  
In keeping with these observations, my group recently demonstrated that ectopic 
lymphoid follicles in RA patients are surrounded by CD138+ plasma cells, some of 
which produce antibodies directed against the citrullinated, but not the unmodified, 
form of fibrinogen [111]. In addition, the use of the HuRA-SCID mouse model allowed 
to directly study in vivo the production of human autoantibodies derived from the 
synovial tissue without confounding production from SLOs and long lived plasma cells 
in the bone marrow.  
By transplanting RA synovial tissues characterised by the presence or absence of ELS, 
my group demonstrated that AID+CD21L+ RA synovial grafts produce human IgG ACPA 
which can be measured at high levels and for several weeks in the mouse circulation. 
This suggests that in RA ELS can form self-sustained niches of autoreactive B cells 
which can differentiate into plasmablast/plasma cells and produce disease-specific 
autoantibodies within the target organ.  
Similarly to RA, in SS there is compelling evidence that ELS participate to humoral 
autoimmunity within the salivary glands. Original evidence that SS salivary glands are 
characterised by the preferential accumulation and selection of autoreactive B cell 
clones derived from analysis of the Ig V repertoire of infiltrating B cells showing an 
abnormal distribution and preferential usage of Ig V and V genes, such as VA27, 
frequently displayed by autoreactive B cells [164, 165]. In support of this initial 
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observation, Salomonsson et al later showed that plasma cells reacting against the 
ribonucleoprotein Ro/SSA and La/SSB preferentially accumulate around ELS in labial SG 
biopsies of SS patients, strongly suggesting that also in SS ELS support in situ 
differentiation of autoreactive plasma cells against disease-associated antigens [150].  
An interesting concept regarding the formation of ELS was recently raised by Le Pottier 
et al demonstrating that, differently from GC in SLOs, ELS arising in the salivary glands 
of SS patients do not exclude autoreactive B cells which are thus capable of entering 
FDC networks, express AID and undergo a GC response [166]. 
According to this hypothesis, ELS fail to exert the physiological peripheral checkpoints 
against autoreactivity which are normally active in SLOs and prevent self-reactive B 
cells from entering the GC and undergo affinity maturation. A plausible mechanism 
implicated in such defective regulation of autoreactive B cell activation in ELS is again 
related to the importance of lymphoid chemokines. In physiological conditions, 
potentially autoreactive B cells are excluded from entering B cell follicles in SLOs 
because they are induced to down-regulate CXCR5 and become less responsive to 
CXCL13 compared to normal B cells which compete for the follicular niche [167]. As a 
consequence, autoantigen-binding B cells are forced to accumulate at the boundary 
between the T and B cell zone of SLOs where they do not receive activatory signals, 
become anergic and die by apoptosis. Although the mechanisms regulating CXCR5 
down-modulation in autoreactive B cells are not well understood, it is possible to 
speculate that within ELS during chronic inflammation these counter-
immunoregulatory pathways normally active in SLOs are deficient, resulting in the 
accumulation of autoreactive B cells within ectopic GCs. 
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Overall the above evidence strongly supports the conclusion that ELS in the RA 
synovium and SS salivary glands are functional and favour the selection, survival and 
proliferation of autoreactive B cells and their differentiation into auto-antibody 
producing plasma cells over and above SLOs. This process is critically dependent on 
chronic antigenic exposure within the target tissue and result in humoral 
autoimmunity against organ-specific antigens.  
An important question, which remains unresolved, is whether ELS are important in the 
initial steps of breach of tolerance to self-antigens or, as it appears more likely, rather 
play a role in the perpetuation of autoimmunity and chronic inflammation. 
Additionally, a fundamental question is which antigen(s) are responsible for driving 
such humoral autoimmune response within the target organs of SS and RA. 
1.4.6 Interfollicular (IF) large B cells in SLOs and ectopic 
lymphoid structures. 
As pointed in Chapter 1.1, in lymphoid organs AID expression is restricted to GC B cells 
and in particular to centroblasts which produce high levels of this enzyme [168]. In 
2006, Moldenhauer et al demonstrated that outside the GC, a high percentage of AID+ 
B cells belonged to a newly characterised subset of B cells, called interfollicular (IF) 
large B cells, and were the only subset of B cells to express AID outside GC [169]. These 
cells, which were described already 20 years ago but never analysed thoroughly, were 
deeply characterised for the first time in the work by Marafioti and colleagues in 2003, 
using normal lymph nodes [170]. They showed that IF large B cells are a unique CD20+ 
B cell population which is distinct from the main established B cell subsets. These cells 
Page | 91  
 
are characterised by a large cytoplasm and are typically found in the interfollicular T 
cell rich area. They can carry mutated Ig genes, supporting AID functionality. The 
presence of somatic mutation also suggests that IF large B cells could be a new subset 
of post-GC B cells. IF large B cells lack detectable levels of the memory B-cell marker 
CD27, many of these cells are proliferating (positive for Ki-67), and about half of the 
cells express multiple myeloma oncogene protein 1 (MUM-1), a transcription factor 
found in plasma cells and a few (late) GC B cells but not in memory B cells. Arguments 
against a plasma cell identity of these cells include negativity for the plasma cell 
markers CD38 and CD138. Moreover, these cells are different from centroblasts 
(negative for Bcl-6) and centrocytes, the main two B cell subsets in the GC. The 
dendritic morphology and close association with T cells might also suggest a role in T 
cell activation, possibly via antigen presentation, although they lack co-stimulatory 
markers as CD80 and CD86. Interestingly, my group provided the first demonstration 
that the population of large IF B cells is not restricted to SLOs but can also be observed 
in the target organ of rheumatic autoimmune diseases, such as synovial tissue (for RA) 
[111] and salivary gland (for SS) [73]. These cells were the only B cell subset expressing 
AID outside FDC networks, though were only observed in the presence of ELS. Similar 
to SLOs, these cells are characterised by a large cytoplasm, by a dendritic-like 
morphology, and are localised in close association with T cells only outside CD21+ 
aggregates. However, the biological significance and the pathogenic role in 
autoimmunity and chronic inflammation as well as their phenotypic characterization in 
ELS have not been clarified as yet. 
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1.5 Immunoglobulin gene usage in rheumatic 
autoimmune diseases. 
1.5.1 Introduction. 
To date whether the Ig V gene usage in patients with autoimmune diseases differs 
from that of healthy individuals has been a matter of controversy. It has been 
proposed that the production of autoantibodies in autoimmune diseases could be a 
result of abnormalities in the Ig variable genes resulting in a preferential gene usage 
both for the H and L chain together with anomalies in receptor editing and in the 
number of somatic mutations. Therefore, the analysis of the Ig V gene repertoire has 
become of particular interest to understand whether the Ig gene usage is skewed in 
patients with autoimmune diseases compared to controls [171]. The analysis of 
productive and non-productive rearrangements in peripheral B cells in healthy 
individuals has revealed that the VH, V and V gene usage is naturally biased. 
Normally, among the seven VH gene families that are used to shape the Ig repertoire, 
VH3 which is the largest variable region family with 22 members, is used more 
frequently, followed by VH4 and VH1 in the productive repertoire. Similarly, in the V 
and V gene families there is a preferential family usage (Table 1.3) [171]. Analysis of 
the gene usage associated with autoantibodies has revealed no evidences for a 
preferential usage of VH, V and V family, expect for few autoantibodies. For 
instance, a marked increase of V3 family usage has been reported for RF together 
with a specific restriction to genes of the VH1 and VH3 family [171]. There are also 
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indications that some autoantibodies, including RF, anti-dsDNA, Ro/SSA, La/SSB, 
phospholipids, histone A2, laminin, and collagen, use more frequently V genes which 
are normally less expressed in the Ig repertoire of healthy individuals [171]. However, 
to date the number of Ig V genes analysed is too small to allow any comprehensible 
correlation between gene usage and autoimmune diseases. 
A briefly overview of the analysis of the Ig repertoire in patients with SS and RA will be 
reported in the following section. 





















VH1 4.0 13.1 V1 47.0 44.0 V1 25.4 29.1 
VH2 8.0 1.9 V2 29.0 19.0 V2 30.9 33.1 
VH3 36.0 53.9 V3 13.0 29.0 V3 5.4 15.7 
VH4 44.0 24.8 V4 6.0 5.0 V4 18.2 5.8 
VH5 4.0 2.9 V5 4.0 2.0 V5 7.3 3.5 
VH6 4.0 2.4 V6 1.0 < 1 V6 3.6 3.5 
VH7 0.0 1.0 V7 
  





V8 1.8 1.2 
JH1 3.8 1.0   
  
V9 1.8 0.6 
JH2  0 2.4 J1 21.0 30.0 V10 3.6 3.5 
JH3 7.7 7.8 J2 40.0 36.0   
 
  
JH4 50.0 55.3 J3 4.0 6.0 J1 5.5 7.0 
JH5 15.4 9.7 J4 20.0 17.0 J2/3 34.5 39.0 
JH6 23.1 23.8 J5 15.0 11.0 J7 60.0 45.1 
Table 1.3. Family gene usage in peripheral CD5-/IgM+ B cells isolated from healthy 
individuals.  
Source: Foreman et al., Autoimmun Rev. 2007 [171]; Lipsky et al., J.Clin.Invest. 1997 
[172] 
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1.5.2 Immunoglobulin repertoire analysis in SS and RA 
patients: a general overview. 
Several studies on the Ig repertoire of B cells isolated from SS patients have been done 
by comparing peripheral blood and inflamed parotid tissue. The importance to study 
the Ig gene usage of B cells infiltrating the parotid is that it might provide a more 
specific scenario of local selection and antigen-dependent proliferation of B cells at the 
local site of inflammation [173]. In particular, Dorner and colleagues [173] have found 
no evidence of different distribution of VH families comparing blood and parotid of SS 
patients. The VH gene usage was also similar to that found in B cells isolated from 
peripheral blood of normal individuals. This suggests that the B cells in the inflamed 
parotid gland are a polyclonal population. In contrast, they have noticed that the 
majority of glandular B cells from SS patients have mutated VH rearrangements with a 
mutational frequency higher within the productive repertoire compared to B cells 
isolated from peripheral blood. Furthermore, they have found differences in CDR3 
length, with glandular B cells showing shorter CDR3 region than the peripheral 
counterparts. They suggested that this may be due to a less usage of JH6 which among 
all the JH segments encodes the longest CDR3 [174]. This result confirms the 
observation that the JH6 segment is positively selected in the expressed pre-immune 
repertoire and negatively in the mutated repertoire [174].  
In contrast to the Ig repertoire of the heavy chain, B cells from parotid gland of SS 
patients showed differences in the productive light chain repertoire with a preferential 
usage of certain Vand V genes [165]. This observation may support the idea that 
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even though the B cells in the parotid represent a polyclonal population with an Ig 
heavy chain repertoire similar to healthy individuals, the local microenvironment may 
allow the clonal expansion and selection of B cells which express particular light chain 
genes [165]. Finally, it was shown that productive VL chain rearrangements of 
glandular B cells (in particular V genes) are characterised by higher mutational 
frequency compared to peripheral blood [165].  
Similar studies in peripheral B cells from RA patients have revealed no significant 
differences in the overall Ig VH gene usage compared to controls. Only a preferential 
usage of particular VH genes (i.e., V4-34, V3-23 and V1-69) has been associated with RF 
[175]. In particular, in RA patients an increase in somatic mutations has been observed 
in the CDRs suggesting an antigen-driven B cell selection in these patients. However, 
whether the increase of somatic mutations is associated with the pathogenesis of RA is 
still unclear [175]. An interesting study [176] has been done also comparing the Ig VH 
repertoire before and after treatment with RTX which has been shown to be beneficial 
for RA patients, as reported in Chapter 1.3. This study showed that at the baseline the 
overall Ig repertoire for the heavy chain was similar to the one expressed in healthy 
individuals with few differences in certain VH genes, already associated with 
autoimmune diseases. These included an over-expression of the VH 1-69 and VH 4-34 
genes and a reduced usage of the VH 3-07 and VH 3-30 genes in RA compared to 
controls. The analysis of the Ig repertoire in the repopulated B cells after therapy (i.e., 
seven month after the first infusion of RTX) showed significantly changes in the VH, D 
and JH gene usage, suggesting a possible therapeutic modulation of the VH gene 
repertoire by RTX treatment [176].  
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1.5.3 Receptor editing. 
Receptor editing is one of the three main mechanisms physiologically used to control 
autoreactive B cells. As explained in Chapter 1.1, this process refers to a secondary 
rearrangement in which the heavy chain combines with a new light chain. Studies of 
the V and V gene usage have revealed that receptor editing is defective in some 
patients with autoimmune diseases. For example, over expression of J2/3 and a 
reduced frequency of J7 was found in peripheral B cells of SS patients, suggesting a 
decreased occurrence of receptor editing [171]. Defects in receptor editing have been 
also observed in SLE patients where a highly skewed use of proximal V and less use of 
downstream J genes was found in anti-DNA antibodies of some SLE patients, whereas 
usage of J proximal genes were decreased with an increase in the distal cluster in a 
patient with untreated SLE, suggesting an increase of receptor editing [171].  
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2 | Rationale of the thesis and aims  
The shaping of the adaptive immune repertoire diversity and the fine balance existing 
between immune protection towards pathogens and the onset of self-reactivity have 
fascinated immunologists since the time of Paul Ehrlich at the beginning of the 20th 
century. This explains why several groups have focused their studies on the 
mechanisms that control and silence autoreactive B cells during the B cell 
development both under physiological conditions and most importantly during 
autoimmunity.  
The importance of B cell activation and autoantibodies in SS and RA is not limited to 
the clinical diagnosis of these autoimmune diseases. For instance, antibodies from SS 
patients have been shown to directly mediate exocrine dysfunction most likely by 
inhibiting muscarinic M3 receptor activity. Similarly, antibodies against citrullinated 
proteins (ACPA) have been implicated in the pathogenesis of RA.  
However, i) the mechanisms regulating breach of humoral B cell tolerance and the 
development/maintenance of autoimmunity in the periphery and in ELS; ii) the nature 
and fine specificities of the (auto)antigens driving B cell autoimmunity and iii) the exact 
pathogenic role of autoantibodies in RA and SS have not been clarified. The possibility 
to tackle the above issues would provide a better understanding of the pathogenesis 
of autoimmune diseases, particularly regarding those characterised by functional B cell 
activation within a target organ, such as the RA synovium and the SS salivary glands.  
One of the limitations in order to address such important aspects is the technical 
challenge of investigating the fine specificity of autoreactive B cells isolated from the 
inflammatory milieu. In addition, the possibility to analyse B cell autoreactivity from 
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circulating and/or lesional B cells of autoimmune patients at single cell level would 
allow a better understanding of the frequency and Ig gene repertoire underlying the 
development of autoimmunity.  
In order to overcome such limitations, in this PhD thesis I have applied the 
breakthrough strategy developed some years ago in the Nussenzweig’s lab [34] which 
allows cloning and expression of recombinant monoclonal antibodies from single 
human B cells. This method has the significant advantage of combining the 
characterization of the Ig gene usage among specific B cell subpopulations from 
patients with autoimmune diseases and healthy individuals linked with the expression 
of recombinant antibodies bearing the identical antigenic specificity of the parental B 
cell in vivo. 
As such, the main aim of my project was to develop and validate such technique in my 
laboratory and characterize the autoreactive B cell response and the impairment in 
tolerance checkpoints i) in the peripheral blood of patients with SS and ii) from lesional 
B cells isolated from RA synovial tissues characterised by functional ELS.  
Results of my work are organised in this thesis as follows: 
- Chapter 4 is focused on the characterization of the V gene repertoire and the 
frequency of self- and poly-reactive circulating naïve B cells from patients with SS in 
order to investigate the possible presence of abnormalities of B cell tolerance 
checkpoints in SS patients. 
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- Chapter 5 describes the characterization of the V gene repertoire and somatic 
mutation rate of circulating IgD-CD27+ memory switched and IgD+CD27+ memory 
unswitched single B cells from patients with SS. Furthermore, characterization of their 
polyreactivity profile is included. 
- Chapter 6 is centred on the generation and characterization of recombinant 
monoclonal antibodies isolated from CD19+ B cells infiltrating the synovial tissue of 
ELS+ RA patients. Analysis of the V gene repertoire, VH gene somatic mutation rate 
and clonal diversification of the synovial B cell clones forms the main part of this 
chapter together with the characterization of their immunoreactivity towards 
citrullinated antigens. 
In the short-term, this project allowed me to generate a large number of recombinant 
antibodies from SS and RA patients and characterise their autoreactivity profile against 
known autoantigens. 
In the long-term, my plan is to use such unique tools in order to i) identify dominant 
antigenic epitopes (self and non-self) recognised among different lesional B clones 
from different patients with RA and SS and ii) test the direct pathogenic role of in situ-
generated autoantibodies in contributing to autoimmunity and chronic inflammation. 
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3 | Patients and Methods 
3.1 Sjögren’s syndrome patients and controls. 
Peripheral blood was obtained using venepuncture from 12 patients with a diagnosis 
of SS (11 primary, 1 secondary to RA) according to the American-European Consensus 
Group classification criteria after informed consent (LREC 05/Q0707/1) [48]. The main 
demographic and clinical characteristics of the RA patients analysed are reported in 
Table 3.1. Naïve B cells generated from one previously reported healthy donor (HD-JH 
[177] and two additional HD - HD2 and HD3) were used as controls. 
3.2 Rheumatoid arthritis patients. 
Synovial tissue was obtained from 4 patients with a diagnosis of RA according to the 
American College of Rheumatology criteria [100]. Synovial tissue was collected after 
informed consent (LREC 05/Q0703/198) by total joint replacement. The demographics 
and clinical features of the RA patients are summarized in Table 3.1.  
3.3 Human Peripheral blood mononuclear cells (PBMCs) 
preparation. 
PBMCs were obtained from heparinized blood by centrifugation on Ficoll-Paque 
gradients. Blood was diluted with 1X PBS, supplemented with 2.5 mM EDTA and 
loaded over a Ficoll-Paque 1077. Density gradient centrifugation was performed at 
800xg at room temperature for 25 min without break to separate mononuclear cells. 
The mononuclear cell layer appears as a cloudy ring at the PBS/Ficoll-Paque interface. 
Finally, the mononuclear cells were harvested from the interface and transferred to a 
Page | 104  
 
new tube and washed twice with PBS (500xg and 400xg with break, respectively). 
PBMCs viability was determined by Trypan blue exclusion test. 
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SS patients SS1 SS2 SS3 SS4 SS5 SS6 (*) SS8 SS9 SS10 SS11 SS12 SS13
Age 64 64 59 54 39 59 68 64 48 62 41 56
Gender F F F F F F F F F M F F
Age SS 
onset




12 14 16 10 7 16 2 2 5 9 14 10
Diagnosis pSS pSS pSS pSS pSS pSS pSS pSS sSS/RA pSS pSS pSS
Anti-
Ro/SSA
+ + + + + + - - + + + +
Anti-
La/SSB






Age 66 75 39 63
Gender F F F F
Age of 
onset
61 na 35 59
RF + - + na









Treatment HCQ HCQ HCQ HCQ N
HCQ PDN 
5mg




Table 3.1 Demographic and clinical features of the SS and RA patients analysed in this study. 
pSS=primary Sjögren’s syndrome; sSS=secondary Sjögren’s syndrome; RA=rheumatoid arthritis; na=not available 
HCQ= Hydroxychloroquine; MTX= Methotrexate; PDN= prednisolone; RTX=Rituximab; SSZ=Sulphasalazine; N=no treatment 
(*) Patient SS7 (not shown in the table) is the same as patient SS13 but analysed at different time points 
(**) Patient RA1 is the same as patient RA3 but two joints replacement (left and right knee, respectively) 
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3.4 Preparation of mononuclear cells from synovial tissue. 
Mononuclear cells were isolated from synovial tissue specimens obtained from hip or 
knee joint replacement surgery. The extracellular matrix in animal tissues is made by 
collagens and other extracellular matrix proteins such as glycoproteins and 
proteoglycans. To isolate single cells without disrupting the cellular structure a 
combination of proteolytic enzymes is necessary to dissociate the tissue. Therefore, 
the synovial tissue was cut into small pieces and enzymatically digested in 1.5 ml RPMI 
(supplemented with 2% FBS) with 37 l collagenase D (100 mg/ml, Roche) and 2 µl 
DNase I (10 mg/ml) at 37 °C for 1 hour under shaking in a water-bath with tiny (~1-1.5 
cm long) magnetic stirrers. After the first digestion, the sample was incubated in 1.5 ml 
RPMI (supplemented with 2% FBS) with 37 l collagenase/dispase mix solution (100 
mg/ml, Roche) and 2 µl DNase I (10 mg/ml) at 37 °C for 30 min under shaking in the 
water-bath. After the second incubation, 15 l of 0.5 M EDTA were added to stop the 
reaction. Collagenase is an enzyme which is used for the dissociation of tissues since it 
breaks down the native collagen that holds tissues together. In particular, collagenase 
D is used to preserve functionality and integrity of cell-surface proteins. Dispase is a 
protease which is able to cleave fibronectin, collagen IV, and to a lesser extent collagen 
I. It is used for gentle dissociation with minimal cell damage. Both enzyme activities are 
inhibited by the addition of EDTA.   
The sample was then filtered through 40 m cell strainer (Sigma) to remove the 
remaining pieces of tissue and centrifuged at 1200 rpm for 10 min. The cells were 
resuspended in complete tissue culture media. Cells viability was determined by 
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Trypan blue exclusion test. The isolated cells were put in culture for 4 days in the 
presence of BAFF (100 ng/ml) in the culture media before starting the isolation of 
single CD19+ B cells by FACS sorting (see paragraph 3.5). A schematic summary of the 
procedure is provided in Figure 3.1. 




Figure 3.1 Preparation of mononuclear cells from synovial tissue.  
Schematic representation of synovial tissue digestion used to isolate mononuclear cells in order to sort single CD19+ B cells by FACS. 
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3.5 Fluorescence-activated cell sorting (FACS). 
Flow cytometry is a technique to measure optical and fluorescence characteristics of 
single cells. Inside a flow cytometer, cells in suspension are drawn into a stream which 
allows the cells to pass individually through a specific point where a beam of light 
(laser light) of single wavelength crosses the cells. Laser light is scattered in all 
directions. Light which scatters in line with the laser beam is called forward scatter 
(FSC); light that scatters perpendicular to the laser beam is called side scatter (SSC). 
FSC and SSC are related to physical properties of a cell which are size and internal 
complexity or granularity, respectively. When cells are stained with fluorochrome-
conjugated antibodies and passed through a laser beam, the fluorescent dyes can 
absorb energy and be induced to an excited electronic state. In returning to their 
normal level, the dyes release energy, most of which is emitted as light known as 
fluorescence emission. The scattered and fluorescent light is detected by 
photomultiplier tubes and analyzed by a computer. The data generated are plotted in 
a single dimension (histogram) or in two dimensions (dot plots). Fluorescence-
activated cell sorting (FACS) is a specific type of flow cytometry since it used for sorting 
a mixture of cells into two or more tubes or directly into 96/384-well plates, one cell at 
the time, based on the specific light scattering and fluorescent characteristics of each 
cell (Figure 3.2). Briefly, during the sorting the stream of cells is broken into 
individually droplets. When a particle is recognized based on predefined sorting 
criteria, an electrical charge is placed to the stream just as the droplet containing that 
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particle break off the stream. The charged droplets then fall through two charged 
plates that divert droplets into containers depending on the droplet charge.  
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Figure 3.2 Schematic explanation of fluorescent-activated cell sorting (FACS). 
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3.6 Phenotypic characterization of B cells by fluorescence 
activated cell sorting (FACS). 
Immunofluorescence labeling for flow cytometry was performed by staining the 
purified mononuclear cells on ice with PerCP-Cy5.5 anti-human CD19, APC anti-human 
CD27, PE anti-human IgD, and FITC anti-human CD3 in order to differentiate CD3-
CD19+CD27-IgD+ naïve B cells, CD3-CD19+CD27+IgD+ unswitched memory B cells and 
CD3-CD19+CD27+IgD- switched memory B cells, as previously described [82]. 
Mononuclear cells isolated from synovial tissues were stained only with PerCP-Cy5.5 
anti-human CD19 and FITC anti-human CD3, in order to isolate single CD19+ B cells. 
Mononuclear cells were aliquoted into an Eppendorf tube and centrifuged at 4300 rpm 
at 4 °C for 4 min. The cell pellet was resuspended in 100 l of FACS buffer staining 
solution containing all the antibodies at the appropriate final concentration (Table 
3.2). Incubation with antibodies was performed in the dark at 4°C for 30 min. The cells 
were washed with 1 ml FACS buffer and resuspended in FACS buffer at a final 
concentration of 107cell/ml. Finally, a blue-fluorescent dye (DAPI) which stains the 
nuclei was added to exclude dead cells. Flow cytometric analysis was performed with a 
FACSAria flow cytometer (Becton Dickinson); 50,000 events were collected for each 
analysis. Single staining was used for setting up the flow cytometer and to perform 
fluorescence compensation. It was done using Becton Dickinson compensation beads, 
according to the manufacturer’s instruction. Further controls were added and they 
were the fluorescence minus one (FMO) controls to set appropriately the cell 
population gates which is an important step especially for the single cell sorting.  











Table 3.2 List of antibodies used for FACS. 
Antibody Clone Conjugation Dilution Source 
CD19 SJ25C1 PerCP-Cy5.5 1/10 BD Biosciences 
IgD IA6-2 PE 1/10 BD Biosciences 
CD27 O323 APC 1/100 eBioscience 
CD3 HIT3a FITC 1/200 eBioscience 
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3.7 Isolation of single human B cells by fluorescence activated 
cell sorting. 
Single cells were sorted on a FACSAria flow cytometer directly into 96-well plates 
(Eppendorf) containing 4 l/well of ice-cold 0.5X PBS, 100 mM DTT (Invitrogen), 40 
U/l RNasin Ribonuclease Inhibitor (Promega) as previously described [34]. Plates 
were sealed with adhesive PCR foil (4titude) and immediately frozen on dry ice before 
storage at -80 °C. 
3.8 Single cell RT-PCR and immunoglobulin V gene amplification. 
cDNA was synthesized in a total volume of 14.5 l per well in the original 96-well 
sorting plate as previously described [34]. Total RNA from single cells was reverse 
transcribed in nuclease-free water (Qiagen) using 300 ng/l random hexamer primers 
(Roche), 25 mM each nucleotide dNTP-mix (Invitrogen), 100 mM DTT (Invitrogen), 10% 
NP-40 (Sigma), 40 U/l RNasin (Promega), and 50 U Superscript III reverse 
transcriptase (Invitrogen).  
Reverse transcription (RT) reaction was performed at 42 °C for 5 min, 25°C for 10 min, 
50 °C for 60 min and 94 °C for 5 min. cDNA was stored at -20 °C. For each cell IgH and 
corresponding IgL chain (Ig and Ig) gene transcripts were amplified independently by 
nested PCR starting from 2-3 l of cDNA as template. The nested PCR is a modification 
of the common PCR in which two sets of primers are used in two consecutive rounds 
of PCR. The second set of primers bind the first PCR product internally ensuring that 
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the product from the second PCR has little contamination, thus increasing the 
sensitivity and specificity of the PCR. 
All PCR reactions were performed in 96-well plates in a total volume of 40 l per well 
containing 50 mM each primer, 25 mM each nucleotide dNTP-mix (Invitrogen) and 1.2 
U HotStar Taq DNA polymerase (Qiagen) (Table 3.3 and 3.4) [34]. The HotStar Taq DNA 
polymerase has an error rate of 2x10-5 / nucleotide and cycle and it was chosen instead 
of high fidelity enzymes which introduce less error because the HotStar Taq DNA 
polymerase has a high amplification efficiency for low copy templates when starting 
from single cells [34]. All the primers used in this study were the same as previously 
published [34] with the exception in the use of a novel C internal primer 
(GGGAATTCTCACAGGAGACGA) in the second round of the nested PCR. All nested PCR 
reactions with family-specific primers were performed with 3 μl of unpurified first PCR 
product. Family-specific primers were selected based on the Ig gene sequence analysis 
(see paragraph 2.10). Each round of PCR was performed for 50 cycles at 94 °C for 30 s, 
58 °C (IgH/Ig) or 60 °C (Ig) for 30 s, 72 °C for 55 s (1st PCR) or 45 s (2nd PCR). All PCR 
products were analyzed on 2% agarose gels (~ 500 base pairs (bp) for IgH chain; ~ 400 
bp for IgL chains). A schematic representation of the strategy for single B cell sorting 
and Ig VH and VL genes amplification is reported in Figure 3.3. 
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Figure 3.3 FACS single cell sorting and immunoglobulin V gene amplification.  
Single cells were sorted on a FACSAria directly into a 96-well plate. cDNA was synthesized in the original sorting plate and used to amplify 
for each cell IgH, Igand Ig independently by nested PCR.  
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3.8.1 DNA electrophoresis on agarose gel. 
Agarose (Fischer Scientific) gels with a concentration of 2.0% in 1X TBE buffer were 
used to separate PCR products. DNA fragments were visualized by staining the gels 
with ethidium bromide (Sigma) in a soaking solution prepared with 25 l of ethidium 
bromide in 0.5 L distilled water. 100 bp marker (NEB) ranging from 100-1,517 bp was 
used as molecular weight standard. 
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3.9 Ig gene sequence analysis. 
Aliquots of VH, V and V chains second PCR products were sequenced with the 
respective reverse primer (Beckman Coulter Genomics) and the sequences were 
analyzed by IgBlast (http://www.ncbi.nlm.nih.gov/igblast/) to identify germline V(D)J 
gene segments with highest homology. IgH complementary determining region CDR3 
length and the number of positively (Histidine (H), Arginine (R), Lysine (K)) and 
negatively charged (Aspartate (D), Glutamate (E)) amino acids were determined as 
previously described [33, 34]. CDR3 length was determined as indicated in IgBlast by 
counting the amino acid residues following framework region FR3 up to the conserved 
tryptophan-glycine motif in all JH segments or up to the conserved phenylalanine-
glycine motif in JL segments. The numbers of V gene somatic mutations (replacement 
and silent mutations) were counted manually for FR1, FR2, FR3 and CDR1 and CDR2. 
Ratios of replacement to silent mutations in FR1-FR3 and CDR1 and CDR2 were 
calculated for each IGH, IGK and IGL chain gene and expressed as total number of 
sequences analysed for each IGH, IGK and IGL chain gene.  
The V gene somatic mutations for the clones isolated from the RA synovium was 
performed using IMGT/V-QUEST search page (http://imgt.org/IMGT_vquest). IMGT/V-
QUEST is a tool which is used to analyse the Ig nucleotide sequences [178]. Similar to 
IgBlast, IMGT/V-QUEST identifies the V, D and J genes and alleles in rearranged V-J and 
V-D-J sequences by alignment with germline Ig gene and allele sequences of the IMGT 
directory. It defines the FR regions and CDR regions and provides a detailed 
characterization of the query sequence. The algorithm used to identify the closest V, D, 
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and J genes and alleles is based on global pairwise alignment followed by a similarity 
evaluation. In particular, I used the nucleotide mutation option available on the 
IMGT/V-QUEST website which characterises the silent versus non-silent mutation in 
each FR region and CDR region in order to determine the R/S ratio.    
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1st PCR: C CH1 ext 1st PCR: C543 1st PCR: C 




1st PCR: C CH1 ext 
1st PCR: C543 
2nd PCR: C 494 
1st PCR: C 
2nd PCR: XhoI C 
2nd PCR: C IgG int 
1st PCR: C CH1 ext 





1st PCR: C CH1 ext 1st PCR: C543 1st PCR: C 
2nd PCR: C CH1 int 2nd PCR: C 494 2nd PCR: XhoI C 
CD3-CD19+ 
2nd PCR: C CH1 int 
1st PCR: C543 
2nd PCR: C 494 
1st PCR: C 
2nd PCR: XhoI C 
2nd PCR: C CH1 int 
1st PCR: C CH1 ext 
2nd PCR: C IgG int 
1st PCR: C CH1 ext 
2nd PCR: C CH1-2 
int 
Table 3.3 Reverse primers used to amplify IgH and IgL chain gene transcripts.  
IgH chain gene transcripts from SS naïve, memory switched and unswitched B cells 
were amplified using primers that bind the C, C or C constant region as indicated in 
the table for each population. cDNA from CD3-CD19+ B cells isolated from synovial 
tissue was amplified using primers that bind the C, C or Cconstant region in three 
independent nested PCR. Ig and Ig chain gene transcripts were amplified 
independently using same reverse primers for all the B cell populations.  
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Primer Sequence 
1st PCR HC Forward 5' to 3'
5'  L-VH 1 ACAGGTGCCCACTCCCAGGTGCAG
5'  L-VH 3 AAGGTGTCCAGTGTGARGTGCAG
5'  L-VH 4/6 CCCAGATGGGTCCTGTCCCAGGTGCAG
5'  L-VH 5 CAAGGAGTCTGTTCCGAGGTGCAG
Reverse 3' to 5'
3'  C  CH1 ext GGAAGGAAGTCCTGTGCGAGGC
3'  C CH1 ext GGAAGGTGTGCACGCCGCTGGTC
3'  C CH1 ext TGGGAAGTTTCTGGCGGTCACG
2nd PCR HC Forward 5' to 3'
5'  AgeI VH1 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAG
5'  AgeI VH1/5 CTGCAACCGGTGTACATTCCGAGGTGCAGCTGGTGCAG
5'  AgeI VH 1-18 CTGCAACCGGTGTACATTCCCAGGTTCAGCTGGTGCAG
5'  AgeI VH 1-24 CTGCAACCGGTGTACATTCCCAGGTCCAGCTGGTACAG
5'  AgeI VH3 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAG
5'  AgeI VH3-23 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGTTGGAG
5'  AgeI VH3-33 CTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG
5'  AgeI VH 3-9 CTGCAACCGGTGTACATTCTGAAGTGCAGCTGGTGGAG
5'  AgeI VH4 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAG
5'  AgeI VH 4-34 CTGCAACCGGTGTACATTCCCAGGTGCAGCTACAGCAGTG
5'  AgeI VH4-39 CTGCAACCGGTGTACATTCCCAGCTGCAGCTGCAGGAG
5'  AgeI VH 6-1 CTGCAACCGGTGTACATTCCCAGGTACAGCTGCAGCAG
Reverse 3' to 5'
3'  C  CH1 int GGGAATTCTCACAGGAGACGA
3'  C IgG int GTTCGGGGAAGTAGTCCTTGAC
3'  C CH1-2 int GTCCGCTTTCGCTCCAGGTCACACT  
Table 3.4 Complete list of primers used in this study.  
The table lists the primers used to amplify the Ig heavy chain. 
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1st PCR  LC Forward 5' to 3' 
5'  L V  1 GGTCCTGGGCCCAGTCTGTGCTG
5'  L V  2 GGTCCTGGGCCCAGTCTGCCCTG
5'  L V  3 GCTCTGTGACCTCCTATGAGCTG
5'  L V  4/5 GGTCTCTCTCSCAGCYTGTGCTG
5'  L V  6 GTTCTTGGGCCAATTTTATGCTG
5'  L V  7 GGTCCAATTCYCAGGCTGTGGTG
5'  L V  8 GAGTGGATTCTCAGACTGTGGTG
Reverse 3' to 5'
3'  C CACCAGTGTGGCCTTGTTGGCTTG
2nd PCR l LC Forward 5' to 3' 
5'  AgeI V  1 CTGCTACCGGTTCCTGGGCCCAGTCTGTGCTGACKCAG
5'  AgeI V  2 CTGCTACCGGTTCCTGGGCCCAGTCTGCCCTGACTCAG
5'  AgeI V  3 CTGCTACCGGTTCTGTGACCTCCTATGAGCTGACWCAG
5'  AgeI V  4/5 CTGCTACCGGTTCTCTCTCSCAGCYTGTGCTGACTCA
5'  AgeI V  6 CTGCTACCGGTTCTTGGGCCAATTTTATGCTGACTCAG
5'  AgeI V  7/8 CTGCTACCGGTTCCAATTCYCAGRCTGTGGTGACYCAG
Reverse 3' to 5'
3'  XhoI C CTCCTCACTCGAGGGYGGGAACAGAGTG
1st PCR LC Forward 5' to 3' 
5'  L V 1/2 ATGAGGSTCCCYGCTCAGCTGCTGG
5'  L V 3 CTCTTCCTCCTGCTACTCTGGCTCCCAG
5'  L V4 ATTTCTCTGTTGCTCTGGATCTCTG
Reverse 3' to 5'
3'  C 543 GTTTCTCGTAGTCTGCTTTGCTCA
2nd PCR k LC Forward 5' to 3' 
5'  Pan V  ATGACCCAGWCTCCABYCWCCCTG
Reverse 3' to 5'
3'  C 494 GTGCTGTCCTTGCTGTCCTGCT
Specific k LC Forward 5' to 3' 
5'  AgeI V 1-5 CTGCAACCGGTGTACATTCTGACATCCAGATGACCCAGTC
5'  AgeI V 1-9 TTGTGCTGCAACCGGTGTACATTCAGACATCCAGTTGACCCAGTCT
5'  AgeI V 1D-43 CTGCAACCGGTGTACATTGTGCCATCCGGATGACCCAGTC
5'  AgeI V 2-24 CTGCAACCGGTGTACATGGGGATATTGTGATGACCCAGAC
5'  AgeI V 2-28 CTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC
5'  AgeI V 2-30 CTGCAACCGGTGTACATGGGGATGTTGTGATGACTCAGTC
5'  Age V 3-11 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACACAGTC
5'  Age V3-15 CTGCAACCGGTGTACATTCAGAAATAGTGATGACGCAGTC
5'  Age V 3-20 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACGCAGTCT
5'  Age V 4-1 CTGCAACCGGTGTACATTCGGACATCGTGATGACCCAGTC
Reverse 3' to 5'
3'  BsiWI J 1/4 GCCACCGTACGTTTGATYTCCACCTTGGTC
3'  BsiWI J 2 GCCACCGTACGTTTGATCTCCAGCTTGGTC
3'  BsiWI J 3 GCCACCGTACGTTTGATATCCACTTTGGTC
3'  BsiWI J 5 GCCACCGTACGTTTAATCTCCAGTCGTGTC  
Table 3.4 Complete list of primers used in this study. The table lists the primers used 
to amplify the Ig light chains (c and c). 
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3.10  Expression vector cloning.  
Before cloning, all PCR products were purified with NucleoSpin Extract II (Macherey-
Nagel) according to the manufacturer’s instruction and the digests were carried out 
with the respective restriction enzymes HF AgeI (20 units/l), HF Sall (20 units/l), 
BsiWI (10 units/l) and HF XhoI (20 units/l) (all from NEB). The digestion was 
performed using one unit of enzyme per reaction for 2 hour at 37 °C (AgeI, SalI and 
XhoI) and a further incubation at 55 °C for 2 hours for BsiWI (kappa chain digestion) in 
40 l reaction volume. Digested PCR products were purified with NucleoSpin Extract II 
and ligated using the T4 DNA Ligase (NEB) into human IgG1, IgK or IgL expression 
vector (Figure 3.4) for 1 hour at room temperature in 10 l reaction volume. The 
vectors were kindly provided by Prof Hedda Wardemann (Berlin, Germany). 





Figure 3.4 Schematic expression vector maps [34].  
Eukaryotic expression vectors contain a murine Ig gene leader peptide sequence (GenBank accession no. DQ407610) and a multiple 
cloning site upstream of the human Ig1, Ig or Igconstant regions. Relevant restriction sites for each vector are indicated. Transcription 
is under the influence of the human cytomegalovirus (HCMV) promoter and bacterial clones containing the vectors can be selected based 
on their resistance to ampicillin. 
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Competent E. coli DH10B bacteria (NEB) (5 l per reaction) were thawed on ice and 3 
l of the ligation product were subsequently added. Cells and DNA were incubated on 
ice for 30 min. This step was followed by an Heat Shock at 42 °C for 20 sec. Cells and 
DNA were left to incubate at 37 °C for 30 min with shaking at 180 rpm. Cells and DNA 
were finally plated into selection LB plates containing 100 g/ml ampicillin and left to 
incubate at 37 °C over night. Colonies were screened by PCR using 5’ Absense 
(GCTTCGTTAGAACGCGGCTAC) as forward primer and 3’ CIgG internal, 3’ C494 or 3’ 
C as reverse primer, respectively. PCR products (analyzed on 2% agarose gels) of the 
expected size (650 bp for Ig1, 700 bp for Ig and 590 bp for Ig) were sequenced to 
confirm identity with the original PCR products. Plasmid DNA was isolated from 4 ml of 
bacteria cultures grown for 16 hours at 37 °C on a shaker (200 rpm) in Terrific Broth 
(TB) medium containing 100 g/ml Ampicillin, using NucleoSpin Plasmid (Macherey-
Nagel). Before purification bacteria cultures were centrifuged for 5 min at 6000 rpm in 
a microcentrifuge. Supernatant was discarded and the plasmid pellet used to start the 
purification procedure, according to the manufacturer’s instruction. After purification 
plasmid concentration was measured with Nanodrop 2000c (ThermoScientific). 
3.11  Recombinant antibody production. 
To express the antibodies in vitro, HEK 293T cells cultured in 150 mm or 6-well plates 
(Falcon, BD) were co-transfected with plasmids encoding the IgH and IgL chains 
originally amplified from the same B cell. Transient transfection of exponentially 
growing 293T cells was performed by Polyethylenimine (PEI) at 60-70% cell confluency. 
PEI is a cationic polymer able to condense the DNA into positively charged particles 
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which are brought into the cells via endocytosis. Once inside the cell, the vesicle 
releases the polymer-DNA complex into the cytoplasm. If the complex unpacks then 
the DNA is able to diffuse into the nucleus.  
On transfection day complete medium was washed off and replaced with “Nutridoma” 
medium before the addition of the transfection solution. Transfection solution was 
prepared by adding each heavy and light chain plasmid at the same concentration (15 
g for 150 mm plate and 0.81 g for 6-well plate), 150 mM NaCl solution, and PEI at a 
3:1 ratio (weight/weight) with total vector DNA (3 g of PEI per g DNA). The solution 
was mixed thoroughly and incubated at room temperature for 10 min and then added 
to the cells. The cells secreted the antibodies into the tissue culture supernatant which 
was collected at day 3 and 5. Culture supernatant was cleared from cell debris by 
centrifugation at 2000 rpm for 10 min and stored at 4 °C with 0.05% NaN3. 
Recombinant antibody concentrations were determined by ELISA (see paragraph 3.13) 
before purification with Protein G beads (GE Healthcare).  
3.12  Purification of monoclonal antibodies using Protein G 
Beads. 
Protein G binds to the Fc region of IgG from a variety of mammalian species. Protein G 
Sepharose 4 Fast Flow (GE Healthcare) is used to isolate and purify classes, subclasses 
and fragments of immunoglobulins from any biological fluid or cell culture medium. 
Cell culture supernatant was incubated with 1 l/ml of Protein G beads for at least 14 
hours at 4 °C under rotation. Supernatant was removed after centrifugation at 2000 
rpm for 10 min and the beads were transferred to a chromatography spin column 
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(BioRad) equilibrated with PBS. After two rounds of washing with 1 ml PBS, antibodies 
were eluted in 3–4 fractions (200 μl each) with 0.1 M glycine (pH 3.0). Eluates were 
collected in tubes containing 20 μl 1 M Tris-HCl (pH 9.0) with 0.5% NaN3. Recombinant 
antibody concentrations were determined by ELISA (see paragraph 3.13). 
3.13  Human IgG ELISA test. 
Recombinant antibody concentrations were determined by ELISA using 1 µg/ml and 3 
g/ml human serum IgG1 (Sigma) diluted in PBS as standards. ELISA plates (Thermo 
Scientific) were coated with 50 µl/well goat anti-human IgG (Fc specific; Jackson) at a 
concentration of 2 µg/ml in 1X PBS. Plates were washed with deionized water before 
incubation for 1 hour with 200 µl/well 2mM EDTA and 0.05% Tween 20 in 1X PBS and 
washed again. Standard and samples were transferred into the ELISA plate and 
incubated for 1 hour. Unbound antibodies were removed by washing before 
incubation for 1 hour with 50 µl/well of horseradish peroxidise (HRP) coupled goat 
anti-human IgG (Jackson) at a concentration of 0.8 µg/ml in 1X PBS, 2 mM EDTA, 0.05% 
Tween 20. Assays were developed using TMB Substrate Reagent Set (BD OptEIA). 
Optical densities (OD) were measured at 450 nm. All steps were performed at room 
temperature. 
3.14  Characterization of polyreactivity and self-reactivity by 
ELISA. 
To test the reactivity against different allo- and auto-antigens, supernatants were 
tested for polyreactivity against double and single-stranded DNA (dsDNA and ssDNA), 
lipopolysaccharide (LPS) and insulin by ELISA, as previously reported [34]. Antibodies 
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that reacted against at least two structurally diverse self- and non-self-antigens were 
defined as polyreactive [33, 34]. Internal controls for polyreactivity were added on 
each plate consisting of the recombinant monoclonal antibodies mGO53 (negative), 
JB40 (low polyreactive), and ED38 (highly polyreactive), as previously reported [34]. 
ELISA plates were coated with 50 l/well of individual antigens at a concentration of 10 
g/ml for dsDNA (Invitrogen), ssDNA and LPS (Sigma), or 5 g/ml for insulin (Sigma) in 
1X PBS. Each plate was washed with deionized water before incubation for 1 hour with 
200 µl/well 2mM EDTA and 0.05% Tween 20 in 1X PBS and washed again. Samples and 
controls were used at three consecutive 1:4 dilutions in 1X PBS starting from 1 g/ml 
and were then transferred into the ELISA plate and incubated for 1 hour. Unbound 
antibodies were removed by washing before incubation for 1 hour with 50 µl/well of 
HRP coupled goat anti-human IgG at a concentration of 0.8 µg/ml in 1X PBS, 2 mM 
EDTA, 0.05% Tween 20. Assays were developed using TMB Substrate Reagent Set (BD 
OptEIA). Optical densities (OD) were measured at 450 nm. All steps were performed at 
room temperature. 
3.14.1 Total ENA, anti-SSA/Ro and anti-SSB/La ELISA. 
Protein G purified antibodies were also tested for reactivity against extractable nuclear 
antigens (ENAs) as well as anti-Ro/SSA and anti-La/SSB using commercially available 
ELISA kits commonly used in diagnostic labs (DIASTAT ENA Single Well Screen and anti-
Ro/La ELISA plates, Euro Diagnostica). In the ENA ELISA each well is coated with a mix 
of six purified antigens (Sm, RNP, Ro/SSA, La/SSB, Scl-70 and Jo-1). All ELISA tests were 
performed according to the manufacturer’s instruction. Briefly, controls and samples 
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were added to the antigen(s) coated plate and incubated for 1 hour at room 
temperature at a concentration of 10 g/ml. Each plate was washed and incubated 
with 100 l of Conjugate (enzyme labelled antibodies to human IgG) for 30 min. After 
further washing the assay was developed using the Substrate solution provided by the 
kit. OD were measured at 550 nm. Besides the internal controls provided by the ELISA 
kit, a further control used for the ENA and anti-Ro/SSA ELISA was the recombinant 
monoclonal antibody SLE175-128 that shows specificity for Ro52 [177].  
3.15  Indirect Immunofluorescence Assay (IIF) using Hep-2 
cells. 
Self-reactivity against anti-nuclear antigens (ANA) was tested by indirect-
immunofluorescence assay (IIF) using human epithelial cells (Hep-2) coated slides as 
substrate (ByoSystems), as previously reported [34]. ANA Hep-2 is used normally for 
determination of antibodies to nuclear and cytoplasmic antigens in clinical diagnostic. 
Several patterns can be distinguished after fluorescence exposure based on the 
nuclear morphology and mitosis phase of the Hep-2 cell. The main nuclear patterns are 
classified as follows: homogeneous, peripheral (rim), speckled (coarse or fine), 
nucleolar, and centromere. In this study, the result was given only as negative, nuclear, 
cytoplasmic and mixed nuclear/cytoplasmic staining patterns. Hep-2 slides were 
incubated with 20 l of protein G purified antibodies at 10 g/ml for 1 hour at room 
temperature in a moist chamber. After washing with 1X PBS the slides were incubated 
for 30 min with Alexa Fluor 488-conjugated goat anti-human IgG in the dark 
(Invitrogen, dilution 1/200). Controls staining with PBS as negative control and ANA 
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positive control sera were added in all experiments. Hep-2 staining patterns were 
visualised using an Olympus BX60 microscope and digital images acquired using 
identical exposure times throughout (1000 msec). ANA were scored independently by 
3 trained observers and considered positive in case of concordance by at least 2 
observers.  
3.16  Anti-CCP ELISA test. 
Protein G purified antibodies generated from RA synovial B cells were tested towards a 
synthetic cyclic peptide containing modified arginine residues (CCP2 peptides) using 
commercially available ELISA kits commonly used in diagnostic labs (Anti-CCP, 
FCCP600, Axis-Shield). Anti-CCP antibodies, mainly known as anti-citrullinated 
protein/peptide antibodies (ACPA), are an important diagnostic marker in RA. In the 
anti-CCP ELISA test, each well is coated with a highly purified synthetic cyclic 
citrullinated peptide containing modified arginine residues. The anti-CCP ELISA test 
was performed according to the manufacturer’s instruction. Briefly, controls and 
samples were added to the coated plate and incubated for 1 hour at room 
temperature at a concentration of 10 g/ml. After a washing step, the plate was 
incubated with 100 l of Conjugate (enzyme labelled polyclonal antibody to human 
IgG) for 30 min. After further washing the assay was developed using the Substrate 
solution provided by the kit. OD were measured at 450 nm. 
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3.17  Histological characterization of lymphocytic aggregates 
within RA synovial tissue. 
Sequential paraffin-embedded 5µm sections of synovial tissue were stained for the 
markers CD3, CD20 and CD138 following routine H&E staining to classify the 
lymphocytic infiltration as aggregate or diffuse, as previously reported [179, 180]. 
Briefly, after de-waxing and re-hydration synovial paraffin sections underwent Ag 
retrieval with Target retrieval solution (pH 6; DAKO). After incubation with protein 
block solution (DAKO), staining for the cellular markers CD3 (1:80 dilution; DAKO), 
CD20 (1:50 dilution, DAKO), and CD138 (1:50 dilution, DAKO) was performed. Primary 
antibodies were incubated at the appropriate dilution for 1h at room temperature. 
After 3 washes with TBS, sections were incubated with the EnVision System (DAKO), 
used according to manufacturer’s instructions, for 30 minutes at room temperature. 
The colour reaction was developed with diaminobenzidine (DAKO). All sections were 
visualised using an Olympus BX60 microscope. 
3.18  Statistical analysis. 
Differences in quantitative variables were analyzed by the Mann-Whitney U test when 
comparing two groups and by the Kruskal-Wallis with Dunn’s post-test when 
comparing multiple groups. χ2 test with Yates’ correction when required or Fisher’s 
exact test when appropriate were used to evaluate associations of qualitative variables 
in the different groups. All the statistical analyses were performed using GraphPad 
Prism version 5.01 for Windows (GraphPad, San Diego, CA). A p value <0.05 was 
considered statistically significant. For the ELISAs, the cut-off OD at which all 
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antibodies were considered reactive was determined for each experiment based on 
the mean OD plus 2 standard deviations of the control antibodies obtained from HD 
(naïve B cell antibodies) or other internal controls (mGO53 antibody [34]).  










Chapter 4 | Results 
Recombinant monoclonal antibodies from 
single naïve B cells of patients with Sjögren's 
syndrome 
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4 | Accumulation of circulating autoreactive naïve B cells 
reveals defects of early B cell tolerance checkpoints in 
patients with Sjögren’s syndrome. 
4.1 Introduction. 
As explained in Section 1.2, SS is a chronic inflammatory/autoimmune disease 
characterised by immune cell infiltration in the salivary and lacrimal glands leading to 
the classical signs and symptoms of xerostomia (dry mouth) and keratoconjuctivitis 
(dry eyes) sicca [69]. Together with exocrine dysfunction, the hallmark of SS is the 
presence of circulating autoantibodies directed against organ- and non-organ-specific 
autoantigens. Sera of 90% of SS patients are characterised by the presence of 
antinuclear antibodies (ANA), some of which react against the ribonucleoproteins 
Ro/SSA (60%) and La/SSB (40%) [88].  
Besides the presence of autoantibodies, SS patients are characterised by profound 
disturbances in the frequency of different B cell subpopulations, both in the peripheral 
compartment and in the inflamed salivary glands. As explained previously, SS patients 
show a large predominance of circulating CD27- naïve B cells and a significant 
reduction of peripheral CD27+ memory B cells, in particular the memory unswitched 
CD27+IgD+ subpopulation [87]. Conversely, a significant accumulation of both CD27+ 
memory and (to a lesser extent) CD27- naïve B cells have been described in the SS 
salivary glands [73, 87, 166], possibly as a result of increased migration/retention in 
the inflamed tissue, particularly in the context of ectopic lymphoid structures which 
develop in ~30% of SS salivary glands [141, 150, 181]. 
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However, despite the evidence of profound peripheral and lesional B cell disturbances 
and humoral autoimmunity in SS, the mechanisms underlying the development of 
breach of self-tolerance and the onset of B cell autoreactivity in SS patients are still 
unclear. 
In physiological conditions, self-reactive (and polyreactive) B cells, which are normally 
generated in the bone marrow as a consequence of random V(D)J recombination 
process, are silenced before entering the mature peripheral B cell compartments at 
two major tolerance checkpoints. The first occurs in the bone marrow between the 
early immature and immature B cell stage, while the second checkpoint between the 
transitional and the mature naïve B cell stage allowing the reduction of 
autoreactive/polyreactive B cells from the peripheral, circulating naïve pool [33, 182, 
183]. Conversely, during autoimmune diseases, such as rheumatoid arthritis (RA) and 
systemic lupus erythematosus (SLE), perturbation of these early B cell tolerance 
checkpoints have been described, as demonstrated by the increased frequency of 
polyreactive and self-reactive B cells in the naïve peripheral B cell compartment [42, 
182]. 
However, whether similar defects in B cell differentiation tolerance checkpoint are 
present in SS patients is currently unknown. In this part of my PhD project I 
characterised the frequency of self- and poly-reactive circulating naïve B cells from 
patients with SS using a recently pioneered approach [33, 34] which allows the analysis 
of reactivity of the B cell receptor (BCR) of single B cells through the cloning and in 
vitro expression of complete (i.e., IgH+IgL chains) recombinant monoclonal antibodies 
which bear identical specificity to the original B cells (for more details see Chapter 2).   
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4.2 SS patients. 
Out of 96 single CD3-CD19+CD27-IgD+ naïve B cell sorted from each of the 4 out of 12 
SS patients (SS3, SS5, SS12, and SS13), I obtained successful sequences from a total of 
119 different VH and JH regions (SS3=19, SS5=53, SS12=17, SS13=30), 73 V and J 
regions (SS3=17, SS5=31, SS12=2, SS13=23), and 36 V and J regions (SS3=13, SS5=10, 
SS12=10, SS13=3). Similarly, we obtained successful sequences from a total of 78 
different VH and JH regions from 2 healthy donors (JH and HD2). Clones with matching 
and productive VH and VL products were used for downstream cloning and 
recombinant antibody expression. All productive VH and VL products displayed 
unmutated germ line sequences. 
4.3 Peripheral B cell subpopulation disturbances in SS patients. 
Previous studies analyzing B cell subpopulations in SS patients have shown a 
significantly reduction of circulating CD27+ memory B cells with accumulation of CD27- 
naïve B cells [82]. Thus, I first used 4-color flow cytometry to analyze the frequency of 
naïve (CD3-CD19+CD27-IgD+), class-switched memory B cells (CD3-CD19+CD27+IgD-) 
and unswitched memory B cells (CD3-CD19+CD27+IgD+) in 12 patients with SS (Figure 
4.1A). This analysis confirmed that in our cohort of SS patients the frequency of 
circulating CD27- naïve B cells was increased compared to HD (mean±SD 68.5±16.0% 
versus 45.8±6.7%, respectively), whereas the frequency of CD27+ switched (6.0±5.2% 
versus 17.5±8.1%) and unswitched (4.9±6.6% versus 20.6±2.4%) memory B cells was 
significantly reduced in peripheral blood of the SS patients analyzed compared to 
controls (Figure 4.1B, including p values).  
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Figure 4.1 Isolation strategy of single naïve B cells and comparison of the frequencies 
of naïve, memory switched and unswitched B cells in SS patients and HD.  
(A) PBMCs from SS patients were surface labeled with fluorochrome-coupled anti-
CD19, anti-CD3, anti-IgD and anti-CD27. CD19+CD3- cells were gated and analyzed for 
IgD and CD27 expression. The sorting gate strategy for single CD19+CD3-CD27-IgD+ 
naïve, CD19+CD3-CD27+IgD+ unswitched memory, and CD19+CD3-CD27+IgD- class-
switched memory B cells is shown. (B) The frequencies of peripheral naïve (CD3-
CD19+CD27-IgD+), memory switched (CD3-CD19+CD27+IgD-) and unswitched (CD3-
CD19+CD27+IgD+) B cells among all CD19+ B cells are shown. Differences between 
patients (n=12) and HD (n=3) were found to be statistically significant using the 
nonparametric Mann-Whitney U test (p value is reported over each graph). Error bars 
indicate standard error of the mean (SEM) for individual patient or control.  
Page | 138  
 
4.4 Immunoglobulin (Ig) gene repertoire characterization of 
naïve B cell antibodies cloned from SS peripheral blood B cells. 
I studied four patients with a diagnosis of primary SS (SS3, SS5, SS12, and SS13) and 
two HD as control (JH [177] and HD2). All 4 SS patients displayed anti-Ro positivity, 
whereas 2 out of 4 reacted against La (Table 2.1). To characterise the Ig genes 
expressed by naïve B cells in these SS patients, I sorted CD3-CD19+CD27-IgD+ naïve B 
cells as single cells by flow cytometry from peripheral blood. The analysis of 119 V(D)J 
gene segments demonstrated a similar variable VH, D and JH gene repertoire in control 
and SS naïve B cells (Figure 4.2A). VH3 was expressed more frequently, as expected 
since it is the largest variable region family, followed by VH4 and VH1 both in SS 
patients and HD. I found a frequent usage of JH4 followed by JH6, JH5 and JH3 while 
JH1 and JH2 were expressed less frequently both in SS patients and controls, as 
previously shown [173]. Similarly, no significant differences in V and J gene usage for 
kappa (, 73 sequences) and lambda (, 36 sequences) chains were observed between 
SS patients and HD (Figures 4.3A and 4.3B). SS naïve Ig gene transcripts displayed a 
significantly higher frequency of positively charged IgH complementary determining 
regions 3 (CDR3s), a feature commonly associated with autoreactive antibodies [33] 
(Figure 4.2B, bottom panel). However, the frequency of long CDR3s, another feature 
frequently displayed by polyreactive antibodies [33], was similar between HD and SS 
patients (Figure 4.2B, top panel). Thus, I concluded that overall there are no major 
abnormalities in the Ig gene repertoire of circulating naïve B cells in SS patients as 
previously reported [82].  
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Figure 4.2 IgH gene analysis of naïve B cells from SS patients and HD.  
Single naïve B cell antibodies from four SS patients and two HD [177] were analyzed for 
(A) IGH V family and J gene usage, and (B) IgH CDR3 aa length and positive charges. 
The absolute number of sequences analyzed is reported over each graph. Error bars in 
bar graphs indicate standard error of mean (SEM) for individual patient or control.  
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Figure 4.3 IgL gene analysis of naïve B cells from SS patients and HD.  
Single naïve B cell antibodies from four SS patients and two HD were analyzed for IGK 
(A) and IGL (B) V family and J gene usage. The absolute number of sequences analyzed 
is reported over each graph. Error bars in bar graphs indicate standard error of mean 
(SEM) for individual patient or control.  
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Table 4.1 IgH and L gene repertoire analysis and reactivity of IgD+ single B cells from 4 SS patients. Clones highlighted in grey are those 
expressed as recombinant antibodies. (-) and (+), negative and positive charges within the heavy chain CDR3; length, number of amino 
acids within the CDR3; +, clones reactive in ELISA/IFA; -, clones non-reactive in ELISA/IFA; ND, not determined; C, cytoplasmic pattern; N, 
nuclear pattern. 
 
Patient 3 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
1n.3 3-74 2-2 1P 1 VLQQPSPLYFDY 0 12  2-14 1 0 SSYTSSSTLV 0 10 - - + - - - -- - -
2n.3 3-30 6-6 6 1 DLYSSSPPGY 0 10  2-11 1 0 CSYAGSYTYV 0 10 nd nd nd nd nd nd -- nd nd
3n.3 3-66 5-12 3 2 PYSGYDPRGAFDI 1 13  3-9 2/3 1 QVWDSSTVV 0 9 - - - - - - -- - -
4n.3 4-61 3-9 4 2 GARTYYDILTGYSTFDY 1 17  1D-39 1 0 QQSYSTPRT 1 9 - - + - + + C + -
5n.3  1-51 1 1 GTWDSSLSAYV 0 11
10n.3  1-40 1 1 QSYDSSLSGSSYV 0 13
11n.3 1-18 1-26 4 1 DLVYSGSYGY 0 10  3-11 2 0 QQRSNWPPYT 1 10 - - - - nd nd -- - -
16n.3 3-11 5-5 3 1 VGGGYQGAFDI 0 11  3-15 1 0 QQYNNWPPWT 0 10 - - - - - + C - -
17n.3  1-9 2 0 QQLNSYPYT 0 9
19n.3 4-39 3-9 4 1 LRGGSPFLFDY 1 11  3-15 1 0 QQYNNWPKT 1 9 - - - - - - -- - -
20n.3 3-13 3-10 4 2 GNFDSYYYGSGSPFDY 0 16  1-5 1 0 QQYNSYSTWT 0 10 - - - - - - -- - -
22n.3  1-5 5 0 QQYNSYSPIT 0 10
24n.3 1-3 3-22 6 2 DDSSGYYY 0 8  1D-33 2 1 QQYDNLPT 0 8 - - - - - - -- - -
27n.3  2-14 3 0 SSYTSSSTWV 0 10
28n.3 3-64 3-22 3 1 SVVTMIVVGGRSAFDI 1 16  3-11 2 0 QQRSNWPPYT 1 10 + - - - + - -- + +
31n.3  2D-29 1 0 MQSIQLPPT 0 9
32n.3 3-7 3-10 6 2 LPRDYYGSGSYLYYFDY 1 17  3-15 4 0 QQYNNWPPLT 0 10 - - - - - - -- - -
35n.3 3-7 3-9 4 2 DILTGYSVTFDY 0 12  3-20 2 0 QQYGSSPMYT 0 10 - - - - - - -- - -
36n.3 4-61 3-10 4 3 TEGDYYGSGSQRGFDY 1 16  1-5 1 0 QQYNSYPWT 0 9 - - - - + - -- - -
37n.3 4-61 4-17 6 3 DHGDRRYYYYYMDV 3 14  2-14 2/3 0 SSYTSSSTLVV 0 11
42n.3  3-15 3 0 QQYNNWPFT 0 9
43n.3  1D-39 5 0 QQSYSTSIT 0 9
44n.3  1-17 2 0 LQHNSYPYT 1 9
47n.3 3-30 3-9 4 3 EDYNSFDY 0 8  1-27 3 0 QKYNSAPFT 1 9 - - - - - + C - -
50n.3  2-14 3 0 SSYTSSWV 0 8
54n.3 4-39 6-25 3 3 HDPGDLRGAFDI 2 12  2-23 2/3 0 CSYAGSSTLV 0 10 - - - - - + C - -
68n.3 3-23 3-9 4 4 DRMGYFDYGDYFDY 1 14  1-47 3 2 AAWDDSLSGWV 0 11 - - - - - - -- - -
78n.3 3-13 6-19 3 3 RRGQWLGADDAFDI 2 14  1-44 2/3 2 AAWDDSLNGVV 0 11 - - - - - - -- - -
79n.3 3-7 2-2 4 1 TRSSTFD 1 7  2-11 2/3 0 CSYAGSYTWV 0 10 - - - - - - -- - -
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Patient 5 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
2n.5 4-59 4-23 4 1 GRTTVVRGNYFDY 2 13  2-14 1 0 SSYTSSSTYV 0 10 - - - - nd nd -- nd nd
3n.5 4-39 6-19 5 2 QKQWLVEYWFDP 1 12
4n.5 3-7 5-5 4 0 VVYSYGYNY 0 9  3-15 1 1 QQYNNWPPET 0 10 - - - - - + C+N - -
5n.5 4-61 3-22 3 3 DSWYYYDRGGAFDI 1 14  3-20 3 0 QQYGSSPFT 0 9
6n.5 3-21 5-5 5 2 NRGYSYGTDWFDP 1 13  1-51 2/3 1 GTWDSSLSAVV 0 11
8n.5 3-11 3-22 5 3 VDQSYYDSSGPHWWFDP 1 17  1-51 2/3 1 GTWDSSLSAVV 0 11
11n.5 1-18 2-8 6 2 VGSTGGDYYYYGMDV 0 15  2-30 1 0 MQGTLART 1 8 - - - + - - -- - -
12n.5 4-4 3-22 4 1 GISSGWAGKFDY 1 12  2-14 2/3 0 SSYTSSSTRRVV 2 12 + + + + + + C+N + +
14n.5 3-30 6-13 6 2 SRERAAAVPGVVMSYGMDV 2 19  1-9 3 0 QQLNSYFT 0 8 + + + + - - -- - -
17n.5 3-30 5-5 4 4 DEGDTAMGPFDY 0 12  1-5 1 0 QQYNSYWT 0 8 - - - - - + C - -
18n.5 3-30 6-13 4 1 DSYSSSPRGY 1 10
19n.5 4-34 6-6 4 1 ESSSHLLGY 1 9  2-28 2 0 MQALQTPRT 1 9
20n.5 3-48 7-27 6 2 DIGINWGFYYYYYGMDV 0 17  1-9 4 0 QQLNSYPPVT 0 10 + - - - + + C+N - +
22n.5 4-4 3-3 5 2 ETIFGVVIISNWFDP 0 15  3-11 4 1 QQRSNWPPELT 1 11 - - - - - - -- - -
23n.5 3-23 2-2 4 1 GPAIVVVPAAMPSWFDY 0 17
24n.5 4-59 4-23 4 1 AVVLDY 0 6  3-20 2 0 QQYGSSPQT 0 9 - - - - - + C - -
29n.5 1-24 4-23 2 1 ASRWYFDL 1 8  3-11 3 0 QQRSNWPFT 1 9
30n.5 3-30-3 3-3 5 1 VRFLEWLFT 1 9   
31n.5 3-30-3 3-22 4 3 DRRYYYDSSGYLDY 2 14
32n.5 3-23 5-5 6 1 GTAMYYYYYGMDV 0 13
33n.5 3-43 2-15 4 1 GGSCSGGSCYVGPDY 0 15  1-39 3 0 QQSYSTPFT 0 9
36n.5 4-34 5-5 4 1 ARYTAMAKCFDY 2 12
37n.5  4-61 5-12 6 1 TATYYYYGMDV 0 11
38n.5 3-30-3 2-15 3 2 EVDCSGGSCYSLAS 0 14  2-28 4 0 MQALQTPVT 0 9
40n.5 1-46 1-26 4 1 GKARSYFDY 2 9  3-20 1 0 QQYGSSPTT 0 9
41n.5 3-49 2-15 4 1 VLYCSGGSCHGAFDY 1 15  1-33 2 1 QQYDNLPYT 0 9
44n.5 3-48 3-22 4 3 VHLYYYDSSGYYYDDY 1 16  3-11 4 0 QQRSNWPLLT 1 10 - - - - nd nd -- - -
45n.5 4-b 3-16 5 2 VERIAGGALARIDP 2 14
50n.5  3-20 1 1 QQYGSSPET 0 9
54n.5 3-30-3 5-5 6 2 DRGLSGYSYGHWAYYYGMDV 2 20  1-51 2/3 2 GTWDSSLSAEVV 0 12 - + - - - - -- - -
56n.5 4-34 6-19 5 2 RGKARYSSGWYKDNWFDP 4 18  2-23 2/3 0 CSYAGSPV 0 8 - - - - + - -- + +
59n.5 3-30 3-9 5 3 DPQNENWSPPYNWFDP 0 16  1-44 1 2 AAWDDSLNGRV 1 11 - - - - - - -- - -
60n.5 3-7 6-13 3 2 AKRQLDAFDI 2 10  3-15 3 0 QQYNNWPSFT 0 10 - - - - - - -- - -
61n.5 3-21 3-16 4 3 IDGLRLGELSLVRSPDC 2 17  3-11 5 0 QQRSNWPPVT 1 10 - - - - + - -- - -
62n.5 3-23 3-22 6 2 EGLIVVVIGGMDV 0 13  1-44 2/3 2 AAWDDSLNGVV 0 11
63n.5 3-30 6-6 6 2 DIAARSYYYYGMDV 1 14  3-15 1 0 QQYNNWPRT 1 9
64n.5 1-24 1-26 5 1 LPWDSGSHGGLV 1 12
66n.5 4-39 4-17 4 4 DHPLYDYGDLGPRVLFDY 2 18  1-44 2/3 2 AAWDDSLNGVV 0 11
67n.5 4-61 1-7 5 1 APRVRVGLDS 2 10  3-20 2 0 QQYGSSPLT 0 9 - + - - - + C - -
68n.5 4-59 5-24 4 1 AGLGYRRYYFDY 2 12  2-29 2 0 MQSIQPYT 0 8
69n.5 1-2 5-18 6 2 TYGDGMDV 0 8  3-20 1 0 QQYGSSLWT 0 9 - - - - - + C - -
72n.5 4-59 6-6 5 1 VGVAARPGGWFDP 1 13  4-1 2 0 QQYYSTPYT 0 9 nd nd nd nd nd nd -- nd nd
73n.5 5-51 4-17 4 3 RDGDYPFDY 1 9  4-1 4 0 QQYYSTPRLT 1 10 - - - - - - -- - -
79n.5 3-30-3 4-17 3 3 GDYGDSPDI 0 9  1-5 1 0 QQYNSYSRT 1 9
80n.5 3-7 2-21 4 0 GLWWCTY 0 7  2-28 2 0 MQALQTPYT 0 9
83n.5 4-b 4-4 2 1 PGKVTTHYWYFDL 2 13  2-14 2/3 0 SSYTSSSTLV 0 10 + - - - - - -- - -
84n.5 4-4 5-24 5 1 GRDGYNYLG 1 9
85n.5 3-30 6-19 5 2 DIAVAGKGGWFDP 1 13  3-11 1 0 QQRSNWPWT 1 9
86n.5 4-61 2-8 4 1 TSTNPFLFDY 0 10  1-5 4 0 QQYNSFPLT 0 9
89n.5 3-11 2-2 6 2 DRNIVPYYYYGMDV 1 14  3-20 2 0 QQYGSSPYT 0 9
90n.5 4-30-2 3-16 5 3 ERGDRGVITRHGWFDP 4 16
91n.5 4-b 3-3 6 3 LPPVLRFLEWFTPGDYYYGMDV 1 22  1-39 4 0 QQSYSTPLT 0 9
93n.5 4-b 3-22 4 2 PTYYYDSSGYWAYYFDY 0 17  3-11 4 0 QQRSNWPLT 1 9
95n.5 4-b 5-5 6 1 QGQLWLPPTSHGMDV 1 15  
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Patient 12 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
3n.12 3-33 4-17 4 1 VGGTTTVTSTTGYYFDY 0 17  3-21 3 2 QVWDSSSDHLWV 1 12 - - - - - - -- - -
25n.12 3-21 5-5 4 1 SGPNARGYSYGFDY 1 14
26n.12 3-15 6-19 4 2 EGGQQWLVRGYYFDY 1 15  1-51 2/3 1 GTWDSSLSVL 0 10 - - - - - + C - -
37n.12 3-23 3-9 4 2 GRSGRRGYFDWLGIDY 3 16  2-14 2/3 0 SSYTSSSTLGVV 0 12 - - - - - - -- - -
38n.12 4-34 3-3 6 2 YDFWSGYYPTAYYYYGMDV 0 19
50n.12 4-59 3-10 4 1 ATPSPGVTMVRGVIRGGYFDY 2 21
55n.12 3-33 2-15 6 2 DVAVVVVNYYYYGMDV 0 16  1-51 2/3 1 GTWDSSLSAV 0 10 + - - - nd nd -- - -
56n.12 3-21 4-17 1 0 HSTTVTTLRYFQH 3 13  3-11 4 0 QQRSNWPLT 1 9 - - + - + + C - -
60n.12 1-69 2-15 5 3 DGRSGGGDWFDP 1 12  3-20 2 0 QQYGSSPRT 1 9
61n.12 3-15 2-8 4 1 DGVVMVYAIGY 0 11  1-47 2/3 2 AAWDDSLSVVV 0 11 + - - - - + C - -
72n.12 4-59 6-25 4 1 GSAPPGGYFDY 0 11  2-11 1 0 CSYAGSYTYV 0 10
82n.12 3-21 6-13 4 4 DAPGDRSGESIAAAPDY 1 17  1-47 2/3 2 AAWDDSLSGVVF 0 12 - - + - - + C - -
84n.12  3-25 2/3 1 QSADSSGTYRV 1 11
85n.12  2-11 2/3 0 CSYAGFVV 0 8
92n.12 1-2 6-6 5 1 GGYSSSRFDP 1 10  1-44 3 2 AAWDDSLNGPV 0 11
95n.12 1-69 4-23 3 2 DPATSFDI 0 8
96n.12 1-69 4-23 6 3 GGRGLPWEPDYYYYGMDV 1 18  
Patient 13 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
19n.13 4-34 4-23 1 1 GAFGGNSVDFQH 1 12  1-39 1 0 QQSYSTPRT 1 9 + - - - - + C - -
30n.13 1-69 1-14 3 2 HDNRGPFDI 2 9
31n.13 3-66 3-22 3 1 VGRITIQSRAFDI 2 13  1-13 4 0 QQFNSYPHRLT 2 11
43n.13 4-39 3-10 5 3 HSMVRGVDVDNWFDP 2 15
56n.13 3-53 3-22 4 3 LRYYDSKGDFDY 2 12
66n.13 3-23 3-22 4 2 EHRITMIVVLIYYFDY 2 16  1-39 1 0 QQSHSTPKT 2 9 - - - - - + C - -
67n.13 3-30 3-3 4 2 DRAGEWLLFST 1 11  1-39 3 0 QQSYSTPLT 0 9
68n.13 5-a 6-6 3 3 PEYSSSSIPILDAFDI 0 16 0
72n.13 3-43 3-10 4 1 ARHYYGSGSYLDY 2 13  3-15 1 0 QQYNNWPPRT 1 10 - - - - - + C - -
78n.13  1-36 3 -
79n.13 4-61 1-7 4 1 GSWNYADY 0 8  3-15 1 0 QQYNNWPGWT 0 10 - - - - - + C - -
83n.13 3-53 5-12 5 1 VQWGGYGLVSNWFDP 0 15  1-39 4 0 QQSYSTPALT 0 10
88n.13  1-44 3 2 AAWDDSLNGPV 0 11
89n.13  2-14 3 0 SSYTTINTL 0 9
5n.13 4-34 2-2 6 1 YCSSTSCPRPYYYYGMDV 1 18  1-39 5 0 QQSYSTLPIT 0 10 - - - - + + C+N - +
24n.13 1-46 2-21 5 0 CTGHRLWWCPPRW 3 13  1-5 2 0 QQYNSSPYT 0 9 - - + - + + C - -
30n.13 3-23 2-15 6 2 GGYCSGGSCYRDYYYYGMDV 1 20  1-5 1 0 QQYNSYPTWT 0 10 - - - - - - -- - -
32n.13 1-8 2-15 5 1 TRSGGGSAGTFDP 1 13  1-5 1 0 QQYNSYWT 0 8 - - - - - - -- - -
36n.13 4-59 3-3 6 3 DSRFLEWPYGMDV 1 13  3-11 2 0 QQRSNWPPYT 1 10 - - - - - + C - -
43n.13 3-43 6-19 4 2 GESSGWYYFDY 0 11  2-14 2/3 0 SSYTSSSTLV 0 10 - - - - - - -- - -
48n.13 4-34 6-13 6 1 GKGSWPYYGMDV 1 12  1-17 3 1 LQDYNYPPFT 0 10 nd nd nd nd nd nd -- nd nd
56n.13 4-59 4-23 4 4 EMDYGGNPREFDY 1 13  3-11 5 0 QQRSNWPPIT 1 10 - - - - - - -- - -
59n.13 3-11 1-26 4 1 IPGNMGATGLDY 0 12  2-30 2 0 MQGTHWPYS 1 9 - - - - - + C - -
69n.13 4-59 3-22 4 1 GITQYYFDY 0 9  3-15 2 0 QQYNNWPPYT 0 10 nd nd nd nd nd nd -- nd nd
70n.13 3-23 3-3 6 5 DHFFGDFWSGYYDLDYYYGMDV 1 22 0
71n.13 5-51 6-25 5 1 SSGGTWFDP 0 9  4-1 3 0 QQYYSTPFT 0 9 - - + - - - -- - -
79bn.13 3-21 3-22 5 1 AAHYYDSSGPR 2 11  3-15 2 1 QQYNNWPPDS 0 10 - - - - + + C+N - -
81n.13 3-9 6-19 4 1 GSGWSYFDY 0 9  1-5 1 0 QQYNSYSWT 0 9 nd nd nd nd nd nd -- nd nd
82n.13 3-11 1-26 6 2 DKVPVGALGGMDV 1 13  1-33 2 1 QQYDNLYS 0 8 - - - - - - -- - -
90n.13 3-30 2-2 6 2 DLNSYCSSTSCYPSYYYYGMDV 0 22
91n.13 3-21 3-16 3 2 GPLSLGEPGAFDI 0 13  1-5 2 0 QQYNSAPVYT 0 10 nd nd nd nd nd nd -- nd nd
94n.13 3-30 6-19 4 3 DSDFQIAMGSGWYLDY 0 16  1-8 4 0 QQYYSYPLT 0 9
95n.13 3-7 6-25 3 2 DRSGRAFDI 2 9  4-1 3 0 QQYYSTPL 0 8 - - - - - + N - -  
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Table 4.2 IgH and L gene repertoire analysis and reactivity of IgD+ single B cells from 2 healthy donors. Clones highlighted in grey are 
those expressed as recombinant antibodies. (-) and (+), negative and positive charges within the heavy chain CDR3; length, number of 
amino acids within the CDR3; +, clones reactive in ELISA/IFA; -, clones non-reactive in ELISA/IFA; ND, not determined; C, cytoplasmic 
pattern; N, nuclear pattern. 
HD2 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
6n.HD2 3-23 2-2 6 2 DGGLHCSSTSCPSLFYYGMDV 1 21  2-40 1 1 MQRIEFPWT 1 9 - - - - - - -- - -
7n.HD2 1-69 2-15 4 3 DDCSGGSCYFDY 0 12
10n.HD2 5-51 6-13 4 2 PRGYRSSSYEAFYFDY 2 16  3-11 4 0 QQRGNWPRLT 2 10 - - - - - - -- - -
16n.HD2 3-23 3-22 3 3 HLSRDSSVLDAFDI 2 14  1-5 2 0 QQYNSYWGA 0 9
20n.HD2  1-33 4 1 QQYDNLALT 0 9
22n.HD2 4-34 2-8 3 1 AKVYASAFDI 1 10  3-20 1 0 QQYGSSPWT 0 9 - - - - - - -- - -
23n.HD2 3-7 3-16 3 3 EDWGAFDI 0 8  1-5 1 0 QQYNTYSPWT 0 10 - nd nd nd nd nd -- - -
24n.HD2 4-39 2-21 4 2 LGVGKMGAYCGGDCYSLFDY 1 20  1-27 3 0 QKYNSAPH 2 8
29n.HD2 3-64 6-13 6 2 FGIAAAGRDYYYGMDV 1 16  3-15 1 0 QQYNNWPPWT 0 10 nd nd nd nd nd nd -- - -
30n.HD2 4-34 2-2 6 1 ARCSSTSCYLRNYYYYYGMDV 2 21  1-39 5 0 QQSYSTPPT 0 9
31n.HD2 3-21 3-10 4 1 SFYGSGTDY 0 9  1-51 2/3 1 GTWDSSLSAGV 0 11 - - - - - + C - +
32n.HD2 3-73 3-10 5 1 TTGFGELF 0 8  1-39 2 0 QQSYSTPLT 0 9
33n.HD2 1-69 3-10 6 2 LPYGSDYYYGMDV 0 13  2-11 1 0 CSYAGSYTVYV 0 11 - + - - nd nd -- nd nd
35n.HD2 3-74 6-19 3 3 DSSGWNDAFDI 0 11  1-39 4 0 QQSYSTPPT 0 9 - - - - - - -- - -
36n.HD2  3-20 4 0 QQYGSSPLT 0 9
41n.HD2 3-23 3-16 4 2 YRAVGYDYVWGSYRTNYFDY 2 20  1-27 4 0 QKYNSAPHT 2 9
43n.HD2 4-39 3-3 5 1 QTRITIFGVVILGWFDP 1 17  2-14 1 0 SSYTSTSTRV 1 10
44n.HD2 1-46 6-19 4 1 ARGIAVAGTLDY 1 12  2-14 1 0 SSYTSSSTFYV 0 11 - - - - - - -- - -
45n.HD2 4-61 6-19 4 2 IAVPGNRRSEAFDF 2 14
47n.HD2  2-28 4 0 MQALQTPL 0 8
48n.HD2 4-39 5-24 5 2 RDGYNFWFDP 1 10  2-23 2/3 0 CSYAGSSTVV 0 10
55n.HD2 1-69 3-22 4 3 DPNYKTYYYDSSGYYYVPVYFDY 1 23  1-44 2/3 2 AAWDDSLNGVV 0 11 - - - - nd - -- - -
56n.HD2 1-69 6-13 4 0 VGIAAAGSSY 0 10  3-15 5 3 QQYNNWPVEA 3 11 - - - - - - -- - -
58n.HD2 1-3 5-24 5 2 DLGTPGAPFDP 0 11  1-44 2/3 3 AAWDDSLNGQDVV 0 13
59n.HD2 4-59 6-13 6 1 YGAAGPTRFYYYGMDV 1 16  1-17 1 1 LQDYNYPPT 0 9
60n.HD2 1-69 3-9 6 2 GYYDILTGPIAYYYYGMDV 0 19  1-39 2 0 QQSYSTPT 0 8
65n.HD2 3-74 6-19 5 2 EVAVAGQGWFDP 0 12  1-39 2 0 QQSYSTPPT 0 9
67n.HD2 1-18 3-16 6 1 LGLMGPRNTPGGWVYGMDV 1 19
68n.HD2 4-61 3-22 4 1 ISRSTFDY 1 8  3-21 2/3 2 QVWDSSSDHPV 1 11
69n.HD2 1-69 2-2 6 1 ACSSTSCYTNYYYGMDV 0 17  1-5 1 0 QQYNSYST 0 8
71n.HD2 3-23 1-7 6 1 TFRYNWNYFSGSRPGYYGMDV 2 21  1-39 4 0 QQSYSTPLT 0 9
72n.HD2 1-69 4-17 4 3 WGGDYQAYGDYAVHFFDY 1 18  3-15 2 0 QQYNNWPYT 0 9
78n.HD2 3-23 3-10 4 1 PRRGLLWFGELPHY 3 14  1-9 4 0 QQLNSYPLT 0 9
79n.HD2 3-21 6-13 4 1 GYSSSCFDY 0 9  1-5 4 0 QQYNSYSP 0 8
80n.HD2 3-20 3-22 4 2 NYYDSSGYYYFDY 0 13  1-39 3 0 QQSYSTPIFT 0 10
81n.HD2  3-11 1 0 QQRSNWPPWT 1 10
82n.HD2 1-3 6-19 4 1 VWYSSGWYDY 0 10  3-11 2 0 QQRSNWPPYT 1 10
84n.HD2 3-33 6-13 4 2 DQSGGAAAGFDY 0 12
87n.HD2  3-15 1 0 QQYNNWPSWT 0 10
88n.HD2 4-59 3-9 6 1 GAGLFLNYYYYGMDV 0 15  1-44 1 2 AAWDDSLNGSYV 0 12
89n.HD2 4-4 3-10 5 1 GGSHYGSGSYYNWFDP 1 16  1-39 3 0 QQSYSTPLG 0 9
90n.HD2 3-21 2-2 6 1 SCSSTSCLYGMDV 0 13  1-47 2/3 2 AAWDDSLSGWV 0 11
91n.HD2 3-33 6-19 4 2 DPPYSSGWYFDY 0 12  2-14 1 0 SSYTSSSTFYV 0 11
93n.HD2 1-24 6-13 5 2 SGSSWDNWFDP 0 11  3-11 4 0 QQRSNWPPT 1 9
94n.HD2 3-11 3-9 6 2 MGYDILTAYYYYGMDV 0 16  1-39 2 0 QQSYSTPYT 0 9
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JH(*) VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
JH.1 D4 7-81 3-10 4 2 GDITMVRVTLADY 1 13  3-20 1 0 QQYGSSAWT 0 9
JH.1 E3 4-34 1-26 6 1 GSYRPPLVYYYYGMDV 1 16  3-20 4 0 QQYGSSPLT 0 9 - - - - nd nd -- nd nd
JH.1 F5 3-30 4-17 4 2 DLFTVTHFDY 1 10  3-15 4 0 QQYNNWPPLT 0 10 - - - - - - -- - -
JH.1 F8 3-21 3-22 6 2 VGAVAGGVDYYYYYGMDV 0 18  2D-28 4 0 MQALQTLALT 0 10 - - - - - - -- - -
JH.1 G8 3-48 1-26 6 1 LSGSYSNYYYGMDV 0 14  1D-12 4 0 QQANSFPLT 0 9 - - - - - - -- - -
JH.1 G10 3-23 2-2 4 4 EGPFDIVVVPAALDFDY 0 17  3-15 2 0 QQYNNWPSYT 0 10 - - - - - + C - -
JH.1 H5 4-59 / 4 2 LGKMDLSPFDY 1 11  3-20 2 0 QQYGSSPRT 1 9 - - - - - - -- - -
JH.1 H11 3-33 / 6 2 DHSVTPYLYYYYGMDV 1 16  2D-28 1 0 MQALQTPRT 1 9 + + - + - - -- - -
JH.2 A2 3-74 1-26 6 3 DPVWELFSAASGGAHYYYGMDV 1 22  1D-39 2 0 QQSYSTPPT 0 9 - - - - - - -- - -
JH.2 A8 3-7 6-19 1 1 DLSGQWLVRGRH 3 12  1-8 4 0 QQYYSYPLT 0 9 - - - - - - -- - -
JH.2 A9 4-31 / 5 3 DTAAETGNNWFDP 0 13  3-11 5 0 QQRSNWPIT 1 9 - - - - - + C - -
JH.2 A11 4-61 / 4 2 DGKGLGYFDY 1 10  4-1 1 0 QQYYSTPWT 0 9 - - - - - - -- - -
JH.2 B5 7-81 3-22 4 4 VPPPNYYATVEEEYYFDY 0 18  3-20 4 0 QQYGSSPRLT 1 10 - + - - nd nd -- nd nd
JH.2 C3 3-23 3-10 5 1 GAAALLWFGEI 0 11  3-20 2 0 QQYGSSPMYT 0 10 - - - - - - -- - -
JH.2 C6 3-23 3-22 4 2 VRGLRPADYYFDY 2 13  1-9 2 0 QQLNSYPYT 0 9 - - - - - - -- - -
JH.2 C10 4-59 3-22 4 2 GPYYYDFDY 0 9  3-15 1 0 QQYNNWPRT 1 9 - - - - - + C - -
JH.2 D7 3-48 / 6 2 EYRLARYYYYGMDV 2 14  3-15 1 0 QQYNNWPYT 0 9 - - - - - - -- - -
JH.2 E3 1-18 1-20 5 3 EPPGPNDVRNDP 1 12  3-20 4 0 QQYGSSPFA 0 9 - - - - nd nd -- nd nd
JH.2 E5 4-39 6-6 6 1 HPRIAAQVYGMDV 2 13  1D-39 4 0 QQSYSTLPLT 0 10 - - - - - + C - -
JH.2 E8 3-9 6-19 5 1 GSHTSSSGWYDY 1 12  3-15 2 0 QQYNNWPMYT 0 10 - - - - - - -- - -
JH.2 F3 7-81 2-15 5 3 AEDIVVVVAAAGFDP 0 15  3-20 4 0 QQYGSSPRT 1 9 - - - - nd nd -- nd nd
JH.2 F9 5-51 6-13 3 1 QYSSRLRGGGAFDI 2 14  3-20 4 0 QQYGSSLT 0 8 - - - - nd nd -- nd nd
JH.1 B11 3-23 3-10 6 1 GATMVRGSLGMDV 1 13  2-14 3 0 SSYTSSSTWV 0 10 - - - - - + C - -
JH.1 C12 4-59 2-2 6 1 ASPAAIGLPYYYYGMDV 0 17  1-40 2/3 1 QSYDSSLSGFVV 0 12 - - - - - - -- - -
JH.1 D2 1-18 4-17 4 3 ETGNSDYWAAPLDY 0 14  2-8 1 0 SSYAGSNNPYV 0 11 - - - - - - -- - -
JH.1 D10 4-59 6-13 4 1 HLPRIAAAAYDY 2 12  2-14 1 0 SSYTSSSTYV 0 10 - - - - - - -- - -
JH.1 F6 1-8 1-20 6 2 GMGLEPYSTIYGMDV 0 15  2-14 2/3 1 SSYTSSSTLDVV 0 12 - - - - - + C - -
JH.1 H6 3-9 6-13 4 2 DMLRLSYSSSWYGAFDY 1 17  2-11 3 0 CSYAGSYTLGV 0 11 - - - - nd nd -- nd nd
JH.2 B12 3-23 6-19 4 2 DPLILATLGSSGFGPFFDY 0 19  2-14 2/3 0 SSYTSSSTLYVV 0 12 - - - - nd nd -- nd nd
JH.2 C12 4-4 / 6 1 GLTGSRQTPYYYYGMDV 1 17  2-14 2/3 0 SSYTSSSTLYVV 0 12 - - - - - + C - -
JH.2 D8 3-21 3-9 4 3 DLFGGVDILTYFDY 0 14  6-57 3 1 QSYDSSNHRV 2 10 - - - - - - -- - -
JH.2 E6 3-33 2-2 4 1 AYCSSTSCYMRDY 1 13  2-11 2/3 0 CSYAGSSVV 0 9 - nd nd nd nd nd -- nd nd
JH.2 F6 1-2 6-19 4 1 DPPASYSSGWYGKLGY 1 16  2-14 2/3 1 SSYTSSSTLDGV 0 12 - - - - - - -- - -
JH.2 G12 5-51 3-22 5 2 GRSYYDSSGYYLQAGWFDP 1 19  2-14 2/3 0 SSYTSSSTLYVV 0 12 - - - - nd nd -- nd nd
JH.2 H4 4-59 3-22 2 4 LLTGADDSSGYYDWYFDL 0 18  1-40 1 1 QSYDSSLSGRHV 2 12 - nd nd nd nd nd -- nd nd  
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4.5 Accumulation of autoreactive naïve B cells in the peripheral 
blood of SS patients suggest impairment of early tolerance 
checkpoints in SS. 
Out of all single naïve B cells isolated from the four SS patients, I managed to obtain 
matching IGH, IGK and IGL chains genes of 66 naïve B cells which were then cloned into 
specific expression vectors and used to generate monoclonal antibodies in vitro (SS3 = 
19; SS5 = 20; SS12 = 7; SS13 = 20). As control, I expressed 45 monoclonal antibodies 
from the 2 HD (JH = 34 [177]; HD2 = 11) (for full details of the repertoire and reactivity 
of the naïve antibodies from SS patients and controls see Tables 4.1 and 4.2). As 
expected, all naïve B cells were characterized by no mutation in their variable Ig region 
showing germline Ig VH and VL genes. 
I used these antibodies to determine the frequency of polyreactivity and self-reactivity 
in the naïve B cell compartment of SS patients and controls.  
Antibody polyreactivity was tested using ELISAs against ssDNA, dsDNA, LPS and insulin 
at 1g/ml. As shown in Figure 4.4, naïve B cell antibodies from SS patients showed 
very low levels of polyreactivity which was similar to HD (3.3% vs 2.4%), as previously 
reported [33]. Only one antibody (SS 12n5) was found to be highly polyreactive against 
all four antigens (Figure 4.4).  
Conversely, the SS naїve antibodies were more frequently reactive towards dsDNA 
compared to controls (13.3% versus 2.3%, respectively, p<0.05, Figure 4.4), suggesting 
accumulation of autoreactive B cells. Autoreactive antibodies from SS naïve B cells 
generally displayed lower binding to dsDNA compared to highly polyreactive 
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antibodies from memory B cells of SLE patients such as JB40 and ED38 [34]. Thus, in 
order to confirm the true autoreactivity of these antibodies, I next investigated the 
frequency of self-reactive naïve B cells from SS patients using the human epithelial cell 
line Hep-2 by IFA, a commonly used test for ANA in clinical diagnostic, as previously 
reported [33, 34]. Positive results were further classified according to the Hep-2 
staining pattern as anti-nuclear, anti-cytoplasmic and mixed anti-nuclear/anti-
cytoplasmic antibodies. Overall, antibodies from SS patients displayed a significantly 
higher prevalence of immunoreactivity to Hep-2 compared to antibodies from HD 
(43.1% versus 25%, p<0.05, Figure 4.5B). The majority of antibodies from naïve B cells 
of SS patients displayed a cytoplasmic pattern while fewer antibodies showed 
antinuclear + cytoplasmic (8.6%) and antinuclear reactivity (1.7%) (Figures 4.5A and 
4.5B). Conversely, among the 25% antibodies from HD showing positive ANA staining, 
none displayed a nuclear Hep-2 pattern.  
Overall, these data demonstrated, both by ELISA and IFA, that autoreactive circulating 
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Figure 4.4 Polyreactivity of naïve B cell antibodies from SS patients and HD.  
Naïve B cell antibodies from SS patients (n=60) and HD (n=41) were tested for 
reactivity with dsDNA (top left), ssDNA (top right), LPS (bottom left) and insulin 
(bottom right) by ELISA. Each graph shows the reactivity at a concentration of 1 g/ml 
and it shows the result of two independent experiments. The cut-off OD (450 nm) at 
which antibodies were considered reactive is shown by the horizontal lines. Data 
points represent individual antibodies. Internal controls for polyreactivity (square dots) 
are shown in each graph and include mGO53 (negative;[34]), JB40 (low 
polyreactive;[34]), and ED38 (highly polyreactive;[34]). Error bars indicate standard 
error of mean (SEM) for the internal controls. 
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Figure 4.5 Hep-2 cell IFA self-reactivity of naïve B cell antibodies from SS patients and HD.  
Naïve B cell antibodies from SS patients (n=58) and HD (n=32) were tested for self-reactivity by Hep-2 cell IFA assay. (A) Examples of 
cytoplasmic, cytoplasmic and nuclear, and nuclear Hep-2 cell staining pattern are shown. (B) Graph bars summarize the frequency of 
Hep-2 cell reactive antibodies with cytoplasmic, nuclear and/or cytoplasmic reactivity in SS patients and HD. P value compares ANA+ 
(nuclear ± cytoplasmic reactive) clones from SS patients and HD.  
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4.6 Presence of naïve B cells reactive against extractable nuclear 
antigens (ENA) in SS patients. 
We then investigated the self-reactivity of the SS naïve B cell antibodies against ENA 
first using a general ENA screening ELISA, which includes the main antigens Sm, RNP, 
Ro/SSA, La/SSB, Scl-70 and Jo-1. Using this approach we observed that SS naïve B cell 
antibodies showed a significant increase in the frequency of ENA auto-reactivity 
compared to HD (19.6% vs 0%, p<  0.01, Figure 4.6A).  
Next, we analysed whether some of these ENA-reacting SS antibodies were directed 
against Ro/SSA and/or La/SSB, which are part of the current classification criteria for 
pSS [48], using a specific diagnostic ELISA test. As shown in Figure 4.6, we observed 
reactivity to Ro/SSA (Figure 4.6B) and/or La/SSB (Figure 4.6C) in 6 out of 58 SS naïve B 
cell antibodies. Importantly, all the 6 clones positive for Ro/SSA and/or La/SSB gave 
matched positive results in the ELISA screening (Figure 4.6), confirming their reactivity. 
Interestingly, one of the Ro/SSA positive clone showed a purely cytoplasmic pattern at 
Hep-2 staining, confirming early evidence that anti-Ro antibodies do not necessarily 
display the classical speckled nuclear pattern but can react with a fibrous cytoplasmic 
network similar to cytokeratin [91].  
Of relevance, one of the SS antibody that showed high levels of reactivity against 
Ro/SSA and La/SSB (SS 12n5), also recognized ssDNA, dsDNA, LPS and insulin and was 
therefore polyreactive.  
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Figure 4.6 SS peripheral naïve B cells contain anti-Ro/SSA and anti-La/SSB clones.  
(A) Naïve B cell antibodies from SS patients (n=56) and HD (n=31) were tested for 
reactivity against extractable nuclear antigens (ENAs) by ELISA. ENAs include a mixture 
of six purified antigens, including Ro/SSA and La/SSB. P value compares ENA+ versus 
ENA- clones from SS patients and HD. Naïve B cell antibodies from SS patients (n=58) 
and HD (n=32) were tested by ELISA specifically for reactivity against Ro/SSA (B) and 
La/SSB (C) antigens. Each graph shows the reactivity at a concentration of 10 g/ml. 
Cut-off OD (560 nm) for positive reactivity is shown by the horizontal lines.  
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5 | Analysis of memory switched and unswitched B cells 
antibodies cloned from peripheral blood B cells of 
Sjögren’s syndrome patients. 
5.1 Introduction. 
As reported in Chapter 4, patients with SS are characterized by a significant reduction 
of circulating IgD-CD27+ switched and IgD+CD27+ unswitched memory B cells which 
could explain their accumulation in the target tissues (i.e., salivary glands) of these 
patients (Figure 4.1). Despite several evidences consistently support that altered B cell 
subpopulations are a feature of SS, further studies are needed in order to clarify 
whether these abnormalities represent primary pathogenic events or are secondary to 
the establishment of a chronic inflammatory process and whether they can predict 
disease evolution and response to treatment. To characterize the reactivity profile of 
circulating memory switched and unswitched B cells in patients with SS, I started to 
clone and express recombinant monoclonal antibodies from peripheral blood CD3-
CD19+CD27+IgD- memory switched or CD3-CD19+CD27+IgD+ memory unswitched B 
cells of patients with SS. In this chapter, I will present data assessing the Ig gene usage 
(HC and LC) for both memory B cell subsets and data regarding the polyreactivity 
profile of the SS memory B cell monoclonal antibodies. Further evaluation of the 
reactivity profile of these antibodies is still under investigation and it will not be part of 
the current thesis. 
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5.2 Immunoglobulin (Ig) gene repertoire characterization of 
memory switched and unswitched antibodies cloned from SS 
peripheral blood B cells. 
To characterize the Ig gene repertoire expressed by memory switched and unswitched 
B cells I studied seven patients with a diagnosis of primary SS (SS3, SS4, SS5, SS6, SS9, 
SS12 and SS13) (Table 3.1). CD3-CD19+IgD-CD27+ memory switched and CD3-
CD19+IgD+CD27+ memory unswitched B cells were sorted as single cell by flow 
cytometry from peripheral blood of these patients. The analysis of 103 V(D)J gene 
segments from the memory switched B cells and 131 V(D)J gene segments from the 
memory unswitched B cells demonstrated a similar VH, D and JH gene repertoire in 
both memory B cell compartments (Figure 5.1A). Memory B cells from healthy controls 
are necessary to perform a better evaluation of the gene usage in SS patients. Thus, I 
performed a comparison with data previously published by the Wardemann’s group. 
SS memory switched and unswitched B cells showed a similar V(D)J gene usage 
compared to controls [177]. Similar to the naïve B cells from SS patients (Chapter 4), 
VH3 was expressed more frequently (more than 50%) followed by VH4 and VH1 in 
both memory B cell compartments. I found a frequent usage of JH4 followed by JH6, 
JH5 and JH3 while JH1 and JH2 were expressed less frequently especially in the 
memory switched B cells. Ig light chain usage (, 41 for memory switched and 74 for 
memory unswitched) was similar between the two memory B cell compartments 
(Figure 5.2A). Analysis of V genes showed a reduced frequency of V2 and a 
significantly increased of V3 gene family usage in the memory switched B cells 
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compared to memory unswitched B cells which showed a higher frequency of V distal 
genes (V4 and V6) (Figure 5.2B). Over expression of J2/3 and a reduced frequency 
of J7 was observed in both memory B cell compartments, as previously reported 
[168], thus suggesting a defect in receptor editing. Furthermore, no significant 
differences in CDR3 length and positive charges within the CDR3 were observed 
between memory switched and unswitched B cells (Figure 5.1B).  
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Figure 5.1 Ig heavy chain gene analysis of memory switched and unswitched B cells 
from SS patients.  
Single memory switched and unswitched B cell antibodies from seven SS patients 
(memory switched) and six SS patients (memory unswitched) were analyzed for (A) 
IGH V family and J gene usage, and (B) IgH CDR3 aa length and positive charges. White 
bar graphs represent healthy controls, IgG+ (n=116) and IgM+ (n=113) for memory 
switched and unswitched, respectively [40, 184]. The absolute number of sequences 
analysed for SS patients is reported over each graph. Error bars in bar graphs indicate 
standard error of mean (SEM) for individual patient. 
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Mutational analysis is normally used to study whether a cell has experienced a positive 
antigen selection. Normally, a nucleotide substitution which brings to an amino acid 
replacement occurs less frequently in the FRs in order to maintain the right Ig fold, 
whereas is positively selected in the CDRs to increase the antigen affinity of the Ig. 
Thus, the comparison of the silent (S) to replacement (R) ratios in the FR and CDR 
regions is used to study the presence of antigen selection. Therefore, the numbers of S 
and replacement R mutations were calculated for each B cell clone within the FR 
regions 1, 2 and 3 and CDR1 and CDR2. CDR3 was excluded from mutational analysis 
since it is complicated to discriminate between point mutations and junctional 
variation as a result of recombination events in this region. As shown in Figure 5.3, R/S 
mutation ratios were calculated for the heavy chain (VH) and both light chains (V and 
V) in the FR and CDR regions separately. The graphs illustrate the R/S value for all the 
clones together. The R/S ratio of the CDRs of VH and both light chains genes from 
memory switched B cells was much higher in comparison with that in the FR regions, 
which is typical of an antigen-driven selection on their IGH genes (Figure 5.3A). 
Unswitched memory B cell antibodies showed a lower R/S ratios in the CDRs compared 
to memory switched B cell antibodies but still higher compared to FR regions, again 
suggesting an antigen-mediated selection in these B cell antibodies (Figure 5.3B). The 
R/S ratio of the CDRs of both light chains genes from memory unswitched B cells was 
lower in comparison with that in the FR regions probably due to the fact that these 
segments are longer, thus it is likely to have more random mutations occurring (Figure 
5.3B). 
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Figure 5.2 Ig light chain gene analysis of memory switched and unswitched B cells 
from SS patients.  
Single memory switched and unswitched B cell antibodies from seven SS patients 
(memory switched) and six SS patients (memory unswitched) were analyzed for IGK (A) 
and IGL (B) V family and J gene usage. White bar graphs represent healthy controls, 
IgG+ (Ig n=72; Ig n=44) and IgM+ (Ig n=72; Ig n=36) for memory switched and 
unswitched, respectively [40, 184].The absolute number of sequences analysed for SS 
patients is reported over each graph. Error bars in bar graphs indicate standard error 
of mean (SEM) for individual patient.  
Page | 159  
 
 
Figure 5.3 Analysis of replacement (R) and silent (S) mutations ratio in FR and CDR 
regions of memory switched and unswitched B cell antibodies. 
Replacement:silent ratios (R/S ratios) were calculated for the complementarity 
determining regions (CDRs) (black) and framework regions (FRs) (white) for both heavy 
and light chains of memory switched (A) and unswitched (B) B cells. The R/S ratios for 
all the clones together are shown.   
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5.3 Polyreactivity profile of memory switched and unswitched B 
cell antibodies. 
Out of all single memory switched and unswitched B cells isolated from SS patients, I 
cloned the matching IGH, IGK, and IGL chains genes of 16 memory switched and 32 
memory unswitched B cells into specific expression vectors and produced the 
recombinant monoclonal antibodies in vitro (for full details of the repertoire and 
reactivity of the memory switched and unswitched B cell antibodies from SS patients 
see Table 5.1 and 5.2). I used only 39 out of 48 monoclonal antibodies to measure the 
polyreactivity by ELISA with structurally different antigens, as previously reported in 
Chapter 4 and [34], since 9 monoclonal antibodies had a concentration < 1 g/ml. I 
observed, on average, 25 % of polyreactivity in the memory switched B cell antibodies 
and 11 % in the memory unswitched B cell antibodies. In details, 3 out of 12 memory 
switched and 3 out 27 memory unswitched B cell antibodies were reactive with at least 
two antigens in this ELISA, thus considered polyreactive (Figure 5.4). Normally, the 
frequency of polyreactive IgG and IgM memory B cell antibodies from healthy donors is 
around 22% and 1%, respectively. For instance, in SLE patients, it has been shown that 
the frequency of polyreactive IgG memory B cell antibodies is not significantly different 
from healthy donors. Therefore, based on the data published in the literature we can 
hypothesize that the frequency of polyreactivity in the memory switched B cell 
antibodies is not increased in SS patients compared to normal individuals [177]. 
Conversely, the frequency of polyreactive memory unswitched B cell antibodies seems 
to be increased compared to normal individuals.  
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These results are extremely interesting as circulating IgM memory B cells bearing a 
marginal zone-like phenotype [185] have long been implicated in the pathogenesis of 
SS [82].   
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Table 5.1 IgH and L gene repertoire analysis and polyreactivity of single memory switched B cells from SS patients. Clones highlighted in 
grey are those expressed as recombinant antibodies. (-) and (+), negative and positive charges within the heavy chain CDR3; length, 
number of amino acids within the CDR3; +, clones reactive in ELISA/IFA; -, clones non-reactive in ELISA/IFA; ND, not determined; C, 
cytoplasmic pattern; N, nuclear pattern. 
Patient 3 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
10s.3 3-30*18 5-5*01 4*02 2 LPPSVDTHMAWSDY 1 14  1-27*01 3*01 0 QSYNSALRGFT 1 11
13s.3 3-9*01 6-13*01 1*01 2 APNSWAAEYFEH 1 12  3-21*01 1*01 2 QVWDSSSDHYV 1 11 - - - - - - -- - -
17s.3 3-15*04 3-10*01 3*02 4 DRDPYDSGSYGVFDM 1 15  1D-39*01 2*01 1 QQSFSSPDT 0 9
24s.3 4-30-4*01 2-2*03 6*02 1 WTVVVPPVSKPNFYYYAMDV 1 20
25s.3 3-23*04 3-16*01 6*04 1 GPRASSLGRPGDV 2 13  2-14*01 1*01 0 CSYTTRGTYV 1 10 + - - - + + C+N - -
27s.3 3-9*01 1-1*01 4*02 3 DAGGNWNDFPYHYFDS 1 16  1-44*01 3*01 1 AACDGSLNGHVV 1 12
28s.3 1-3*01 6-19*01 5*02 2 DLLSYIIVAGRGWFDP 1 16  2-14*01 3*02 0 KSYTSTGSTPWI 1 12
29s.3 4-39*01 6-19*01 1*01 0 QAVAGRVRYFQH 3 12  8-61*01 7*01 0 VLYMGSGISV 0 10 + + - + + + N + +
31s.3 3-15*01 6-19*01 5*02 2 DGSSGRFTGWFDP 1 13  4-1*01 1*01 1 QQYYSSPET 0 9
33s.3 4-34*01 3-16*01 4*02 3 DGSLYEMGSYFDF 0 13  1-5*03 2*01 1 QEHTSSSYT 1 9
35s.3 4-39*02 4-17*01 4*02 5 HVRDYDDDFGYDY 2 13
36s.3 3-30*17 6-19*01 4*02 1 GLSVTGTVATGFDY 0 14  4-1*01 4*02 0 QQYSRIPLT 1 9
37s.3 3-23*04 6-19*01 4*02 2 GEISNGWTYYSDY 0 13  1-5*03 1*01 0 QQYNTHNT 1 8
40s.3 5-a*01 3-10*01 5*02 0 HSTVSLVRGLSA 2 12  1-44*01 3*02 2 LAWDDTLHGPV 1 11
42s.3 4-b*02 3-3*02 4*02 1 LGFVGVVKIDS 1 11  1-44*01 3*02 1 ATWNNDVLNGPWV 0 13
43s.3 3-21*01 6-13*01 6*03 2 VAAQLDYYYMDV 0 12  1-5*03 2*03 0 QQYNSYMYS 0 9
45s.3 3-7*01 3-3*01 6*03 3 VYDFWSGSSANDNYYYYMDV 0 20  1D-39*01 2*01 0 QQSFSTPYT 0 9
46s.3 4-b*02 5-12*01 4*02 2 VTTMTDYFDF 0 10  1-5*03 1*01 0 QQYNSFWT 0 8 - - - - - - -- - -
54s.3 3-49*07 2-8*01 4*02 1 GPFTRIPPLKPVDY 2 14
 3-20*01 2*02 0 QQYGSSPQT 0 9
 3*01 1 GTWDSSLSSVV 0 11
56s.3 4-59*02 5-24*01 4*02 1 QRWLQVFDN 1 9
58s.3  3-20*01 1*01 0 QQCGSFGT 0 8
59s.3 4-39*01 6-19*01 4*02 1 GPVASTRYFDY 1 11
60s.3 5-51*01 1-26*01 4*02 1 ANLGVLGRTYFDY 1 13  3-11*01 2*01 1 QQCSDWLYT 0 9
65s.3 3-48*01 4-23*01 3*01 4 EGNGELISDALDV 0 13  2-23*02 3*02 0 YSYAGSSSFGNWV 0 13
71s.3  1-51*01 1*01 1 GTWDSSLSVGI 0 11
72s.3 3-23*04 6-19*01 4*02 1 DLGSAWYMGS 0 10
78s.3 3-21*01 2-8*02 4*03 1 GRGANYWSSFES 1 12  1-44*01 3*02 2 AAWDDSLNAWV 0 11
93s.3  2D-40*01 2*01 1 VQRKEFPYT 2 9
55s.3
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Patient 4 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
2s.4 1-2*02 3-3*02 5*02 2 GVMRPPRPEGWFDP 2 14  1D-39*01 3*01 0 QQSYSMPRT 1 9 - - - - - - -- - -
3s.4 3-23*04 3-22*01 4*02 2 DSHPFPSGQYYFDY 1 14  1D-12*02 5*01 0 QQANSFPSIT 0 10 - - - - + - -- - -
8s.4 3-48*01 5-5*01 6*02 2 EGAYGYNHGYQYYYGLDV 1 18
33s.4 1-18*01 3-22*01 4*02 1 MSKSSGLYPYYFES 1 14  2-14*01 1*01 0 SSYTSPSR 1 8
34s.4 1-18*01 3-22*01 6*02 3 DLSYFDPAGPSFYYGMDV 0 18  1-44*01 3*02 2 SVWDDSLNGWV 0 11
37s.4 4-b*02 3-9*01 5*02 2 DLKGGRYYDLLARGNH 4 16  1-5*03 2*04 0 QQYNSYPVQ 0 9
40s.4 4-31*03 4-17*01 4*02 2 GVVYGGYADYCFDS 0 14
42s.4 1-46*03 6-6*01 4*02 4 AQPSYSDSSDDFDY 0 14
44s.4 4-34*01 3-9*01 5*02 0 GRRSNAYLRGASFGP 3 15
49s.4 3-23*04 1-1*01 4*02 1 SGSNWNTYFDN 0 11  2-11*01 1*01 0 SSYAGSYTAV 0 10 - + - - - + C - -
50s.4 3-74*01 5-24*01 4*02 3 DGGFYFDD 0 8
54s.4 3-21*01 3-22*01 4*03 2 VLPVNTTDMGFDS 0 13
62s.4 4-28*03 1-1*01 3*02 2 TSNHWNDAWAVDI 1 13  1-44*01 1*01 2 AAWDDSLNGLYV 0 12 - - - - - - -- - -
64s.4 3-33*03 4-4*01 4*02 3 DGNDHSNYYFDS 1 12  2-8*01 1*01 0 SSYVGSNQYVF 0 11 - - - - - - -- - -
73s.4 3-11*03 1-26*01 6*03 5 DNSEVGGTMDDFYYYMDV 0 18
77s.4 3-48*01 6-13*01 4*02 2 DLPIAAADY 0 9
78s.4 3-23*04 3-22*01 4*02 1 SSGTVYHHFDF 2 11
80s.4 3-23*04 2-2*03 6*03 3 IAIGYDDYYMDV 0 12
86s.4 3-23*04 3-9*01 5*02 1 GMTSWDP 0 7  1-44*01 3*01 2 AAWDDSLNGVV 0 11
89s.4 3-7*01 3-9*01 4*02 1 VGANWIIYYLDY 0 12  2-8*01 3*02 0 SSYTGSYTLGV 0 11
91s.4 3-48*02 2-2*03 3*02 4 GRRCDGSCYLPYDDALDI 2 18  
Patient 5 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
21s.5 3-30-3 3-10 3 2 YDTMVLWAGAFDM 0 13  3-15 1 1 QHYENWWT 1 8
26s.5 3-53 4-17 4 3 EFSPTVITRYCFDD 1 14
35s.5 3-23 6-13 4 1 AWLGSSWMGYFDY 0 13  4-1 1 0 QQYYSTSTWT 0 10 - - + - - - -- - -
65s.5 4-59 2-21 4 1 RGVATVGAYYFDY 1 13  1-17 3 1 LQDGNYPFS 0 9
72s.5 3-72 1-7 4 3 AEKYSANYYAGDD 1 13  1-16 5 1 QQFNDYPLT 0 9
80s.5 3-9 2-21 6 1 GMGPCIIGACYAGYYNYYMDV 0 21  3-20 4 0 QQYGSSSPLS 0 10
84s.5 3-7 5-24 3 2 DLFLGGSNSRNVFDI 1 15  4-1 4 0 QQYYSTPLT 0 9
86s.5 3-30 3-3 4 3 DGDFWSGYCDY 0 11  1-13 2 0 QQFNNYPHT 1 9
Patient 6 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
5s.6 3-48 3-22 4 2 RGLYYDTSGSLKYFDF 2 16
3-15 6-13 4 1 AGMGSSRAEY 1 10  3-20 4 0 QQYGSLPHT 1 9
 1-44 3 2 AAWDDSLMGV 0 10
29s.6 1-2 2-15 5 1 VGIVVVLAATRGSYWFDP 1 18  1-51 3 1 GTWDSSLSAVV 0 11
37s.6 3-23 2-15 4 1 VGIVVVLAATRGSYWFDP 1 18
76s.6 3-15 1-26 6 1 VGIVVVLAATRGSYWFDP 1 18  3-20 2 0 QQYSSSSYT 0 9
79s.6 3-15 6-6 4 1 DQFYSNFWYYFNY 0 13  3-11 2 0 QQRSNWLPYT 1 10
95s.6  3-20 4 1 QQYDSSPFT 0 9
28s.6
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Patient 9 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
6s.9 3-15 1-26 5 1 DGHLVGANV 1 9  7-46 3 0 LLSYNNARV 1 9 - - - - - + C+N - -
20s.9 1-2 3-10 4 2 GYIGLGSYYGDCDY 0 14
22s.9 4-31 3-10 4 3 LDGSGRHYDKGLDY 3 14
23s.9 3-23 2-2 4 0 ASGVGCNSTSCYSAY 0 15  3-20 4 0 QQYGSSPPLT 0 10
24s.9 1-3 3-9 6 6 DPSTDRRYYDILTGYTEDYYGMDV 2 24
30s.9 3-23 2-2 4 3 DDETAMLGVFQN 0 12  1-39 1 0 QQSYSTGAWT 0 10 - - - - - - -- - -
32s.9 3-15 6-19 3 2 ENASGSNLYAFDF 0 13
33s.9 3-9 3-16 3 3 DMGSVIVPADAFDF 0 14
34s.9 3-30-3 2-21 4 3 APDVDSAVVVGGSFDY 0 16
39s.9 3-11 2-2 6 2 DRNIVPYYYYGMDV 1 14  2-23 3 0 CSYAGSPV 0 8 - - - - - - -- - -
47s.9 3-48 2-15 3 1 RRAIVVAGGALDV 2 13
54s.9 3-74 5-24 6 1 DVGSPPGGIYSYALAV 0 16  2-14 3 0 ISYRSSKTWV 2 10
58s.9 4-28 4-17 6 1 VMRSTVTTSYYYYAMDV 1 17
60s.9 3-30 2-15 3 2 EVDCSGGSCYSLAS 0 14  2-23 3 0 CSYAGSPV 0 8
81s.9 1-8 3-10 4 2 IGESWGSLFDH 1 11
84s.9 5-51 3-16 3 1 QGAPNAFDV 0 9
92s.9 3-11 2-2 6 2 IGPISASISYDFAMDV 0 16  3-15 1 1 QHFDSWPRT 2 9
94s.9 3-48 2-21 3 2 IGPISASISYDFAMDV 0 16
95s.9 3-33 7-27 4 3 DSGTVGPSGDLDY 0 13
96s.9 3-30 2-2 5 1 GQGYCSNINCYPFDP 0 15  
Patient 12 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
7s.12 1-69 3-22 4 2 QTSGIVVVQENFFDS 0 15
9s.12 1-18 3-10 5 2 DHSLVRGAGDL 2 11  1-39 2 0 QQSYTTPYT 0 9
10s.12 4-59 3-10 6 2 VMYYYGSGNYLESYYYYGLEV 0 21  1-27 3 0 QSYNSALRGFT 1 11
20s.12 3-74 6-13 4 2 PAVSWEGFLDS 0 11  3-20 2 1 QQYDSPPRT 1 9 - - - - + - -- + +
34s.12 3-9 6-19 4 2 VAGSGWDYHFDL 1 12  1-5 2 0 QYYNTFSAT 0 9
35s.12 3-21 3-3 4 6 ENEEFDDFWSGFPRLYYFDY 1 20
48s.12 3-7 6-6 6 2 DRQPSSYNGLDV 1 12  2-28 2 0 MQGLQTPRT 1 9
64s.12 4-39 3-10 6 2 QGADRRGSAYFFGMDV 2 16  2-23 3 0 CSSASFTISWV 0 11 - - - - - - -- - -
65s.12 3-9 3-3 4 2 DIRSGPGGLDS 1 11  1-44 3 1 AACDGSLNGHVV 1 12
68s.12  3-20 1 0 QQFGSSPLWT 0 10
78s.12 3-23 2-21 5 1 ESVAARGYFQF 1 11  2-23 3 0 SSYAGNGTVA 0 10 - + - + - + N - -
79s.12 5-51 3-9 5 3 GGVVPDHDWFDQ 1 12
89s.12 3-11 6-25 4 1 SLLSGTLSRVGYFDY 1 15  3-15 1 0 QQYNQWPRT 1 9
93s.12 4-61 2-21 2 3 AALGFTGGDYVDSSRYWYFDL 1 21
94s.12 3-9 3-22 3 2 DMRTLSTMIVRGSDL 2 15
23s.12 4-59 1-26 6 2 DQKIFSGSYSAYYYYGMDV 1 19  1-39 4 0 QQTYGTPLT 0 9
66s.12 3-23 4-23 6 2 GTTDMDV 0 7  2-30 1 0 MQVSHWPRT 2 9
67s.12 3-23 1-1 6 1 QQGFRVYYSALDV 1 13
86s.12 1-46 1-1 4 1 GTDNSPTY 0 8
90s.12 3-23 3-16 3 3 ESTVYMGNDAFDL 0 13  1-40 3 1 QSYDTGLTGLKV 1 12  
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Patient 13 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
11s.13  2-14 3 0 SSYSTNGPLV 0 10
17s.13 4-4 2-2 6 0 FSLGGHCSGTNCTPV 1 15
23s.13 3-30 3-22 6 4 RGDYYDYYDSYYGMDV 1 16
48s.13 4-4 6-19 3 1 ARTGWNLVNAFDL 1 13  1-51 3 1 GVWDGSLSAVV 0 11
59s.13 3-23 3-3 5 2 AWSSSVFGVDTLFDL 0 15  1-47 3 2 AAWDDSLSGPV 0 11
60s.13  1-9 4 0 QQLNSHLT 1 8
91s.13 3-30 4-17 6 2 QGLRDKTLNHYYIMDV 3 16  1-40 3 1 QSYDSSLISWV 0 11
96s.13  1-36 3 2 AAWDDSLNGLGV 0 12  
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Table 5.2 IgH and L gene repertoire analysis and polyreactivity of single memory unswitched B cells from SS patients. Clones highlighted in 
grey are those expressed as recombinant antibodies. (-) and (+), negative and positive charges within the heavy chain CDR3; length, number 
of amino acids within the CDR3; +, clones reactive in ELISA/IFA; -, clones non-reactive in ELISA/IFA; ND, not determined; C, cytoplasmic 
pattern; N, nuclear pattern. 
Patient 3 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
1u.3 4-59 6-13 1 1 DTAYSSSWLPQRG 1 13  1D-39 1 0 QQSYSTPRT 1 9
2u.3  4-69 3 1 QTWDTGIRV 1 9
3u.3 4-b 6-13 4 1 VGRAAAGIPDY 1 11
6u.3 3-30 2-8 2 2 DPGTDIGPGLFILVHV 1 16  1-5 1 0 QQYKSYPGT 1 9
7u.3 3-43 1-7 6 4 DAYDWKHGSDPYFSYVDI 2 18  1-51 3 1 GTWDSGLSAGV 0 11 - - - - + - -- - -
8u.3  1-5 1 0 QQYKSYPGT 1 9
9u.3  2-30 2 0 MQGTHWPPYT 1 10
13u.3 3-23 5-18 5 1 SHEWMQSLLRPHYLTPGP 3 18
16u.3 3-74 5-24 4 4 GAGWDEDLATIQYFD 0 15
19u.3 4-39 4-23 4 0 QVRYGTNPRFLTTG 2 14  4-1 1 0 QQYYSTTQT 0 9
20u.3  4-1 1 0 QQYSGSPPSWT 0 11
23u.3  1-9 5 0 QQLNSYPIT 0 9
25u.3 3-23 6-19 5 1 GHLYSSGWEWSTPG 1 14  1D-39 1 0 QQSYSTLTWT 0 10
26u.3  1-16 1 0 LQYNIYPRT 1 9
28u.3 3-48 3-22 4 3 DGHPNYYESSSSYYVPANYFDY 1 22  3-15 4 0 QQYNNWPPFT 0 10
32u.3 3-23 4-23 6 1 GAVVNNYYYYGMDV 0 14
34u.3 5-a 4-23 4 3 HQEDYSYKSNSFDY 2 14  1D-39 4 0 QQSYSAPLT 0 9
35u.3 3-23 1-26 6 1 GLGNVGGTGGLETGC 0 15  1-9 4 0 QQLNSYPLT 0 9
37u.3  1-47 3 2 AAWDDSLSGPV 0 11
41u.3 3-7 2-2 4 0 PRPAAISRLTLV 2 12
43u.3 3-23 3-9 3 4 DDSNFYDAFDI 0 11
47u.3 4-59 4-17 6 2 GNYGDVCVDV 0 10  1-5 1 0 QQYNSYSST 0 9
48u.3  3-15 3 0 QQYINWPQFT 0 10
51u.3  1D-39 5 0 QQSYSTSIS 0 9
54u.3 3-21 5-24 4  3-20 5 0 QQYGSSPIT 0 9
59u.3 3-7 3-10 4 2 DSIFGFGELWGSVY 0 14  1-40 3 1 QSYDSSLSAYWV 0 12
60u.3 4-61 3-10 4 1 DKGSGSYYVLTTGP 1 14  4-1 1 0 QQYFSSPT 0 8
63u.3 3-48 3-3 6 3 DRGYDFWSGGGYMDV 1 15
64u.3 3-7 6-13 4 3 DGTEAAGYYFDY 0 12  4-69 3 1 QTWDTGIRV 1 9 - - - - - - -- - -
65u.3 3-43 3-10 6 1 CKGMVRGVSGYYYYYYMDV 2 19  3-20 5 0 QQYGSSPPIT 0 10
68u.3 4-34 3-10 4 1 GPLTDYYGSGSLTTG 0 15
70u.3 4-4 3-22 3 1 GGYDGSGYCLTLVT 0 14   
72u.3 3-30-3 6-19 4 1 GGTGYSSGWADY 0 12  1-5 1 0 QQYNSYSWT 0 9
73u.3 3-49 2-2 6 2 DGSHLVPAAQGYYYYYYMDV 1 20
74u.3 3-20 3-9 2 0 TSYSNRGWTPATGYSITGPAA 1 21  3-20 2 0 QQYGTSPNT 0 9
75u.3 4-34 2-2 5 2 SMSCDSSSCKGRGWFDR 3 17  4-1*01 1 0 QQYYSPPPWT 0 10 - - - - + - -- - -
76u.3 3-74 3-10 4 1 ALGFYGSGSYSGDY 0 14  2-14 3 0 NSYTTSSTLV 0 10 - - - - - - -- - -
78u.3  3-20 5 0 QQYHSSPVT 1 9
79u.3 3-30 2-21 3 2 PAGVVVTDDAINI 0 13
80u.3  3-11 4 0 QQRSNWSLT 1 9
85u.3 4-61 2-8 5 2 SPPTNGGEWFDP 0 12
86u.3 5-51 2-2 4 0 RYCLSASCYTPLTTG 1 15
87u.3 3-11*01 2-2*03 3 2 DRGCSSPSCYGGAFDL 1 16  4-69 3 1 QTWDTGIQV 0 9 - - - - - - -- - -
88u.3 3-23 4-11 6 2 GGNDYNNAYYYYYYMDV 0 17  2-8 3 0 ASYTGSNNFV 0 10
93u.3 3-23 6-13 4 0 NRASSSWYYLTTG 1 13
94u.3  2D-28 4 0 MQTLQIPLT 0 9  
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Patient 4 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
1u.4 4-59 3-16 6 1 QNSHNYYYYMDV 1 12
3u.4  1-40 3 1 QSYDSSLSGSV 0 11
4u.4 5-51 1-7 6 4 LKGENWNYHYYGMDV 5 16  2-23 3 0 CSHAGSSLSL 1 10 - - - - - - -- - -
11u.4 3-64 3-22 3 3 SWDTSGNPHDVYDI 1 14
13u.4 3-23 3-3 6 2 DRGGVRIFGGYYYGMDV 2 17  3-11 5 0 QQRSNWPIT 1 9 - - - - - - -- - -
19u.4 3-23 6-6 6 2 NGDHSSSSSMDV 1 12  3-15 1 0 QQYNNWPPWT 0 10 - - - - - - -- - -
22u.4 1-46 6-19 6 2 DRRYSSVYGMDV 2 12  2-D28 3 0 MQALQTPFT 0 9 - - - - - - -- - -
25u.4 3-21 3-10 6 2 DSPPGGPGSGSSLTTTGMDV 0 20
30u.4 3-21 6-19 6 2 PGGYSSGWYKDFYYYMDV 1 18
33u.4 3-7 3-10 3 3 GDYHSGTFIDAFDI 1 14
34u.4 3-23 2-2 1 2 DLWSCSSSSCDVGTCY 0 16
40u.4 3-72 5-12 4 1 GYVGAAQSNFDY 0 12  1-5 5 0 QQYNSYPITF 0 10
41u.4  3-20 2 0 QHYGSSRWT 2 9
42u.4 4-61 3-22 2 2 AVYESSGYQGIYWYSDL 0 17
46u.4 3-23 6-19 4 1 DGVGSSGWYYLATG 0 14
50u.4 3-72 2-21 6 5 AYCDDDCYSDFYYYMDV 0 17  1-51 1 1 GTWDSSLIAYV 0 11
52u.4 3-23 2-2 6 3 DNAGYRGADYYYYMDV 1 16  1-44 3 2 AAWDDSLNGPV 0 11
53u.4  2-11 1 0 FSYAGSYTYV 0 10
61u.4  3-11 4 0 QQRSNWPQT 1 9
 7-46 3 0 FLFYSGAWV 0 9
65u.4 3-23 2-2 6 2 RDCSSTSCYLVTLDH 2 15  1-9 4 0 QQVNSYPPT 0 9
67u.4 3-30 2-2 6 1 GRVPAAIYYYMDV 1 13
75u.4 3-15 2-8 6 2 GADYYYYYMDV 0 11
76u.4 3-33 2-2 6 2 EYQMVKAGYMDVW 1 13  3-15 2 0 QQNNWPRT 1 8  
Patient 5 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
11u.5 Apr-59 3-10 6 2 LGPDSVYHYYYMDV 1 14   2-40 3 0 MQSLQTFTF 0 9 - - - - - - -- - -
24u.5 3-23 6-19 4 1 VGGFGPPLDN 0 10  3-11 4 0 QQRANWPLT 1 9
29u.5 5-51 6-19 4 1 LGGAVTLHYFDY 1 12  1-44 3 2 AAWDDSLMGV 0 10 - - - - - + N - -
32u.5 3-73 2-8 1 1 LMGSPEYFGH 1 10  1-16 4 0 QQYNRHPLT 2 9
36u.5 4-34 6-13 5 2 DGNLTAAATRWFDP 1 14  1-8 1 0 QQYYSYPRT 1 9 - - - - - - -- - -
71u.5 4-61 6-19 6 1 ALPPYYYYYGMDV 0 13  1-51 3 1 GTWDSSLSAGV 0 11
76u.5 3-7 3-16 4 1 MPFDY 0 5  1-17 4 0 LQHNSYPLT 1 9
77u.5  7-43 3 0 LLYYGGVRV 1 9
80u.5 4-30-2 3-10 4 2 DGSGSSLPFDY 0 11  3-20 1 0 QQYGTSPWT 0 9 - - - - - - -- - -
81u.5 4-34 3-3 4 2 KHWSTDVTTNLDY 2 13
84u.5 4-4 3-22 1 4 DLYYYDSSGYYLYYFQH 4 18  3-20 2 0 QQYGSSPYT 0 9 - - - - - + N - -
96u.5 3-21 3-16 5 1 GTLTSGGGPYNWFDP 0 15  
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Patient 6 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
11u.6 1-46 3-9 5 3 DEGSTGYSRLDP 1 12  1-39 2 0 QQSYRYPYT 1 9
12u.6 3-48 6-25 6 3 DLRDGYGMDV 1 10  3-20 4 0 QQSGSSLT 0 8
19u.6 3-53 1-26 2 2 ARDSGSYYVHWYFDL 2 15
23u.6 4-34 7-27 4 0 GRLGGAAN 1 8  1-27 1 0 QNYNSAPRT 1 9
24u.6 4-39 5-5 6 1 QYGMDV 0 6  2-14 3 0 SSYTNSNTFWV 0 11
31u.6 4-4 3-22 4 1 GISSGWAGKFDY 1 12
39u.6  2-23 3 0 SSYAGGKTWV 1 10
41u.6 3-48 2-15 4 2 GGYCSGDSCYGGYYFDY 0 17
42u.6 4-31 4-17 3 4 REGDPDAFDI 1 10
48u.6 3-7 4-17 6 1 PIYGSSSGLSGMDV 0 14  1-39 1 0 QQSYSSLWT 0 9
51u.6 3-21 3-10 3 1 VTGNPGAFDI 0 10  2-11 3 0 CSYTGSYTSV 0 10
55u.6  1-39 2 0 QQSYNTPYT 0 9
67u.6 7-4-1 3-22 3 2 TYYDSSGYYYVFDI 0 14  3-20 2 0 QQHGSSPYT 1 9 - - - - - - -- - -
69u.6 3-72 1-7 3 1 GGITGPRITFDI 1 12  1-5 4 0 QHYNSYPLT 1 9 - - - - + - -- - -
74u.6 3-23 2-2 6 1 CGLAGSSTSCYSYGMDV 0 17
75u.6 3-23 3-3 3 2 LSWGEPNGDFFGI 0 13  1-17 4 0 LQHNSYPLT 1 9 - - - - - - -- - -
77u.6 4-39 5-5 4 2 SGFFYDSDGYPMYNFHY 1 17  3-11 4 2 QQRSNWPL 4 9
81u.6 1-2 4-23 4 3 VRDSIGNSELDF 1 12  1-5 4 1 QQYDTFPLT 0 9 - - - - + + C + +
83u.6  7-43 1 0 LLYYGGGYV 0 9
87u.6 3-21 6-19 6 2 LTVAGNHDYYFYGVDV 1 16  2-28 4 0 MQAKQAPPT 1 9
89u.6 3-7 3-10 4 1 VHNYYGSGSYSSYYFDY 1 17  2-14 3 0 SSYTSSSTLGV 0 11 - - - - - + C+N - -  
Patient 12 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
1u.12 1-3 6-19 4 2 DLAVAGSQFDS 0 11
4u.12 4-34 3-10 4 1 GRGVALRGPNYFDY 2 14
5u.12 3-30 3-22 6 2 ASVSGFSSGYYGDYYYGMDV 0 20
9u.12 1-18 3-22 4 3 DAYYYDSSGYYYPHYFDY 1 18
26u.12 4-4 6-6 4 0 PGILRPH 2 7
28u.12 3-7 ??? 5 2 EPWFDP 0 6  3-20 5 1 QQYDRKT 2 7 - - - - - - -- - -
29u.12 3-11 3-10 2 2 DANYYGSGIIGWYFDL 0 16  1-39 4 0 QQSYSTPLT 0 9
31u.12 3-7 6-6 3 3 HRQWAAARPDDAFDI 3 15
32u.12 3-11 3-3 6 1 LGFWGSYGMDV 0 11  2-8 1 0 SSYAGSNNYV 0 10 - - - - - - -- - -
40u.12 3-23 6-19 4 1 GRASGWTSFDY 1 11
45u.12 3-23 3-22 5 3 AGRYNDYDIWFDP 1 13
46u.12 4-59 4-23 3 3 HDYGGNAHADSFDI 2 14
47u.12 4-39 1-7 4 2 HALGGNYDFDY 1 11  3-20 5 0 QQYGT 0 5
52u.12 3-23 4-17 4 3 DTGDYGNSFDY 0 11
59u.12 5-51 1-1 5 0 HRAPAGTFQPFHL 3 13  3-20 3 0 QQYGSSPPKT 1 10
62u.12 4-59 3-16 4 2 RYYGLGEYHDY 2 11  2-11 3 0 CSYAGSYTSFVV 0 12
65u.12 1-46 3-10 6 2 DPMVRGLSYHGMDV 2 14
69u.12 3-23 3-9 4 2 GRSGRRGYFDWLGIDY 3 16  6-57 3 2 QSYDNDNLWV 0 10
75u.12 3-30 6-19 4 2 GREWLHPFDY 2 10
77u.12 4-39 2-8 5 0 PYKASGWWQGGHF 2 13  1-9 3 0 QQLNSYPPFT 0 10
80u.12 3-23 2-8 4 2 GHCANGVCYDSVDY 1 14  1-9 2 0 QQLNTYPRT 1 9
81u.12 1-18 5-5 4 2 KESHQLLVFDY 2 11  2-14 3 0 SSYTTINTL 0 9
86u.12 4-59 3-16 4 1 AGGGTPFDY 0 9  1-44 3 3 AAWDDSLNGHWE 1 12
87u.12 5-51 3-3 4 2 PRREWEPPRY 3 10  1-39 1 0 QQSYSAPVT 0 9
91u.12 5-51 3-9 4 1 GSGYFDY 0 7  3-20 1 0 QQFGSSPRT 1 9
92u.12 4-59 6-25 4 2 AGGIQSEQGIFDH 1 13  1-5 2 0 QQYNSYSYT 0 9
93u.12 4-59 4-4 4 2 YGVDYFDY 0 8  3-15 2 1 QQYNNGPPDYT 0 11 - - - - + + N - -  
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Patient 13 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length dsDNA ssDNA LPS Insulin ENA Hep-2 Pattern anti-Ro anti-La
6u.13  1-5 1 0 LQYNGNTWT 0 9
7u.13 1-24 ? 5 1 LRARAWFDP 2 9  2-14 3 1 SSYRSNNTLDVV 1 12 - - - - + - -- - -
8u.13 1-2 4-17 6 4 ESDYDPIMDV 0 10  4-1 4 0 QQYYSTPLT 0 9 - - + - - - -- - -
 2-14 3 0 CSYSSSSTSVV 0 11
9u.13 3-30 4-17 5 3 VNDYGDYGWFDP 0 12  3-11 5 0 QQRSNWPPIT 1 10
10u.13 1-18 3-22 3 2 TLTSRITMIVVVIDAFDI 1 18  1-47 3 2 AAWDDSLSGPV 0 11
11u.13 4-39 3-22 2 1 LYFSMTVALRYFDL 1 14  3-9 3 1 QVWDSSIGV 0 9 - - - - - - -- - -
21u.13 1-18 3-22 4 3 DRGAYYYDSSGYYVGFDY 1 18  7-43 3 0 LLYYGGAQGV 0 10
34u.13 3-9 5-24 4 2 DIGYNYGLRGFDS 1 13
46u.13 5-51 3-22 5 2 HNKNYYDRSQLGFDP 3 15  1-44 3 2 AAWDDSLNGPV 0 11
47u.13 3-30 3-10 4 3 DYVGDNSFFDH 1 11  4-69 1 1 QTWDTGIQV 0 9 - - - - - - -- - -
48u.13 1-2 2-2 4 2 LEVVPAAMNDY 0 11  3-11 1 0 QQRSNWPPWT 1 10
56u.13 5-51 4-23 4 1 RGGSGSNVYFDY 1 12  1-51 3 1 GTWDSSLSAVV 0 11 - - - - - - -- - -
57u.13 4-59 ? 3 3 DGADAFDI 0 8  4-1 1 0 QQYYSTPWT 0 9 + + + + + - -- + +
58u.13 1-2 3-16 4 3 PIWGDDVEGY 0 10  4-60 3 3 ETWTSKEEI 1 9
59u.13 3-9 3-3 4 2 DAQLSGFNYFDS 0 12  1-5 1 0 QQYHFYST 1 8
60u.13 3-11 3-10 4 1 SKGDY 1 5  3-11 4 0 QQRSNWPLT 1 9
68u.13 3-30 6-19 4 2 DLAPGFTSAFDY 0 12  3-15 1 0 QHYNNWPPWT 1 10
71u.13 3-48 1-26 5 2 DRELVGATKFNP 2 12
72u.13 3-30 3-10 4 2 DLAPGFTSAFDY 0 12  3-15 1 0 QHYNNWPPWT 1 10 - - - - + - -- - -
79u.13 3-30 6-13 6 1 SQVAAAGRYGMDV 1 13  1-40 3 1 QSYDSSLSGWV 0 11
81u.13 4-34 2-15 4 1 GPRSSPIVVVVAVDY 1 15  3-11 5 0 QQRSNWPPVT 1 10
 1-51 3 1 GTWDSSLSAV 0 10
82u.13 4-59 5-5 4 1 ALGYNYGYRYFDY 1 13
83u.13 3-7 3-3 6 3 DVIFEVLRFYYYGMDV 1 16  1-17 1 1 LQDYNYPRT 1 9
92u.13 3-7 5-24 3 2 LSRDGYNYNAFDI 1 13  1-39 1 0 QQTYSAPGRSAK 2 12 + + + + + - -- - -
93u.13 3-23 5-5 3 1 GIQLWPGGAFDI 0 12  2-28 2 0 MQALQTPYS 0 9 - - - - - + N - -
94u.13 3-9 6-19 4 2 DSRRKSIAVAGAYFDY 3 16  1-12 2 0 QQANSFPYS 0 9 - + - - - + N - -
96u.13 3-30 6-19 4 2 DLAPGFTSAFDY 0 12  3-15 1 0 QHYNNWPPWT 1 10  
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Figure 5.4 Polyreactivity of memory B cell antibodies from SS patients and HD.  
Memory B cell antibodies from SS patients (n=39) were tested for reactivity with 
dsDNA (top left), ssDNA (top right), LPS (bottom left) and insulin (bottom right) by 
ELISA. Each graph shows the reactivity at a concentration of 1 g/ml. The cut-off OD 
(450 nm) at which antibodies were considered reactive is shown by the horizontal lines 
and it shows the result of two independent experiments. Data points represent 
individual antibodies. Internal controls for polyreactivity (empty dots) are shown in 
each graph and include mGO53 (negative; [34]), JB40 (low polyreactive; [34]), and 
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ED38 (highly polyreactive; [34]). Error bars indicate standard error of mean (SEM) for 
the internal controls. 
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6 | Characterization of synovial B cell monoclonal 
antibodies. 
6.1 Introduction. 
As previously reported in Chapter 1.3, a subset of RA patients can develop ectopic 
lymphoid structures in the synovium which represent functional niches of autoreactive 
B cells contributing to autoimmunity independently from SLO. However, whether 
antibody production within RA synovium is driven by the same antigen(s) as in SLO is 
poorly understood. Moreover, previous studies have shown that local B cell activation 
and differentiation of B cells into antibody-producing plasma cells may occur directly in 
RA synovial tissue [163]. In the present study I analysed the V gene usage, mutational 
frequency and clonal diversification of RA synovial single-sorted B cells. In particular, 
clonal relationship analysis has been done in order to support the idea that in RA 
synovial tissue a continuous activation and differentiation of specific B cell clones may 
occur as a result of a local antigen-driven process. The novelty of my work is the 
possibility of investigating the nature of such putative dominant antigen(s) by 
identifying the immunoreactivity of synovial-derived monoclonal antibodies. For the 
purpose of the thesis, I will present data on the reactivity of synovial B cells towards 
citrullinated antigens.   
6.2 RA patients. 
Out of 96 single CD19+ B cell sorted from each of the 2 out of 4 RA patients used, I 
obtained successful sequences from a total of 139 different VH and JH regions (RA1-
3=83, RA2=56), 94 V and J regions (RA1-3=67, RA2=27), and 81 V and J regions 
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(RA1-3=53, RA2=28). Clones with matching and productive VH and VL products were 
used for downstream cloning and recombinant antibody expression. All productive VH 
and VL products were analysed for the presence of V gene somatic mutations. 
6.3 Immunohistological characterization of synovial tissue of 
patients with RA. 
Synovial tissue was obtained from knee joint replacement surgery from 4 patients with 
established RA (Table 3.1). All samples were assessed by immunohistological staining 
in order to define the stage of lymphocytic aggregation, i.e. the presence of B (CD20) 
and T (CD3) cells, plasma cells (CD138) and macrophages (CD68). The sample RA1 was 
classified as grade 3 which defines larger aggregates with often T/B cell 
compartmentalization and the presence of FDC network (Figure 6.1A and 6.1B). The 
second sample RA2 showed mainly plasma cells infiltration (Figure 6.1C). Sample RA4 
displayed larger aggregates with T/B compartmentalization and the presence of FDC 
network, thus classified as grade 3. Sample RA5 displayed few lymphocytes infiltration, 
thus classified as diffuse (data not shown). For the latter two samples, single CD19+ 
synovial B cells were sorted but the generation of recombinant antibodies and their 
analysis is still under way.  




Figure 6.1 Representative immunohistological characterization of synovial tissue sample from patients with RA.  
In order to assess the presence of B cells, T cells and plasma cells paraffin tissue sections were stained for CD20 (A), CD3 (B) and CD138 
(C), respectively.  
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6.4 V gene repertoire analysis of synovial B cells. 
Single CD19+ B cells were sorted from synovial cell suspensions and the V gene 
repertoire was determined (Figure 6.2A). Analysis of the B cell heavy chain isotype 
showed that 33% of the synovial B cells expressed IgM, while 40% expressed IgG, and 
27% expressed IgA (Figure 6.2B). A sequence analysis of the synovial B cells showed 
that the VH gene repertoire was not significantly different when compared to 
peripheral blood CD5-IgM+ B cells in healthy donors (Figure 6.3A). As previously 
published by the Berek’s group [163, 172], CD5-IgM+ B cells denote naïve B cells 
characterised by V genes in an unmutated germline configuration and they were used 
as controls in previous publications [163]. In the IgM+ and IgA+ populations an 
overrepresentation of VH1 rearrangements was observed but it was not statistical 
significant. Statistical significant differences were found mainly in the JH gene 
repertoire of synovial B cells when compared to controls. Both JH2 and JH3 were 
overrepresented in the IgM synovial B cells. In the IgG synovial B cells JH4 was found 
less frequently and JH5 was overrepresented compared to controls. The CDR3 length 
analysis showed that the IgM+ synovial B cells were characterised by significantly 
longer CDR3 compared to IgG and IgA, as expected since 40% of the IgM V genes were 
in an unmutated germline configuration (Figure 6.3B, top panel). Significant 
differences in the CDR3 positive charges were observed in the IgA+ and IgG+ synovial B 
cells with more positive charges compared to IgM+ synovial B cells (Figure 6.3B, 
bottom panel).   
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Figure 6.2 Isolation strategy of single CD19+ synovial B cells and comparison of the frequencies of , , and  heavy chain isotype.  
(A) Mononuclear cells from RA patients were surface labelled with fluorochrome-coupled anti-CD19 and anti-CD3. The sorting gate 
strategy for single CD19+CD3- is shown. (B) The frequencies of , , and  heavy chain isotype among all CD19+ B cells are shown. 
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Figure 6.3 IgH gene analysis of single CD19+ synovial B cells from RA patients. 
(A) The VH and JH gene repertoire of single CD19+ synovial B cells for each individual 
heavy chain isotype,  (white),  (grey), and  (black) is shown. The red bars indicate 
the VH and JH gene repertoire of peripheral blood naïve B cells [172]. (B) IgH CDR3 aa 
length and positive charges is shown for each heavy chain isotype separately. The 
absolute number of sequences analysed is reported over each graph. Error bars in bar 
graph indicate standard error of mean (SEM) for individual patients. P values compare 
data from RA synovial B cells to peripheral blood naïve B cells or from RA synovial B 
cells with different heavy chain isotype and it was calculated using the chi-square test 
(* P < 0.05; ** P < 0.01; *** P < 0.001). 
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Similarly, no significant changes in V and J gene usage for kappa and lambda chains 
were observed between the synovial B cells and CD5-IgM+ B cells used as control 
(Figure 6.4). Only a trend towards an increase in V1 and J1 gene usage was observed 
in the synovial B cells (not statistically significant) suggesting a possible defect in 
receptor editing.  
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Figure 6.4 IgL gene analysis of single CD19+ synovial B cells from two RA patients.  
Single CD19+ synovial B cell antibodies were analysed for IGK (A) and IGL (B) V family 
and J gene usage. The red bars indicate the VH and JH gene repertoire of peripheral 
blood naïve B cells [172]. The absolute number of sequences analysed is reported over 
each graph. Each bar in the graph indicate the mean + standard error of mean (SEM) 
for individual patients. P values compare data from RA synovial B cells to peripheral 
blood naïve B cells and it was calculated using the chi-square test (*** P < 0.001). 
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6.5 Somatic diversity and clonal relationship of synovial B cells.  
According to the isotype, the synovial B cell clones showed an increasingly high 
number of somatic mutations in their V region (IgM < IgG < IgA). V genes of IgM+ 
synovial B cells carried on average 4 IGH gene mutations, IgG+ and IgA+ synovial B cells 
carried on average 15 and 17 IGH gene mutations, respectively (Figure 6.5A). Synovial 
B cells carried on average 18 IGK and 8 IGL V gene mutations (Figure 6.5B). All CD19+ B 
cell antibodies showed high ratios of replacement to silent mutations in CDR1 and 
CDR2 compared with those in FR1-3 regions (Figure 6.5C). This difference was less 
marked in the IgM+ antibodies.  
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Figure 6.5 Number of somatic mutations and analysis of replacement (R) and silent (S) mutations ratio in FR and CDR regions of CD19+ 
synovial B cells.  
The Ig gene sequences of CD19+ synovial B cells were analyzed for absolute numbers of somatic mutations in VH genes for IgM, IgG and 
IgA individually (A), VL genes ( and ) (B), and frequency of replacement and silent mutation ratio in FR (white) and CDR (black) regions 
for IgM, IgG and IgA individually (C).  
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Ig sequences of the heavy chain are determined by a specific V(D)J rearrangement 
which defines a unique CDR3. Further diversity is introduced by N nucleotide addition 
during gene rearrangement and by point mutations through the process of SHM during 
clonal expansion of the B cells, as described in Chapter 1.1. The latter event increases 
the antigen binding affinity and brings to the formation of clonally related B cells. Thus, 
the Ig gene of these clonally related B cells derives from a single germline 
rearrangement and is characterised by the same V, D and J gene usage. The analysis of 
the VH gene repertoire of RA synovial B cells showed the presence of clonally related 
Ig genes. In particular, two sets of synovial B cells expressed the same V(D)J 
rearrangement with the same CDR3 and a different pattern of somatic mutations in 
the sample RA1. In this patient clones IgA11 with IgA82 and clones IgA88 with IgA91 
were highly diversified from germline sequences but differed by one single mutation 
(Figure 6.6A). This suggests that in the joints of this patient IgA+ B cells underwent 
intra-synovial diversification. Similarly, two clonally related B cells were found in the 
sample RA2 (IgG35 and IgG80) and three in RA3 (IgG47, IgG80 and IgG91) (Figure 
6.6A). Moreover, in sample RA2 two sets of proliferating clones (IgG33, IgG48 and 
IgG88 as well as IgG5, IgG35, IgG39, IgG83 and IgG91) were characterised by the same 
V(D)J rearrangement, identical CDR3 and the same pattern of somatic mutations. 
These data support the notion that the RA synovium is characterised by an active 
proliferation of synovial B cells due to an antigen-selected differentiation within the 
synovial tissue, as originally suggested by the Berek’s group [163]. 
Interestingly, we found shared heavy CDR3 (HCDR3) regions between the two RA 
patients (Figure 6.6B). Two clones from RA1 (IgM12 and IgA64) shared two HCDR3 
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regions with RA2. IgM12 shared the same CDR3 with IgG33, IgG48 and IgG88 from RA2 
(VH3-15, D 2-21, JH 5; CDR3=HFESCGGDCSNW). IgA64 shared the same CDR3 with 
IgG5, IgG35, IgG39, IgG83 and IgG91 (VH 3-9, D 3-22, JH 4; CDR3=DISSYDDTSGYYYN). 
Three clones from RA3 (IgG47, IgG80, IgG91) shared one HCDR3 with two clones from 
RA2 (IgG35, IgG80) (VH 3-48, D 3-22, JH 4; CDR3=VHMYYYDSSGYYYDDY). The presence 
of B cell clones with identical CDR3 but different V(D)J among different RA patients 
strongly suggest that common antigens may be driving humoral (auto)immunity within 
the joints and provide a fascinating scenario whereby identification of such antigenic 
forces may provide novel critical clues regarding RA pathogenesis. 
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Figure 6.6 Lineage tree analysis of synovial B cells. 
Schematic presentation of the sequence analysis of single CD19+ B cells in RA synovial 
tissue sample from two patients is shown. (A) Genealogic trees generated by 
comparison of Ig VH sequences of synovial B cells from sample RA1 and sample RA2. 
The synovial B cell clones are depicted as white circle, the putative common progenitor 
as grey circle and the germline sequences as black circle. The number inside the circle 
corresponds to the name of the clone and the number beside the line represents the 
additional mutation acquired. At the bottom of each clone the correspondent Ig VL 
sequence are indicated. “na” means not applicable and indicates those genes that we 
could not amplify. (B) Venn diagram represents the number of shared clones displaying 
an identical heavy chain CDR3 region between the different patients and samples. 
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6.6 Recombinant synovial B cell antibodies reactivity profile 
towards citrullinated antigens.  
Out of all single CD19+ B cells isolated from the RA synovium, I manage to clone the 
matching IGH, IGK, and IGL chains genes of 66 individual B cells into specific expression 
vectors and produced the recombinant monoclonal antibodies in vitro (for full details 
of the repertoire of the synovial B cell antibodies see Table 6.1). 
These antibodies have been used to investigate whether the RA synovial B cell 
antibodies were reactive against citrullinated antigens using a specific diagnostic ELISA 
test which is based on the detection of autoantibodies in human serum or plasma 
towards a synthetic cyclic peptide containing modified arginine residues (CCP2 
peptide). This test has a sensitivity of 78% and a specificity of 99%, as reported by the 
manufacturer. Of the 66 antibodies, 59 were tested in the anti-CCP ELISA as 7 
antibodies could not be used since their concentration was too low for the test (<1 
g/ml). 
As shown in Figure 6.7, I observed a significant reactivity toward cyclic citrullinated 
peptides in 3 out of 59 RA synovial B cell antibodies (2 IgA and 1 IgG) and low reactivity 
in 5 more clones (3 IgG and 2 IgM). Of relevance, one of the 3 highest RA monoclonal 
antibodies positive for CCP (RA2 IgG80) was one of the clones clonally related with the 
RA2 clone IgG35 (Figure 6.6A) and it shared the same CDR3 with three clones from 
RA3 (Figure 6.6B).  
These results, if confirmed in more refined studies (i.e. by testing the antibodies on 
specific citrullinated proteins (or derived peptides) associated with RA such as 
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vimentin, fibrinogen, etc.) would identify specific CDR3 regions shared among different 
RA patients responsible for the binding of B cells to citrullinated proteins (similarly to 
the HLADRQ “share epitope”). 
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Table 6.1 IgH and L gene repertoire analysis of CD19+ synovial B cells from RA patients.  
Clones highlighted in grey are those expressed as recombinant antibodies. (-) and (+), 
negative and positive charges within the heavy chain CDR3; length, number of amino 
acids within the CDR3. 
RA015/11 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length

88 4-4 3-10 2 2 EVPTPYFDL 0 9  1-39 2 0 QQSYSTPYT 0 9
94 1-3 4-17 3 4 GGEDGYGDSYNAFDL 0 15  1-5 1 0 QQYNSYSWT 0 9

58 3-64 1-26 5 1 EIVGANRWVPVGP 1 13  3-15 1 0 QQYNNWPQST 0 10
68 4-31 6-25 6 2 AISWADGYYMDV 0 12  1-40 3 1 QSYDSSLSGSV 0 11
69 1-24 5-5 6 1 ASSPFYYFYSMDV 0 13  2-23 3 0 CSSAGSSAVV 0 10
96 3-30 1-1 5 3 DPQNENWSPPYNWFDP 0 16  1-39 2 0 QQSHSIPYT 1 9

48 3-66 3-3 4 3 EGDLWSGSIDY 0 11  1-44 1 2 AAWDDSLNGRV 1 11
63 4-34 3-3 5 2 APQRFVEWLFWFDP 1 14  1-39 2 0 QQGYTALYN 0 9
74 4-59 5-24 6 1 GSAGGGYYYYYGMDV 0 15  1-40 2/3 1 QSYDSSLSGSGV 0 12
81 1-2 4-17 3 1 GAYGDPLHI 1 9  3-21 1 3 QVWDSSFDRPD 1 11
82 1-3 2-2 4 3 DRDIVVVPTARSLGYSYGSFDS 2 22  1-39 1 0 QQSYTNPRT 1 9
83 4-4 2-21 3 2 GPGTATSEAFDI 0 12  2-23 3 0 CSHVIGGIWV 1 10
91 3-21 3-10 4 1 WRAGVPSYFDY 1 11  1-33 3 0 QQYANVFT 0 8
95 1-58 3-16 4 1 GGSYVDY 0 7  4-1 2 0 QQYYSNPYT 0 9
RA015/11 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length

11 1-3 2-2 4 3 DRDIVVVPTARSLGYSYGSFDS 2 22
17 3-23 3-3 4 4 SPTDFWDDYLYYFDS 0 15  3-20 1 0 QQYGSSPWT 0 9
53 1-2 3-10 5 2 SEGFTHYFDP 1 10  3-15 1 1 QQYNDWPQT 0 9
62 3-48  6-25 4 2 EGHNSGYDY 1 9  3-11 3 0 QQRYHWPPFT 2 10
64 3-9 3-22 4 3 DISSYDDTSGYYYN 0 14  3-11 1 0 QQRSNWPGT 1 9
66 4-4 6-6 3 3 KGTYSTDSYDGFDI 1 14  2-23 1 0 CSYAGSSTLYV 0 11
72 1-69 3-10 5 2 ELLRGDVVPAF 1 11
75 3-33 3-16 4 2 DVGITGMINTFDY 0 13
80 3-9 2-8 5 2 DISRGGSSAVFEF 1 13
86 3-23 5-24 4 2 GDGYNPGVFFDY 0 12
88 3-11 2-2 5 1 QPWGSTNWFDP 0 11
91 3-11 2-2 5 1 QPWGSTNWFDP 0 11
95  1-44 3 2 ASWDDSLNVWV 0 11

3 1-18 6-6 4 3 DDSYSSSFDY 0 10
9 3-23 4-17 6 1 GQSHSWSAMDV 1 11  1-17 4 0 LQHNSYPLT 1 9
12 3-15 2-21 5 2 HFESCGGDCSNW 1 12  3-21 2/3 2 QVWDSSSDHPGV 1 12
19 1-2 5-5 6 3 VGGGRQLWLKDNYDYFYMDV 2 20  3-20 2 0 QQYGSSHT 1 8
22 4-59 2-2 2 1 IPAAPSYWYFDL 0 12
23 3-11 6-19 4 1 SGQQWPWDY 0 9
70 3-23 6-19 4 1 LAFVAATWRGPFDS 1 14  1-16 4 0 QQYYGYPPT 0 9
74  3-15 2 0 QQYYRWPPYT 1 10
78 3-30 2-21 6 3 ELGFPYCGGDCFSSMDV 0 17
83 3-48 6-13 4 2 DMPHFLYSSRWYPFDY 2 16  1-9 4 0 QQLNSYPLT 0 9
87 5-51 5-5 4 3 AYGYIWENSRYPENFDY 1 17  4-1 4 0 QQYYTTPLT 0 9
89 3-11 3-9 4 2 AYSDILTGSPYDY 0 13  3-15 4 0 QQYNNWPPLT 0 10
90 4-4 2-15 4 1 LTSKLGYCSGGSCYPYFDY 1 19  1-40 1 1 QSYDSSLSGSYV 0 12
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RA056/11 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length

23 4-59 6-19 5 2 LIAVAGTSDWFDP 0 13  1-44 3 2 AAWDDSLNGPV 0 11
41  3-15 1 0 QQCNNWPLT 0 9
70  3-25 1 1 QSADSSGTHV 1 10
95 3-23 3-9 5 1 VPHQLVPIWFDP 1 12  2-14 1 0 NSISSTSTNNV 0 11
3-30-3 5-24 3 2 DARGVRNAFDL 2 11  1-17 1 0 LQHNSFPWT 1 9
 7-43 3 1 LLYYDGGLWV 0 10

29 1-8 3-3 4 1 AAGVGVALDY 0 10  3-20 3 1 QHYESSPPVFT 1 11
33 3-15 2-21 5 2 HFESCGGDCSNW 1 12  4-69 1 1 QTWDTGIQV 0 9
35 3-48 3-22 4 3 VHMYYYDSSGYYYDDY 1 16  2-8 1 0 SSYAGSNNYV 0 10
45 3-30 2-2 3 2 PHRLLDSCSSTSCYVVAFDL 2 20  4-69 1 1 QTWDTGIQV 0 9
56 3-23 6-19 4 1 GTLSGFATTFDY 0 12  2-14 1 0 SSYTSSSSLLYV 0 12
60  1-44 3 2 AAWDDSLNGPV 0 11
66 4-39 1-26 4 1 RHIGRHYYFDY 4 11  2-11 3/2 0 CSYVGSYTVA 0 10
68 4-61 6-6 6 2 DASIAARPPWGMDV 1 14  2-23 3 0 CSYAAGNTRV 1 10
72 3-23 4-4 4 0 GARPSPSNYLYY 1 12  1-44 3 2 AAWDDSLNGPV 0 11
76 1-69 3-3 5 2 VRITIFGVVMVKSDNWFDP 2 19  3-15 2 2 QQYNNLYT 3 9
78 4-4 6-13 3 3 KGTYSTDSYDGFDI 1 14
80 3-48 3-22 4 3 VHLYYYDSSGYYYDDY 1 16  2-14 3/2 0 SSYTSSSTVV 0 10
83 3-9 3-22 4 3 DISSYDDTSGYYYN 0 14  1-51 3/2 1 GTWDSSLSAVV 0 11
 3-15 4 0 QQYNAWPLIT 0 10
 1-44 3 2 AAWDDSLNGPV 0 11
91 3-9 3-22 4 3 DISSYDDTSGYYYN 0 14 / 3-20 4 0 QQYGSSPLT 0 9

54 5-51 3-22 4 2 RYYYDSSGYTTFDY 1 14
89 3-15 3-3 4 2 LGGYYDFWSGYYRIDY 1 16




RA056/11 VH D JH (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length

35
58 1-3 2-2 4 0 SLYCSTHSCSFLHLY 2 15  3-20 2 0 QQYGSSPGT 0 9
93 4-4 3-3 4 1 TFWSGSYSRYFDS 1 13  3-15 5 0 QQYYNWPPIT 0 10

5 3-9 3-3 4 3 DISSYDDTSGYYYN 0 14
6 4-31 3-10 4 2 AVNVLLRFGELRHYFDQ 3 17  3-20 5 0 QQYGSLPLI 0 9
12 4-59 4-17 4 2 YGVDYFDY 0 8  1-51 2/3 1 GTWDSSLSAVV 0 11
20 5-51 3-22 6 2 QGYYDRSPRPHYMDV 3 15  3-11 1 0 QQRSNWPPT 1 9
21 3-30 2-2 4 1 ETCSPTNCYPRN 1 12  3-11 4 0 QQRSNSLT 1 8
23 3-33 6-25 4 1 VTSRVVAAAGGYFDH 2 15  3-9 2/3 1 QVWDISSVV 0 9
26 1-69 5-5 4 3 EGTAMVLEGFLDY 0 13  1-44 3 1 AACDGSLNGHVV 1 12
27 4-4 2-15 6 1 GFVVVPSAMKQGNSRIPYYSYYMDL 2 25  2-8 1 0 SSYAGSNNYV 0 10
3-9 3-22 4 3 DISSYDDTSGYYYN 0 14  3-15 4 0 QQYSYWFT 0 8
 1-51 2/3 1 GTWDSSLSAVV 0 11
36 4-39 1-26 4 1 RHIGRHYYFDY 4 11  2-14 2/3 0 SSYTSSSTLV 0 10
39 3-9 3-22 4 3 DISSYDDTSGYYYN 0 14  1-47 3 2 AAWDDSLSGWV 0 11
42  4-1 4 0 QQYYSTLALT 0 10
45 3-30 2-2 6 2 DIVVVPAATSLLGGYYYYYMDV 0 22  1-39 4 0 QQSSTTPLT 0 9
48 3-15 2-21 5 2 HFESCGGDCSNW 1 12  1-39 2 0 QQSYSTPYT 0 9
54 1-46 1-7 6 3 DGLEARRTTSSHPHYYMDV 4 19  3-11 4 0 QLRSNWRT 2 8
56 4-34 6-6 6 1 KKGRVGIAYMEV 3 12  1-39 3 0 QQSFSMPFT 0 9
3-9 6-13 4 2 DSAAGTPVYFDY 0 12  1-33 4 1 QQYDNLPLT 0 9
 1-44 3 2 AAWDDSLNGPV 0 11
63 5-51 3-3 5 1 HRGPTTIFGVAIGAFDP 2 17  1-44 3 2 AVWDDSLNGPV 0 11
66 4-30-4(4-31) 3-9 5 3 GVFDNFFNRRLETNWFDP 2 18  3-11 3 0 QQRSSWPPT 1 9
72 3-15 2-21 5/4 2 HFESCGGDCSNW 1 12  6-57 2/3 2 QSYDNDNLWV 0 10
75 4-59 5-5 2 2 TPYPPLDWYFDL 0 12  4-1 1 0 QQYYITPPT 0 9
88 3-15 2-21 5/4 2 HFESCGGDCSNW 1 12  1-44 1 2 AAWDDSLNGYV 0 11
94 3-30 3-10 4 3 EVREYTDY 1 8  3-11 4 0 QLRSNWLLT 1 9
95 3-23 1-26 4/3 0 LVGITHLSAAPWT 1 13  2-23 3 0 CSYAGTWV 0 8

2  1-44 3 2 AAWDDSLNGPV 0 11
3 3-21 3-22 3 3 DYYDSSGYLSAFDI 0 14  1-44 3 2 AAWDDSLNGWV 0 11
1-18 4-17 4 2 ASYGDYSDY 0 9  1-13 2 0 QQYYSTPPYT 0 10
 1-44 3 2 AAWDDSLNGPV 0 11
9 3-23 3-10 3 4 CETGERRWYYYGSGTIREAFDI 3 22  3-11 4 0 QQRSNWPPT 1 9
15 1-69 4-17 4 1 DQATTVTTRVWFVY 1 14  1-47 3 2 AAWDDSLSGRV 1 11
24 1-3 2-2 4 0 VGIVVVPAAALGY 0 13
25  1-44 3 2 AAWDDSLNGPV 0 11
34 3-21 6-13 5 3 PRQLGSVWFDP 4 12  1-9 4 0 QQLNSYPLT 0 9
38 3-33 6-13 4 2 DRSSSWYFDH 2 10  2-14 3 0 SSYTSSSTWV 0 10
39  1-47 3 2 AAWDDSLSGWV 0 11
41 3-23 3-10 4 1 GSGTFDY 0 7  3-21 1 2 QVWDSSSDHYV 1 11
48 4-31 6-6 6 1 VSLNSSSSLIHYYYYMDV 1 18  1-39 2 0 QQSYSTPYT 0 9
67 3-30 5-12 6 3 DYTAWLLNEYYYYGMDV 0 17  1-47 3 2 AAWDDSLSVWV 0 11
81 3-64 3-3 4 3 EYDFWSGYYYRGATRTTPNFDY 2 22  3-15 2 0 QQYNNWPLWT 0 10
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RA057/11 VH D HJ (-) CDR3(aa) (+) Length / V/V J/J (-) CDR3 (+) Length

6 3-30 2-15 4 0 AHIVVVVAASYYFAY 1 15
12 3-11 3-3 4 1 SFWNGYHFDY 1 10  2-14 2/3 0 SSYTTSGTYVV 0 11
25 3-7 6-13 6 3 DQVEQQLVLGYFYYYYMDV 0 19  1-44 1 1 AAWDASLKV 1 9
43 3-33 4-17 6 2 ADYGNSYYYYMDV 0 13  2-8 1 0 SSYAGSNNYV 0 10
3-7 3-3 4 4 DPRAYDYWSGYYEGYFDY 1 18  3-20 1 0 QQYGSSPGT 0 9
 2-23 3 0 CSSASFTISWV 0 11

3 4-39 2-15 5 1 LFGPGIPGWWLDP 0 13  3-20 4 0 QQHGSSRGLT 2 10
5 1-2 5-5 5 1 TSMGYTSTWAYNWFDP 0 16  2-23 2 2 CLYAGEEVL 0 9
10 4-34 5-5 6 2 GVRGGYTSDSFPLYYFMDL 1 19  1-12 5 0 QQANSFPVT 0 9
26 3-21 1-14 3 1 TPNWNHRGGAFDI 2 13
29 1-69 3-16 6 1 GRLPWRYMDV 2 10
31 1-18 2-15 6 1 TPRYYYYYMDV 1 11
4-28 2-2 6 1 RALYHHYMDV 3 10  3-20 2 0 QQHGSSPYT 1 9
 2-8 2/3 0 SSYAGVHTVI 1 10
47 3-48 3-22 4 3 VHLYYYDSSGYYYDDY 1 16 / 3-20 1 0 QQYGSSPGT 0 9
50 3-9 3-16 6 1 GSYRYYYYCIDV 1 12  3-20 2 0 QQYGSSPVYS 0 10
52 4-31 3-3 3 2 LVGIFGGDAFDI 0 12  1-51 2/3 2 EVWDSGLSVRL 1 11
57 3-48 6-19 4 1 AGLSGSGPFDY 0 11  1-47 2/3 2 AAWDDSLSGVV 0 11
68 3-30 6-19 4 1 PAVVGASLHFDY 1 12 / 3-20 2 0 QQHGSSPYT 1 9
69  1-27 1 0 QKYNSAPRT 2 9
72 3-23 1-26 5 1 HWDS 1 4  1-44 1 1 SAWDNSLNGYF 0 11
77 3-72 1-7 6 2 VKATYGWKINVDQFLDV 2 17 / 1-39 1 0 QQSFRTPWT 1 9
78 3-21 3-3 4 1 LGYDFWSGHRH 3 11  6-57 1 2 WSYDNYQEI 0 9
3-48 3-22 4 3 VHLYYYDSSGYYYDDY 1 16  3-20 1 0 QQYGTSPWT 0 9
 1-47 2/3 2 AAWDDSLSGVV 0 11
89 4-59 ?? 2 2 TPYPPLDWYFDL 0 12 / 1-47 2/3 2 AAWDDSLSGVV 0 11
3-48 3-22 4 3 VHLYYYDSSGYYYDDY 1 16  3-20 2 0 QQHGSSPYT 1 9
 2-14 2/3 0 SSYTSSSTRRVV 2 12
93 3-74 3-3 6 5 DGGEAYDFWSDNHRFYFYYYMDV 2 23  2-14 2/3 1 SSYTTSSDLV 0 10

2 1-46 4-23 4 3 FGRHDYGGKDDY 3 12  1-33 2 1 QQYDNLPYT 0 9
17 4-31 3-10 6 3 DQITMVRGGDGQNYYYYYMDV 1 21 / 1-39 3 0 QQSYSTPPLST 0 11
20 3-9 6-19 4 2 DSRRKSIAVAGAYFDY 3 16 / 2-8 1 0 SSYAGSNNYV 0 10
21 3-23 3-9 6 3 DGRPSTIFWDYMDV 1 14  2-14 2 0 RSYTTINNLST 1 11
28 3-21 2-21 4 3 DVGDIVVVTASLDY 0 14  1-44 2 2 AAWDDSLNGVV 0 11
29 3-23 5-5 3 1 GIQLWPGGAFDI 0 12
30 3-30 3-10 4 2 DLAPGFTSAFDY 0 12  4-1 4 0 QQYYTLPLT 0 9
3-23 3-22 4 3 DGYYDRRGGTVDY 2 13  3-15 1 0 QQYNNWPPWT 0 10
 2-8 1 0 SSYAGSNNYV 0 10
35 4-34 6-13 4 1 GWAYSSSWYRRMISFDY 2 17 / 3-20 2 0 QQHGSSPYT 1 9
44 1-46 3-22 4 2 VGGGYYDSSGGALDY 0 15  1-5 1 0 QQYNSYPWT 0 9
48 3-23 5-12 4 2 VGYSGYDLRVYYFDY 1 15  2-8 1 0 SSYAGSNNYV 0 10
51 4-59 2-21 3 2 RVGSPYCGGDCYPAFDI 1 17  1-8 3 0 QQYYSYPT 0 8
56 5-51 2-2 6 2 ILVDCSSTSCYYYYYYMDV 0 19  3-25 2 1 QSADSSGLV 0 9
58 3-30 1-7 4 1 QWGATGTLDY 0 10  4-1 3 0 QQYYSTPT 0 8
61 3-21 6-13 4 1 GGSSWYYFDY 0 10  1-44 3 2 AAWDDSLNGWV 0 11
3-7 3-3 4 1 ELFHILSY 1 8  1-33 2 1 QQYDNLPLT 0 9
 1-44 2/3 2 AAWDDSLNGPV 0 11
3-11 6-13 6 2 EMGGSSWSIYYYYYYMDV 0 18  1-5 2 0 QQYNSSPYT 0 9
 1-47 2/3 2 AAWDDSLSGVV 0 11
67 4-59 7-27 3 2 RESSRLGNAFDI 2 12  2-23 2/3 0 CSYAGSSTL 0 9
1-18 5-24 4 2 DLNSYYFDY 0 9  4-1 4 0 QQYYSTPLT 0 9
 2-8 1 0 SSYAGSNNYV 0 10
75 3-21 1-7 2 1 AGNWNYYWYFDL 0 12  2-8 1 0 SSYAGSNNYV 0 10
1-24 1-26 3 1 PIVLGAFDI 0 9  3-20 2 0 QQYGSSPPYT 0 10
 2-23 2 0 CSYAGSPV 0 8
1-18 2-2 6 1 RYCSSTSCYKGSYYYYYYYMDV 2 22  3-20 4 0 QQYGSSPLT 0 9
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Figure 6.7 RA synovial B cell antibodies reactivity against cyclic citrullinated peptide.  
Synovial B cell antibodies (n=59) from two RA patients were tested for reactivity against 
cyclic citrullinated peptide by ELISA. The graph illustrates the reactivity at a 
concentration of 10 g/ml. The horizontal line shows the OD value for the negative 
control (human plasma negative for CCP) supplied by the ELISA kit.     
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7 | Discussion 
Sjögren’s syndrome (SS) and rheumatoid arthritis (RA) are two common inflammatory 
autoimmune diseases characterised by peripheral B cell disturbances in the naïve and 
memory B cell compartments. The presence of profound B cell disturbances is a pivotal 
feature of patients with SS and RA and has been demonstrated to play a fundamental 
role in disease pathogenesis and clinical evolution [47, 186]. Both SS and RA are 
characterised by high affinity circulating autoantibodies and by the formation of 
functional ectopic lymphoid structures (ELS) in the respective target organs, i.e. the 
salivary glands and the joint synovium, respectively. In these structures autoreactive B 
cells can undergo antigen selection and affinity maturation. Furthermore, evidence 
that treatment with B cell depleting biological therapies (i.e., rituximab) is associated 
with clinical improvement in RA patients (with extremely promising results also in pilot 
clinical trials in SS) confirms the importance of autoreactive B cell activation in disease 
pathogenesis [2, 187]. In SS the exact stage at which errors in tolerance checkpoints 
accumulate is unknown, whereas it has been shown that RA patients are characterised 
by presence of defective central and peripheral tolerance checkpoints [43].  
Thus, in the first part of my work I aimed to investigate whether peripheral naïve IgD+ 
B cells with germline IgV H and L genes from patients with SS displayed an 
accumulation of autoreactive B cell receptors as one of the possible mechanisms 
leading to breach of B cell self-tolerance and development of enhanced B cell 
autoreactivity in SS.  
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In RA, as well as in SS, the nature of the antigens driving the humoral autoimmune 
response within the joint synovium and salivary glands characterised by ELS is still 
unknown. Their identification would provide novel essential information on the 
aetiology and pathogenesis of these autoimmune diseases. Therefore, in the second 
part of my work I aimed to identify the antigenic specificity of synovial B cells single-
sorted from the synovial tissue of patients with RA with ELS. 
7.1 Accumulation of circulating autoreactive naïve B cells reveal 
defects of early B cell tolerance checkpoints in patients with 
Sjögren’s syndrome. 
As mentioned, SS patients display presence of circulating immune complexes, 
hypergammaglobulinemia, serum organ-specific and non-specific autoantibodies, 
characteristic disturbances of peripheral B cell subsets, formation of ectopic lymphoid 
structures in the salivary glands, and increased risk of developing extranodal B cell 
lymphomas [47]. However, the mechanisms leading to breach of B cell self-tolerance 
and development of enhanced B cell autoreactivity in SS patients are still unclear. In 
order to address this aspect, as reported in Chapter 5, I employed a novel approach 
[33, 34], which allowed me to generate a large number of complete (i.e., IgH + IgL 
chains) recombinant monoclonal antibodies from single peripheral CD27-IgD+ B naïve 
cells bearing identical specificity to the original B cells. By these means I provided 
evidence for the first time that patients with SS display a significant accumulation of 
autoreactive naïve B cells in the peripheral blood compared to age and sex matched 
healthy individuals. Although the reactivity observed appeared to be generally of lower 
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affinity compared to antibodies previously generated from mutated switched memory 
B cells of SLE patients, evidence that unmutated germ line clones from SS patients 
display increased reactivity to Hep-2 cells (nuclear and/or cytoplasmic), ENA and 
dsDNA compared to HD clearly demonstrates a specific accumulation of self-reactive 
naïve B cells in SS patients. 
In physiological conditions, a large proportion of self-reactive and polyreactive B cells 
which are normally generated in the bone marrow during B cell development (75% and 
55%, respectively) are efficiently silenced at two major tolerance checkpoints before 
entering the peripheral compartment as naïve B cells [182, 188]. The first checkpoint 
removes most polyreactive B cells in the bone marrow (central tolerance checkpoint) 
[42, 189]. The second checkpoint in the periphery ensures that only a relatively small 
percentage of self-reactive and polyreactive mature naïve B cells (20% and 6%, 
respectively, as also confirmed in healthy donors in my study) survive [42, 189]. This 
physiological fraction of polyreactive and autoreactive naïve B cells is believed to form 
a reservoir of “natural” antibodies exerting a first-line protective role by recognizing 
invading pathogens [189, 190].  
Thus, the evidence from my work that an increased proportion of autoreactive CD27-
IgD+ naïve B cells accumulate in the peripheral blood of SS patients strongly supports 
the conclusion that early B cell tolerance checkpoints are significantly impaired in SS. It 
remains to be clarified whether this represents a primary event early in the 
pathogenesis of SS or is secondary to chronic inflammatory stimuli and whether the 
accumulation of autoreactive naïve B cells is a critical step towards the development of 
autoimmunity in patients with SS. Although this is the first evidence of such defects in 
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SS, previous reports demonstrated similar abnormalities in patients with SLE, RA and 
type 1 diabetes, suggesting that defects in central/peripheral B cell tolerance 
checkpoints are a common denominator of autoimmune diseases [177, 182]. Although 
the exact mechanisms regulating the early selection of auto/polyreactive B cells are 
not fully characterised in humans, it has been suggested that AID plays a fundamental 
regulatory role in early B cell tolerance as AID-deficient patients display similar 
accumulation of autoreactive naïve B cells [191] and AID-deficient mice develop 
autoimmunity [192].  
An important observation from this study, which confirms previous evidence in SS and 
other autoimmune diseases [35, 41, 42, 189] is that the analysis of IGH, IGK and IGL 
chain gene repertoire showed no significance differences in gene family usage 
between naïve B cells from SS patients and HD, suggesting that family usage per se is 
unlikely to be responsible for the observed accumulation of autoreactive B cells in the 
periphery. However, I did notice a significantly higher frequency of positively charged 
amino acids within the IgH CDR3s, a feature commonly associated with autoreactive 
antibodies [33]. The increase of positively charged CDR3s in autoreactive naïve B cells 
with germ line sequences is of interest as accumulation of positively charged amino 
acids normally results from clonal diversification in germinal centres in SLO. 
In keeping with the evidence that naïve B cells with germ line V genes can display 
autoreactivity in SS, previous reports demonstrated that one of two anti-Ro52 
monoclonal antibodies and 4 out of 10 RF monoclonal antibodies generated from SS 
patients via EBV transformation and hybridoma technology were characterised by 
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completely unmutated germ line genes [193, 194]. Among the antibodies that I 
generated from naïve B cells of SS patients, 6 clones displayed a low reactivity towards 
Ro/SSA and/or La/SSB although at levels significantly higher compared to HD, a result 
that was confirmed in two independent assays (ENA screening and anti-Ro/La ELISA). 
Although circulating autoantibodies against Ro/SSA and La/SSB antigens are not known 
to be cross-reactive, some of the SS recombinant monoclonal antibodies showed a 
cross-reactivity among these antigens (Figure 4.6). Since the reactivity was confirmed 
in two ELISA assays independently, the cross-reactivity may be explained by the fact 
that these recombinant monoclonal antibodies could behave as polyreactive 
antibodies which are able to recognize structurally different antigens.  
Thus, overall, the results provided during my PhD work together with previous data 
support the conclusion that a sizeable proportion of autoreactive B cells in SS patients 
resides within the naïve B cell population. 
Although in this work I specifically focussed on CD27-IgD+ naïve B cells, there is strong 
evidence that patients with SS also display significant abnormalities in the peripheral 
CD27+ memory B cell compartment. Specifically, as also confirmed in this work and 
shown in Chapter 5, SS patients are characterised by a dramatic reduction in the 
percentage and total number of circulating CD27+ memory B cells, possibly as a result 
of accumulation in the affected salivary glands [82]. Within the inflamed salivary 
glands of SS, lesional memory B cells are characterised by high mutational load and 
evidence of ongoing clonal diversification, strongly suggesting a local antigen-driven 
process [72]. This is particularly evident in the context of ELS, which develop in 30-40% 
of SS patients [73, 141] and are characterised by the formation of functional germinal 
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centres promoting the selection and differentiation of autoreactive B cells, leading to 
generation of Ro/La immunoreactive plasma cells [73, 150, 195]. Importantly, my 
group and others previously showed that a subset of IgD+ B cells preferentially 
accumulate within ectopic B cell follicles in SS salivary glands [166]; furthermore, Le 
Pottier et al also showed that IgD+ B cells with a type-2 transitional-like phenotype 
infiltrating SS salivary glands are frequently autoreactive [166]. Thus, the 
demonstration that SS patients have an enlarged pool of autoreactive naïve B cells in 
the circulation may be relevant to SS pathogenesis as these cells can migrate from the 
periphery into the inflamed glands and give rise to B cell follicles where high affinity 
autoreactive clones can be selected and undergo differentiation in ectopic germinal 
centres (Figure 7.1).  
In this regard, it is well known that in order to prevent selection of high affinity 
autoreactive clones a third tolerance checkpoint (the so called pre-germinal center 
checkpoint [189]) excludes self-reactive naïve B cells from entering germinal centre 
reactions, thereby avoiding their expansion and differentiation into long-lived plasma 
and memory B cells [189]. In physiological conditions in secondary lymphoid organs, 
autoantigen-binding B cells are excluded from entering B cell follicles because they 
down-regulate CXCR5 and are thus less responsive to CXCL13 compared to non-
autoreactive B cells which compete for the same follicular niches [167]. As a result, 
autoreactive B cells accumulate at the boundaries between the T and B cell zone 
where they become anergic and/or die by apoptosis. However, this mechanism of 
follicular exclusion has been shown to be impaired in SS salivary glands, allowing 
autoreactive naïve and memory B cells to enter the ectopic germinal centres and 
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undergo clonal selection and affinity maturation [166], similarly to what has been 
described in SLO of patients with SLE [177]. Although the signals responsible for the 
regulation of CXCR5 expression on autoreactive B cells are unknown, it is possible to 
speculate that within ELS developing during chronic inflammation the generation of 
the suppressive, counter-immunoregulatory pathways normally active in SLO is 
impaired.  
Page | 200  
 
 
Figure 7.1 Peripheral self-tolerance checkpoint impairment in SS patients.  
The cartoon shows how a defect in peripheral tolerance checkpoints could bring to the 
accumulation of autoreactive naïve B cells which can migrate from the periphery into 
the inflamed glands and possibly give rise to B cell follicles where high affinity 
autoreactive B cell clones can be selected and undergo differentiation in ectopic 
germinal centres leading to the production of autoantibodies producing plasma cells 
(A). The reduction of circulating memory B cells in SS patients is explained as a result of 
their migration/accumulation in the affected salivary gland where lesional memory B 
cells can be selected and undergo further clonal diversification, thus contributing to 
the production of autoantibodies producing plasma cells (B). 
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In summary, the work dedicated to the analysis of peripheral IgD+CD27- B cells in 
patients with SS demonstrates for the first time the accumulation of a larger 
proportion of self-reactive naïve B cells in the peripheral compartment strongly 
suggesting the presence of defective early tolerance checkpoints in patients with SS. It 
is possible to speculate that the continuous supply of newly generated autoreactive B 
cells could potentially contribute to SS pathogenesis by promoting and maintaining the 
autoimmune process either in SLO and/or within ELS. Furthermore, this work has 
potential implications in the understanding of the mechanisms responsible for the 
repopulation of autoreactive B cell clones following B cell depleting therapies in SS.  
As reported in Chapter 4 and Chapter 5, SS patients are characterised by a distinctive 
distribution of peripheral B cell subpopulations. Analysis by several groups [47] 
confirmed by data from my own work, showed that pSS patients are characterised by 
normal total B cell counts in the peripheral pool but characteristic qualitative B cell 
disturbances with a predominance of CD27- naïve B cells and diminished peripheral 
CD27+ memory B cells [186], especially the circulating IgD+CD27+ memory unswitched 
subpopulation (Figure 4.1). These findings are in contrast with the normal pattern of 
peripheral B cells normally found in healthy individuals where CD27- naïve B cells and 
CD27+ memory B cells represent around 60-70% and 30-40%, respectively, of all 
CD19+ B cells [47]. To date, this altered distribution of circulating B cells seems to be 
unique for SS patients since patients with SLE have shown to have more circulating 
CD27+ memory B cells and reduced numbers of CD27- naïve B cells, whereas RA 
patients have shown a similar distribution of both populations in the periphery with a 
markedly increase of IgD+CD27+ memory unswitched B cells [47].  
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The reduction in circulating CD27+ memory B cells has been explained as result of 
migration to, or retention in, sites of inflammation since we and other groups observed 
an accumulation/retention of CD27+ memory B cells in the inflamed salivary glands of 
SS patients [82]. Molecular studies on B cells obtained from both peripheral blood and 
salivary glands of patients with SS have shown a polyclonal accumulation of memory B 
cells in the inflamed tissue characterised by a similar VH gene repertoire when 
compared to the peripheral counterpart. Moreover, lesional B cells have been shown 
to be characterised by heavily mutated Ig V region and shorter CDR3, supporting 
accumulation of memory B cells in the inflamed glandular tissue [47]. 
In parallel with the naïve B cells reactivity characterization, I also started to clone and 
express monoclonal antibodies from memory IgD-CD27+ switched and IgD+CD27+ 
unswitched B cells. As shown in Chapter 5, I analysed the Ig V gene usage of circulating 
memory switched and memory unswitched B cells isolated from peripheral blood of 
patients with pSS. This analysis provided no indication of clear abnormalities in Ig VH, 
V and V gene usage in SS patients, confirming data previously published [47]. 
Although results are not conclusive due to the relatively low number of memory B cells 
that can be cloned from the periphery of SS patients. I could not observe an altered 
level of polyreactivity in the circulating switched memory B cell antibodies comparing 
our data with previous analysis on memory B cells antibodies from normal individuals 
[40]. Conversely, the frequency of polyreactive memory unswitched B cell antibodies 
seemed to be increased compared to normal individuals. These results are extremely 
interesting as circulating IgM memory B cells bearing a marginal zone-like phenotype 
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[185] have long been implicated in promoting autoimmunity, chronic inflammation 
and evolve towards MALT lymphomas in SS patients [82]. 
In normal conditions, self-reactive memory B cells have been shown to be anergic or 
produce only low affinity non-pathogenic autoantibodies [40]. However, in susceptible 
individuals peripheral autoreactive memory B cells may eventually develop into 
autoantibodies producing plasma cells, either in SLO, followed by migration into the 
site of inflammation, or directly within ELS, and thus directly contribute to the 
development of autoimmunity [40]. 
Whether autoantibodies in SS play a pathogenic role is still unclear. Several 
autoantibodies against non-organ and organ specific autoantigens have been 
described in patients with SS. Among all of them, organ specific autoantibodies 
directed against the M3 muscarinic acetylcholine receptor (M3R) have been implicated 
in inducing impairment of salivary glands function [47, 87]. In particular, Tsuboi and 
colleagues showed that anti-M3R antibodies against the second extracellular loop of 
the M3R could be implicated in reducing salivary gland secretion by suppressing the 
increase in intracellular Ca2+ concentration involved in inducing salivary secretion [87]. 
Since the strategy used in this work allowed me to express recombinant monoclonal 
antibodies from memory B cells of SS patients, it will be interesting to determine 
whether the SS monoclonal antibodies produced are reactive towards the M3R. 
Several methods have been used to analyze anti-M3R antibodies. For instance, ELISA 
and Ca2+-influx assays for the 2nd extracellular loop of anti-M3R can be used, as 
previously reported [87]. Second, to clarify the pathogenic role of anti-M3R 
autoantibodies in SS, the monoclonal antibodies reactive against the M3R could be 
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transfer to immunodeficent mice in order to investigate the secretory function and 
pathology in the salivary glands [87]. These are part of the next steps of my 
investigation as detailed in the Future Plan section (Chapter 8). 
7.2 Characterisation of recombinant monoclonal antibodies from 
single B cell isolated from the rheumatoid arthritis synovium. 
In parallel with the characterisation of recombinant antibodies generated from naïve 
and memory B cells isolated for peripheral blood of SS patients, I also successfully 
generated large number of recombinant antibodies derived from single B cells isolated 
from synovial tissue of RA patients. 
My group has recently provided the first direct evidence of ELS functionality in the RA 
synovium by demonstrating that these structures support the expression of activation-
induced cytidine deaminase (AID) [111], the enzyme responsible for somatic 
hypermutation (SHM) and class switch recombination (CSR) of the Ig genes which 
normally take place in the germinal centres of SLO. In keeping with AID functionality, 
ELS also support the expression of I-Ccircular transcripts, which are specific 
transcribed by-products of CSR from IgM to IgG. Although synovial AID expression 
requires the formation of B cell follicles, also fibroblast-like synoviocytes can directly 
induce AID expression and circular transcripts in naïve B cells via release of BAFF and 
APRIL, two pivotal B cell survival and proliferating factors [196, 197]. Thus, stromal-
immune cell interactions within ELS regulate B cell activation in the RA synovium and 
local plasma cell differentiation. This is indicated by the close correlation between ELS 
and synovial plasma cell number [160, 162] and by the analysis of Ig V gene repertoire 
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demonstrating clonal relationship between activated B cells, isolated using laser 
capture microdissection from synovial ELS, and surrounding plasma cells [163]. 
Furthermore, a significant proportion of CD138+ plasma cells migrating out of synovial 
ELS produce antibodies directed against the citrullinated but not the unmodified form 
of fibrinogen [111]. Accordingly, RA synovial tissues with AID+ ELS display sustained 
production of human IgG ACPA when engrafted into SCID mice in the absence of re-
circulating cells, suggesting that synovial ELS can form self-sustained niches of 
autoreactive B cells which can differentiate into plasmablast/plasmacells and produce 
disease-specific autoantibodies within the target organ. 
Additionally, these findings, which support a pathogenic role for ELS in RA, may also 
explain why drugs that effectively clear B cells from the bloodstream, such as the anti-
CD20-specific monoclonal antibody Rituximab (RTX), do not always produce a marked 
clinical improvement in RA and might influence relapse/resistance to RTX therapy. 
However, despite peripheral B cell depletion is achieved in all cases and the treatment 
is beneficial in up to 60% of patients [198], most patients relapse within 6-8 months. 
The mechanisms of resistance/relapse to RTX are currently unknown and it is unclear 
whether disease relapse is determined by B cell repopulation of the synovial 
membrane and whether this repopulation comes from the systemic circulation or from 
“escaped” clones surviving in “protected” synovial niches.  
Overall, the above evidence demonstrates that an antigen-dependent autoimmune 
response takes place locally and triggers a self-sustained proliferation of B cells and 
local autoantibody production in the absence of re-circulating immune cells.  
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However, the proportion of synovial autoreactive B cells towards a particular antigen 
and the exact nature of the antigens driving the humoral autoimmune response within 
the RA joints in the presence of ELS are unknown and their clarification would provide 
novel essential information on the aetiology and pathogenesis of RA. 
In order to address the above questions, I analysed 139 Ig VH gene sequences and 
generated 66 complete recombinant IgG, IgA and IgM monoclonal antibodies with 
matching H + L chains from single CD19+ synovial B cells FACS-sorted from the 
synovium of RA patients with functional ELS.  
To confirm previous data, I did not observe a skewed distribution of the V gene usage 
(H + L) in the synovial B cells compared to the distribution of the V families in healthy 
individuals. 
Interestingly, several synovial B cells with an identical rearrangement and an identical 
pattern of somatic mutations were found within the RA synovium which is an 
indication of proliferating B cell clones within the RA synovial tissue. Of relevance, I 
also observed highly mutated and clonally related synovial B cells which could suggest 
that within the inflamed synovial tissue there is a constant activation and 
differentiation of B cells and that this activation is antigen-driven. This hypothesis has 
long been suggested by previous studies performing analysis of the V-gene repertoire 
showing that a significant proportion of B lymphocytes accumulating within the 
synovial membrane of RA patients display an oligloclonal repertoire with highly 
mutated V regions, compatible with a local antigen driven reaction [156, 157]. 
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However, the novelty of the experimental approach employed during my PhD is that it 
combines sequence analysis with recombinant monoclonal antibodies generation, 
allowing not only lineage tree and clonal relationship analysis, but also the 
identification of the antigenic specificity of lesional synovial B cells.  
In particular, the fine specificity of the antigen(s) recognised by synovial B cells is 
unknown and it would be extremely relevant to clarify if dominant antigens are driving 
the activation and proliferation of B cells directly at the site of inflammation, within 
the same joint and across the synovium of different RA patients.  
As first screening I started to evaluate the reactivity towards citrullinated antigens 
since anti-citrullinated protein/peptide antibodies (ACPA) are an important diagnostic 
marker for RA and could be pathogenic for this autoimmune disease. Among all the 
clones analysed, 3 monoclonal antibodies showed a positive reactivity in the anti-CCP 
ELISA test and further 5 clones displayed a low level immunoreactivity, although 
further analysis should be done in order to confirm this reactivity by testing the 
antibodies on specific citrullinated proteins (or derived peptides) associated with RA 
such as vimentin, fibrinogen, alpha-enolase, etc. Very interestingly, one of the 3 clones 
resulted positive in the anti-CCP ELISA test (RA2 IgG80) was found to be clonally 
related with another clone within the RA synovium of one patient and showed to have 
a share CDR3 with clones isolated from the RA synovium of a different patient. These 
results, if confirmed in more refined studies, could identify specific CDR3 regions 
shared among different RA patients responsible for the binding of B cells to 
citrullinated proteins (similarly to the HLADRQ “shared epitope”).  
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I now aim to fully characterise the fine reactivity of these recombinant antibodies 
towards a large panel of RA-specific and non-specific (auto)antigens using a well 
characterised protein array platform which has been developed by Prof William H 
Robinson at Stanford University (see Future plan, Chapter 8) [121]. If successful, this 
novel approach will allow the elucidation of the mechanisms triggering humoral 
autoimmunity in situ and could shed novel light into the aetiology and/or pathogenesis 
of RA. Moreover, the identification of relevant synovial autoantigens and distinct 
antibody profiles in different RA patients could allow i) improving the accuracy of the 
diagnosis in the early stages of the disease, ii) stratifying patients in different disease 
subsets and iii) paving the way for tailored vaccination strategies based on the main 
autoantigens actively triggering autoimmunity within the RA joints. 









Chapter 8 | Future plans 
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8 | Future plans 
8.1 Future plan: Rheumatoid arthritis. 
The number of potential antigens in RA is extensive and to date there is no direct 
evidence of specific RA antigens driving the immune response within the RA joints. 
Together with the classical rheumatoid factor and anti-citrullinated peptide/proteins 
antibodies (ACPA) [100], other potential autoantigens include cartilage-specific 
proteins such as type II collagen, human cartilage gp39 (or CD40 ligand), proteoglycans 
and aggrecans. Among the non-articular antigens, circulating autoantibodies against 
glucose-6-phosphate isomerase, heterogeneous nuclear ribonucleoprotein A2/B1 and 
heat shock proteins have been described [121]. Additionally, it may be very well 
possible that a certain number of unknown endogenous and exogenous antigens are 
the target of an (auto)immune response within the RA synovium.  
Thus, my short-term future plan in the context of RA is the identification of the fine 
specificity of the immunoreactivity of synovial B cells arising within ectopic germinal 
centres which are now well established in their ability to support an antigen-driven 
differentiation and proliferation of autoreactive B cells. Elucidation of the mechanisms 
triggering humoral autoimmunity in situ could shed novel light into the aetiology 
and/or pathogenesis of RA and could be used for disease stratification and prognosis in 
order to identify early-stage RA patients, as well as to classify responders and non-
responders to anti-rheumatic therapies [199]. 
Recent advances in proteomic technologies have enabled large-scale analysis, parallel 
measurements of several proteins using small quantities of biological fluids. In 
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particular, the introduction of antigen microarray has been invaluable to profile 
autoantibodies specificities in patients with autoimmune diseases [121, 200]. 
Furthermore, the antigen microarrays overcome several limitations of the routine 
assays used in clinical laboratories to measure autoantibodies which require large 
quantities of biological samples and allow the detection only of one antibody at a time 
[200].  
The antigen microarrays commonly used are the solid-phase, planar arrays. In the 
planar microarray the antigens are immobilized on nitrocellulose membranes or onto 
poly-L-lysine-coated microscope glass slides in an ordered array. The array is then 
probed with samples of interest (e.g. sera, plasma or culture supernatants), thus a 
secondary antibody conjugated either to an enzyme or to a fluorochrome is added to 
the array in order to visualize and quantify the antigen-specific antibodies. Hämmerle 
and colleagues were the first group to develop an antigen microarray to detect 
autoantibodies in biological fluids [201]. Afterwards, several antigen microarrays have 
been developed and adapted to specific autoimmune diseases. Robinson and 
colleagues have modified the antigen microarrays with specific antigens found in the 
synovial tissue of the joint for profiling of RA, with myelin peptides for profiling of 
multiple sclerosis, or with nuclear antigens for profiling of SLE. The advantage of this 
approach is the possibility to test post-translationally modified antigens as opposed to 
native proteins which are frequently poorly immunogenic in vivo. Thus: 
1) the short-term plan is to take advantage of the recombinant monoclonal antibodies 
generated from B cells isolated from the RA synovium and characterize the fine 
specificities of the (auto)reactivity profile of these monoclonal antibodies using the 
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antigen microarray platform which has been developed by the laboratory of William 
Robinson at Stanford University (Figure 8.1) [121]. In particular, Robinson’s lab has 
developed a synovial array which is characterized by >200 peptides and proteins 
spotted on a 1536-feature array. This panel of antigens which are candidate 
autoantigens in RA include native and in vitro citrullinated keratin, fillagrin, vimentin, 
and fibrinogen, as well as heat-shock proteins, heterogeneous nuclear 
ribonucleoproteins (hnRNPs) A2/B1, glucose-6-phosphate isomerase, human cartilage 
gp39 and many others [121].  
For the purpose of my project, the RA antigen microarray will be probed with the 
purified recombinant monoclonal antibodies that I have generated. This platform is 
extremely powerful since the current assays such ELISA, western-blot analysis and 
radioimmunoassay do not allow a large-scale multiplex characterization of 
autoantibody response and most importantly they require large amount of antibodies 
or patient samples. A collaboration has been established with Prof Robinson’s lab and I 
will spend some times at Stanford in order to carry out this part of the project.  
 
Page | 213  
 
 
Figure 8.1 Antigen array for antibody profiling. 
Synovial antigen microarray containing peptides and proteins representing candidate RA autoantigens are used to profile autoantibodies 
in samples of interest (e.g. sera from RA patients or recombinant monoclonal antibodies) and to identify autoantibody biosignatures 
correlated with clinical features that can predict development of more severe arthritis [121]. 
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2) in the longer term, I am planning to i) develop synovial cDNA libraries as an 
alternative approach to identify potential novel autoantigens. This work is planned in 
collaboration with the University of Novara, Italy, where synovial cDNA libraries are 
being developed. The advantage of this approach is the possibility of a high throughput 
and unbiased analysis of the antigenic specificities with the potential for the 
identification of novel autoantigens. The disadvantage, as mentioned before, is the 
limitation of testing the antibodies on native antigens, possibly limiting antigenicity. 
The identified autoantigens, either by protein arrays or synovial cDNA libraries will be 
then assessed on larger cohorts of RA patients and controls in order to assess 
specificity for RA and stratify patients having similar autoantigen responses towards 
“dominant” antigens. Additionally, I am planning ii) to expand the analysis of CDR3 
sequences shared by a large number of clones in different patients as this approach 
could allow the identification of common autoreactive CDR3 signatures (i.e. towards 
citrullinated antigens), which would provide a clue on how the humoral autoimmune 
response towards a particular antigen is shaped within the synovial microenvironment. 
Finally, a foreseeable future step of my research is iii) testing the recombinant 
monoclonal antibodies with autoreactive profile for pathogenicity. For this purpose, I 
will challenge my recombinant antibodies in animal models of arthritis such as the 
collagen-induced arthritis model where it has been shown that ACPA can worsen the 
disease [202].  
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8.2 Future plan: Sjögren’s syndrome. 
The obvious direction of my research post-PhD in SS will be mirroring the work done 
on the RA joints and translate this into the analysis of lesional B cells in the salivary 
glands of SS patients. 
Similarly to RA, I will focus on the 30% of patients who develops functional germinal 
centres in the salivary glands, which accounts to around 30% of SS patients. As 
discussed throughout this thesis, ELS in the SS salivary glands are fully functional and 
support the differentiation of autoreactive B cells towards plasma cells producing high 
affinity autoantibodies.  
Here the experimental approach will be similar to RA, and I will focus primarily on SS 
patients developing swelling of the major salivary glands (i.e. parotids and 
submandibular) as they will provide larger material for B cell separation. Additionally, 
this would be very relevant clinically, as patients with salivary gland swelling are more 
prone to develop lymphoma at a later stage of disease.  
Thus, in this context, I have already collected and store B cells isolated from parotid 
glands of SS patients which are ready to be used for recombinant monoclonal antibody 
production. The aims of my future plans in SS mirror those listed in the context of RA 
and can be summarised as follows: 
1) analysis of the autoreactivity profile of lesional B cells with identification of novel 
autoantigen specificities and/or fine mapping of dominant epitopes driving the 
autoimmune response in the salivary glands. 
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2) assessment of pathogenicity of lesional B cells. In particular I will focus on the 
reactivity towards the muscarinic M3R, which is the most promising target of direct 
autoantibody-mediated exocrine dysfunction in SS patients. Upon successful 
identification of anti-M3R antibodies (in collaboration with Prof Tsumida in Japan), I 
will then test their capacity to induce salivary hypofunction in rodents. 
3) identification of the antigenic specificities of malignant B cells in MALT lymphomas 
of the salivary glands. This is a main priority of my work as it has enormous clinical 
relevance. Malignant MALT-L B cells have the unique characteristic of originating from 
autoreactive B cells with around 40% of lymphomatous parotid B cells displaying 
rheumatoid factor reactivity [203]. These lymphomas arise as a result of a continuous 
antigen driven immune response in the glands leading to the accumulation of genetic 
instability resulting in oligo- and then monoclonal proliferation and escape of 
malignant clones. This process is believed to take place in ectopic germinal centres 
which have been shown to be independent risk factor for lymphoma development in 
SS patients [73, 181]. Thus, I will use my experimental approach and investigate the 
autoantigenic profile of lymphomatous B cells, in particular focusing on the putative 
60% of clones which do not display RF reactivity. The clarification of such 
immunoreactivity could allow a better understanding of the process leading to 
lymphoma development as well as potentially the identification at an early stage of SS 
patients at higher risk of B cell lymphoma. 
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Solutions and buffers 
 
 1X PBS (Lonza): 144 mg/L KH2PO4, 9,000 mg/L NaCl, 795 mg/L Na2HPO4 without 
calcium and magnesium (pH: 7.3-7.5). 
 10X TBE (Gibco): 1M Tris, 0.9 M Boric Acid, 0.01 M EDTA. 
 10X TBS (pH 7.5): 9.7 g Trizma Base (Sigma), 66.1 g Trizma Hydrochloride (Sigma), 
90 g Sodium Chloride (Sigma) dissolved in 1 L of distilled water. 
 Ultrapure 0.5 M EDTA pH 8.0 (Gibco): sterile filtered solution prepared by 
dissolving Na2EDTA•2H2O in distilled, deionized water and adjusting the pH to 8.0 with 
sodium hydroxide.  
 Histopaque – 1077 (Sigma): solution of polysucrose 57 g/L and sodium diatrizoate 
90 g/L, adjusted to a density of 1.077 g/ml (pH: 8.8-9.0). 
 Trypan Blue solution 0.4% (Sigma): prepared in 0.81% sodium chloride and 0.06% 
potassium phosphate, dibasic. Used at a concentration of 0.2%, diluted in PBS.  
 Sodium azide (NaN3) 5%: 2.5 g NaN3 (Sigma) dissolved in 50 ml of distilled water. 
 FACS buffer staining solution: 1X PBS supplemented with 0.5% fetal bovine serum 
(FBS) (Gibco). 
 Nutridoma SP (Roche): serum-free medium supplement composed of albumin, 
insulin, transferrin, and other defined organic and inorganic compounds. Nutridoma 
contains no other growth factors, mitogens, hormones, or sterols. 
 Complete culture medium (293T): Dulbecco’s Modified Eagle Medium/Nutrient 
Mixture F-12 (DMEM/F-12) with high concentration of glucose (GlutaMAX) (Invitrogen) 
supplemented with 10% heat-inactivated FBS (Gibco), 100 g/ml streptomycin, 100 
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U/ml penicillin G and 0.25 g amphotericin (all from Invitrogen), and 500 g/ml 
Geneticin (Invitrogen). 
 “Nutridoma” medium (293T transfection): Dulbecco’s Modified Eagle 
Medium/Nutrient Mixture F-12 (DMEM/F-12) with high concentration of glucose 
(GlutaMAX) (Invitrogen) supplemented with 1% Nutridoma SP (Roche), 100 g/ml 
streptomycin, 100 U/ml penicillin G and 0.25 g amphotericin (all from Invitrogen). 
 Lysogeny broth (LB) Agar plates: 10 g BactoTryptone, 5g Yeast Extract, 15 g Agar, 5 
g NaCl are added to 1 L distilled water. The solution is autoclaved and allowed to cool 
down below 50 °C before adding the Ampicillin (Sigma) at a concentration of 100 
g/ml. Mix thoroughly before pouring into petri dishes. 
 Terrific broth (TB) medium (1L): 12 g BactoTryptone, 24 g Yeast Extract, 4 ml 
Glycerol are added to 900 ml distilled water. The solution is sterilized by autoclaving 
and allowed to cool down to room temperature. Finally 100 ml of a filtered sterilized 
solution made with 2.31 g KH2PO4 and 12.54 g K2HPO4 is added to reach a final volume 
of 1L. 
 0.1 M Glycine (pH 3): 3.8 g glycine dissolved in 500 ml distilled water. 
 1M Tris-HCl (pH 8.0): 60.6 g Trizma Base (Sigma) dissolved in 500 ml distilled water.  
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Bacteria strains and human cell lines 
 
 Genotype competent cells DH10B (NEB): araD139 ∆(ara-leu)7697 fhuA lacX74 
galK (ϕ80 ∆(lacZ)M15) mcrA galU recA1 endA1 nupG rpsL (StrR) ∆(mrr-hsdRMS-mcrBC). 
 Human embryonic Kidney (HEK) 293T: human cell line derived from embryonic 
kidney cells transformed with adenovirus 5 DNA. 293T is a highly transfectable 
derivative of the 293 cell line containing the SV40 T-antigen.  
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